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Abstract
Haemoxygenase-1 (HO-1) is an important enzyme involved in the breakdown of 
pro-oxidant haem, producing carbon monoxide (CO), free iron and biliverdin 
(subsequently converted to bilirubin). These mediators appear to have important 
roles; CO is a vasodilator and an inhibitor o f VSMC proliferation / apoptosis; 
Bilirubin is a potent anti-oxidant; free iron produces ROS and induces ferritin 
expression.
HO-1 was induced using haemin and inhibited using tin protoporphyrin (SnPP). 
The effect o f HO-1 on ischaemia/reperfusion injury was determined in the 
isolated rat heart perfused at either a constant-flow of 1 0  ml/min or a constant- 
pressure o f 70 mmHg over a range of ischaemic periods (20-40 min). The effect 
o f haemin pre-treatment was also determined in other vascular beds such as the 
perfused kidney and perfused mesenteric vascular beds.
At constant-flow; haemin pre-treatment significantly improved the recovery o f 
cardiac function (2 0 min ischaemia), produced a vasodilator response and 
increased tissue bilirubin. The recovery was dependent on cycloxygenase (COX) 
products and NO was involved in the dilator response. At constant-pressure; 
haemin pre-treatment did not aid protection (as recovery was ~80% in both 
treatment groups) but was accompanied by a vasoconstrictor effect pre- 
ischaemia. Increased ischaemic insult abolished recovery in both perfusion 
models. Desferrioxamine restored the recovery o f cardiac function at constant- 
pressure. At a constant pressure of 130mmHg haemin-induced recovery from I/R 
and also produced a vasoconstrictor effect. The vasoconstrictor response 
observed at constant-pressure was not related to endogenous autoregulatory 
mechanisms. Haemin did not affect the vascular responsiveness in the perfused 
kidney and mesentery.
In conclusion, haemin pre-treatment can confer protection from I/R in both the 
constant-flow and constant-pressure perfused heart due to the anti-oxidant effects 
o f bilirubin and the vasodilatory effects o f CO. However the response appears to 
involve more complex mechanisms, including the release o f other vasoactive 
mediators (COX products & NO), the pro-oxidant effects of iron, the method of 
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1.1 Ischaemia-Reperfusion injury o f the heart.
Myocardial ischaemia-reperfusion (I/R) occurs when a temporary coronary 
occlusion results in the absence of fluid perfusion through a specific tissue region 
and induces a temporary hypoxia. I/R injury is a common occurrence in a 
number of pathophysiological situations such as coronary heart disease, 
myocardial infarction and coronary bypass surgery. Myocyte damage may be 
reversible or irreversible dependent upon the length of ischaemic insult. 
Reversible damage is observed as a mitochondrial swelling, a loss o f dense 
mitochondrial granules, and an absence of granular flocculent densities within 
the mitochondria. Irreversibly damaged myocytes have shrunken nuclei, 
formation of sarcolemmal blebs, myofibril fragmentation and sarcoplasmic 
reticulum disruption (Virmani et al., 1990). After short periods o f ischaemia (5- 
1 0  min), there is generally complete recovery o f function, but recovery of 
function decreases as the ischaemic period increases to 20-60 min (Taegtmayer 
et al., 1997).
It is now widely agreed that the majority o f injury received as a result o f I/R 
occurs during the reperfusion phase o f the insult, since short periods of 
reperfusion do not produce injury, while longer periods o f reperfusion are 
associated with a progressive injury (Virmani et al., 1990). For example, during 
ischaemia-induced injury there is an increase in platelet activation and altered 
cardiac metabolism, demonstrated by thrombosis, vasoconstriction and ATP loss 
(Diagram 1). The use o f preventative treatment has a similar outcome whether 
initiated upon reperfusion or during the pre-ischaemic period (Grisham et al.,
1989). Furthermore, there must be molecular oxygen present during reperfusion 
to induce the tissue injury associated with I/R injury (Korthuis et al., 1989), and 
for recovery from I/R to occur. Thus, as indicated in diagram 1, reoxygenation is 
required for neutrophil recruitment and reactive oxygen species (ROS) 
generation. Therefore, the resultant injury post-I/R occurs as a result o f a 
combination of direct ischaemic and reperfusion-enhanced injury.
9
There are a number o f structural and functional changes in response to I/R. For 
example; I/R has a profound effect on the endothelium, as intercellular junctions 
are disrupted producing partial or complete detachment o f the endothelium from 
the sub-endothelium. There is an increase in both intracellular and extracellular 
oedema due to a reduction in intact endothelium. Further pathologic changes 
observed include abnormalities in vasomotor function, coagulation, vascular 
permeability, inflammatory responses and intimal proliferative responses 
(Verrier, 1996), and increased vascular resistance producing a reduced blood 
flow (Quillen et al., 1990). A number o f vasoactive mediators are released in 
response to tissue damage (see Diagram 1), these include; prostaglandins and 
thromboxanes, nitric oxide (NO), ROS, smooth muscle derived relaxing factors, 
catecholamines and products of the renin-angiotensin system (Verrier, 1996). 
The cumulative effect of these tissue responses is the impairment o f coronary 





























TISSUE INJURY & NECROSIS
Diagram 1: The mechanisms involved in I/R injury in both ischaemia alone and 
reperfusion enhanced pathways fLefer & Lefer. 1993T
Thromboxane A2 (TXA2), 5-hydroxytryptamine (5-HT), platelet activating factor 
(PAF), intercellular adhesion molecule-1 (ICAM-1), reactive oxygen species 
(ROS) and leukotriene B4 (LTB4).
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One o f the potentially serious side effects from I/R is the development of 
reperfusion-induced ventricular arrhythmias. This disruption in cardiac function 
may be life threatening and can be a cause o f sudden cardiac death in patients. 
Upon restoration o f coronary flow after myocardial ischaemia, there is an 
increased incidence of reperfusion-induced arrhythmias such as ventricular 
fibrillation (VF) and ventricular tachycardia (Tosaki et al., 1993). Reperfusion 
arrhythmias may be avoided by the administration o f calcium antagonists, which 
have been demonstrated to suppress reperfusion-induced VF (Farkas et al., 
1999). The calcium antagonist verapamil has an increased selectivity in the 
ischaemic myocardium due to the increase in extracellular K+ concentration 
during acute ischaemia (Curtis & Walker, 1986). The pathological changes after 
I/R thought to be mainly responsible for the induction o f arrhythmias involve the 
increase in levels o f substrates involved in the modulation o f conductance of gap 
junctions, such as Ca2+, Mg2+, protons and lipid metabolites. In combination with 
decreased ATP levels, the increase in the levels of these mediators produces poor 
gap junction conductance and increased intercellular resistance. The increasing 
gap junction resistance is accompanied by cell-to-cell uncoupling, activation 
delay and conductance block (Smith et al., 1995).
Catecholamines are particularly important in the regulation o f normal cardiac 
function. In the heart, stimulation of P-adrenoceptors results in an increase in the 
rate and force o f contraction, whereas activation of a-adrenoceptors can produce 
vasoconstriction. Therefore, modulation o f catecholamine metabolism or 
signalling may be important in determining the outcome or severity o f the injury 
produced in response to I/R. In particular, during acute ischaemic insult of 
>15min duration, local noradrenaline concentrations are increased and this in 
combination with an enhanced responsiveness of myocytes to catecholamines, 
increases the occurrence o f I/R-induced arrhythmias (Schomig et al., 1991). This 
is confirmed in a study by Lameris et al., (2000), where the release of 
noradrenaline, adrenaline and dopamine progressively increased in the 
myocardial interstitial fluid during ischaemia. In addition, after regional 
occlusion o f the rat coronary artery, ischaemic myocardial noradrenaline content 
is significantly reduced as a result o f increased release (Holmsgren et al., 1981).
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The release o f catecholamines during the first 5-10 min o f ischaemia is closely 
regulated by adenosine (Headrick & Willis, 1989), which inhibits the 
catecholamine-induced activation o f adenylate cyclase activity (Stangl et al., 
1999). Increased catecholamine release appears to counteract various 
cardiodepressant mediators released in response to I/R (Stangl et al., 1999), 
thereby increasing myocardial oxygen demand and increasing the severity of 
ischaemic insult. Excess catecholamine levels can produce cellular necrosis via 
p-adrenoceptor activation resulting in intracellular Ca2f overload and lipolysis 
(Opie et al., 1979). The role o f adrenoceptors in the progression o f I/R has been 
extensively studied. For example, the activation o f a  1-adrenoceptors appears to 
be important in the formation o f ventricular arrhythmias that occur during I/R. 
(Sheridan et al., 1980). In contrast, P-adrenoceptor receptor density is increased 
in ischaemic myocardium during the progression o f myocardial infarction 
(Maisel et al., 1985). This was also demonstrated in the guinea-pig heart exposed 
to global ischaemia, where increased pi-adrenoceptor density and increased 
adenylate cyclase activity was present after 30min ischaemia (Thandroyen et al.,
1990).
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1.2 Mechanisms o f post-ischaemic tissue injury
1.2.1 The role o f reactive oxygen species
The most significant ROS involved in I/R-induced tissue damage are the 
superoxide anion radical, hydrogen peroxide (H2O2), and the hydroxyl radical 
(Diagram 2). The importance of oxygen for the induction of tissue injury during 
reperfusion may be due to the requirement o f oxygen for the formation o f ROS. 
ROS are involved in the peroxidation of various lipid components o f cell 
membranes. These changes can result in the elimination or interference o f a 
number o f cellular functions such as, structural/contractile/transport proteins, 
enzymes, receptors, membrane glycoproteins and nucleic acids. Tissues exposed 
to oxidants thought to be involved in the I/R-induced destruction have similar 
structural and functional changes as I/R tissues. ROS have also been implicated 
in the pathogenesis of post-reperfusion myocardial “stunning”, contractile 
dysfunction and Ca2+ transport (Sekili et al., 1993). Finally, oxidant production 
inhibitors or ROS scavengers attenuate I/R injury (Granger & Korthuis, 1995).
The natural defence to ROS in the body involves the enzymes superoxide 
dismutase (SOD), catalase (CAT) and glutathione peroxidase (see Diagram 2), in 
combination with a number of non-enzymatic antioxidants such as vitamins C 
and E and glutathione (GSH). SOD converts the superoxide anion into hydrogen 
peroxide and CAT and glutathione peroxidase convert hydrogen peroxide into 
water and oxygen. Under hypoxic conditions, the levels o f these enzymes 
decrease (Wems et al., 1986). It is postulated that a reduction in ROS scavengers 
increases the level of lipid peroxidation by ROS. The supplementation of 
perfusion media with CAT and SOD increases the recovery of cardiac tissue 
from reperfusion damage. For example, the use o f a ROS scavenger such as 
human SOD just before the onset of reperfusion-induced damage has been shown 
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Diagram 2: A diagramatic representation of the metabolism of O? under normal 
conditions and during reperfusion.
GSH has two methods of ROS removal; firstly it can scavenge oxygen and 
nitrogen radicals and secondly, it donates electrons to lipoperoxide and hydrogen 
peroxide, effectively neutralising their effects (Leichtweis & Ji, 2001). In this 
study, hearts depleted o f GSH and exposed to I/R were shown to display a 
reduction in cardiac contractility, left ventricle pressure, and left ventricle work 
compared with control tissues. This suggests that GSH homeostasis is important 
in the protection of intact hearts from reperfusion injury.
As stated above, the antioxidants vitamin C and E may be beneficial in the 
protection from I/R injury, for example an analogue o f vitamin E such as Trolox 
can increase functional recovery but not reduce infarct size (Klein et al., 1991). 
Axford-Gately & Wilson, (1993) reported a reduced infarct size after I/R in 
rabbits treated with dietary supplementation o f vitamin E. Vitamin E analogue 
supplementation may aid the prevention of reperfusion-induced arrhythmias 
(Walker et al., 1998). Vitamin C can decrease membrane lipid peroxidation in 
response to I/R induced by cardiopulmonary bypass (Dingchao et al., 1994). 
Moreover, hypoxic preconditioning increases functional recovery from I/R and
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decreases cellular necrosis after global ischaemia via a mechanism which may be 
linked to the preservation o f vitamin C levels (Engelman et al., 1995).
Two of the most characterised sources o f ROS in I/R injury are the enzymes 
xanthine oxidase and neutrophil NADPH oxidase. Both enzymes are responsible 
for the production o f superoxide and H2O2. In a study by Terada et al. (1992), 
inhibition of xanthine oxidase produced a reduction o f post-ischaemic tissue 
injury, confirming the involvement of xanthine oxidase induced oxidants in I/R. 
A major cause of injury are the myeloperoxidase (MPO) and NADPH oxidase 
products released during the neutrophil respiratory burst. The cytotoxic effect of 
MPO comes from its involvement in the formation o f hypochlorous acid (HOC1) 
from hydrogen peroxide (Harrison & Schultz, 1976) (see Diagram 2). HOC1 can 
have detrimental effects on a number of cellular components due to its ability to 
oxidise or chlorinate primary amines.
It has been suggested superoxide may interact with substances in extracellular 
fluid to produce a leukocyte chemoattractant (Virmani et al., 1990). A study by 
Petrone et al., (1980) has illustrated the ability o f plasma treated with an oxidant- 
generating system to induce chemotaxis of leukocytes; this process is inhibited 
by removal of superoxide. It is thought that oxidant formation during reperfusion 
may be involved in the expression of adhesion molecules on both endothelium 
and leukocytes, which may encourage the adhesion o f leukocytes in post- 
ischaemic tissue. Neutrophil exposure to H2O2 produces an increase in 
CD ll/C D  18; inhibition of this process reduces the accumulation of neutrophils 
in the affected tissue (Suzuki et al., 1991). In cardiac myocytes, post-ischaemic 
cardiac lymph induces expression of ICAM-1 (Hansen, 1995). Inhibition of 
ICAM-1 has been shown to prevent neutrophil adhesion to peroxide-stimulated 
endothelial cell monolayers (Lo et al., 1993). Therefore, ROS are responsible for 
a number o f activities in the pathophysiology o f I/R-induced damage. The 
resultant mechanical effects o f ROS include the induction of vascular contraction 
in isolated arteries, exacerbation of coronary endothelial dysfunction in the post- 
ischaemic heart and a reduction in left ventricular mechanical performance 
(Hansen, 1995).
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The rate o f production of ROS is greatly increased in the presence of the metal 
ions such as Fe3+. In a study by Ambrosio et al., (1987), the administration o f the 
iron chelator desferoxamine (DFO) at the time o f reperfusion significantly 
increased recovery o f myocardial function, restored normal intracellular pH 
levels, and gave better protection of mitochondria. Similarly Bernier et al., 
(1986), demonstrated a reduction in reperfusion-induced VF in hearts treated 
with DFO.
1.2.2. The role o f leukocytes in post-ischaemic injury.
There have been a number o f studies indicating the role o f leukocytes in the 
pathogenesis of I/R injury. Firstly, granulocytes have been shown to accumulate 
in tissue exposed to I/R. Secondly, depletion o f neutrophils significantly reduces 
the cellular dysfunction involved in I/R injury. Finally, inhibitors o f neutrophil 
activation and leukocyte-endothelial cell adhesion can reduce I/R tissue injury 
(Hansen, 1995). Neutrophils release the proteolytic enzyme elastase and can 
promote activation of metalloproteinases such as collagenase and gelatinase 
(Weiss, 1989). Elastase appears to be the most significant effector in neutrophil- 
mediated damage. Due to its cationic nature it can damage tissue by altering 
target cell charge, or by enhancing binding to cell membranes or extracellular 
matrix components (Henson & Johnson, 1987). The direct effect of elastase 
involves the hydrolysis o f proteins in the extracellular matrix, for example 
elastin, fibronectin, and collagen types III & IV. Furthermore, neutrophil 
depletion or antibody-mediated removal o f neutrophils has been demonstrated to 
reduce lipid peroxidation, cellular dysfunction and necrosis (Romson et al., 1983, 
Simpson et al., 1990).
Activated neutrophils are also responsible for the release o f other pro- 
inflammatory mediators. They can release phospholipase A2 (PLA2) into 
extracellular fluid (Lanni & Becker, 1983), thereby enhancing the production of 
eicosanoids and PAF by other cells (Feinmark & Cannon, 1986). The 
implications of these effects include a chemoattractant effect o f leukotriene B4 
(LTB4) (Linbom et al., 1982) & PAF, coronary vasoconstriction (LTC4, D 4 ,  E 4 ,
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TxA2 and PAF) and depression o f left ventricular function (Lucchesi & Mullane,
1986).
The extent of neutrophil accumulation in the heart is proportional to infarct size 
(Smith et al., 1988). Interestingly, after short periods o f ischaemia there is no 
associated neutrophil accumulation during reperfusion (Lo et al., 1988). 
However, accumulation of neutrophils in myocardial capillaries after I/R is 
responsible for the “no-reflow” phenomenon (Jacob et al., 1980). This effect 
occurs as a result o f excessive endothelial cell swelling, producing large 
endothelial cells and protrusions which interact with neutrophils, red blood cells 
and platelets to block capillaries (Engler et al., 1983). This phenomenon 
contributes to the production o f infarcted tissue, as there is poor perfusion of 
surrounding tissue resulting in cell death and the continuation o f ischaemia. The 
“no-flow” phenomenon caused by neutrophils can be prevented by the 
administration o f thrombolytic agents, and this therapeutic approach has resulted 
in a reduction in infarct size. For example, streptokinase and tissue-type 
plasminogen activator can be used to dissolve thrombi and reduce the no-flow 
response whilst producing vasodilation of coronary arteries (Darius et al., 1986) 
The expression o f adhesion proteins on the surface o f leukocytes (CD11/CD18, 
L-selectin) and endothelial cells (P- and E- selectin) is important for the 
accumulation o f neutrophils within an ischaemic area. CD11/CD18 expression 
can be increased by a number o f inflammatory mediators such as LTB4 and PAF 
(Harlan & Liu, 1992). Various studies using antibodies against CD11, CD18, P- 
and L-selectin have indicated a role for these adhesion molecules in the 
accumulation o f neutrophils at the site of ischaemic injury (Granger & Korthuis, 
1995, Lucchesi & Mullane, 1986). Furthermore, I/R-induced necrosis is 
attenuated when pre-treated with antibodies against CD11/CD18 (Ma et al.,
1991). Finally, inhibition o f P-selectin protects the ischaemic myocardium by 




94-Increased intracellular Ca can activate a number o f signalling pathways due to 
its effects on various phospholipases, endonucleases and protein kinases. The
94*level o f intracellular Ca can influence whether a cell lives or dies by its effect 
on DNA repair (Trump & Berezesky, 1995). There is further evidence that 
cellular calcium overload and oxidative stress are the two main factors involved 
in apoptosis or necrosis of cells exposed to I/R. Both ischaemia and reperfusion 
are associated with an increase in Ca2+ content in the damaged myocardium 
(Tani, 1990). This increase in Ca2+ content is associated with a reduction in 
mechanical function o f the heart (Tani & Neely, 1988), and may be due to a
94~primary event in myocardial cell injury. The increase in cytosolic free Ca may
94-involve disruption of the transport of Ca across the sarcolemmal membrane 
(Crake & Poole-Wilson, 1986). Furthermore, the associated reduction in 
membrane integrity and increased permeability are also essential in allowing the
9 +  9-1-diffusion of Ca into the cells o f the damaged myocardium. The increase in Ca 
levels may be responsible for the induction of various arrhythmias in the 
ischaemic-reperfused myocardium (Corr & Witkowski, 1983). This is 
demonstrated by the reduction in ventricular fibrillation post I/R in greyhounds 
treated with nifedipine prior to the onset of ischemia (Coker & Parratt, 1983). 
However, Ca2+ antagonists used during or at the start o f ischaemia do not aid 
recovery from I/R (Watts et al., 1980), but when administered prior to or at the 
start o f ischaemia the extent o f Ca2+ accumulation is reduced (Nayler et al., 
1980). This suggests that L-type Ca2+ channels may be responsible for Ca2+ 
accumulation during ischaemia but are not effective or are inactive during 
reperfusion. It is also possible that there may be further factors involved in the
94- 94-protective response o f Ca channel antagonists. For example, Ca antagonists 
may prevent the depletion of energy stores and protect the oxidation of 
mitochondria during I/R.
9-1- 9-1-Ca antagonists may influence Ca accumulation by preventing a reduction in 
Na+/K+ ATPase activity (Tani, 1990). A reduction in sarcolemmal Na+/K+ 
ATPase activity in response to I/R produces an elevation o f intracellular Na+ 
(Van Emous et al., 1998) (see Diagram 3 (i)). The resultant decrease in pH
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associated with I/R also induces an increase in intracellular Na+ via Na+/H+ 
exchange which in turn results in Ca2+ loading via Na+/Ca2+ exchange (see
9 +Diagram 3 (ii)). Therefore, this leads to an elevated [Ca ]j and potential 
myocardial damage (Allen & Xiao, 2000).
Intracellular Na+ levels are decreased upon reperfusion via an increase in 
Na+/K+-ATPase activity despite continuing Na+ influx during reperfusion via the 
Na+/H+ exchanger (Van Emous et al., 1998). Sarcolemmal Ca2+ pumps are
9 -Presponsible for Ca homeostasis. During ischaemia, the activity of the
I
sarcolemmal Ca ATPase is reduced in membrane vesicles (Tani, 1990),
^ I
producing an increase in intracellular Ca , which is accentuated upon 
reperfusion o f the tissue.
jNa7K+ ATPase 













|  Na+ Accumulation
Diagram 3: The mechanisms involved in the production o f Ca2+-mediated tissue 
damage.
The balance of mediators released during I/R may have an effect on the
9 +  9 +maintenance o f intracellular Ca . Activation o f a-receptors can increase Ca 
influx, as demonstrated by the use o f adrenoceptor antagonists (Nayler et al., 
1985). A number of studies have implicated the involvement o f ROS in Ca2+
I ^ |
transport in cardiomyocytes, primarily via the Na /Ca exchange (Kaneko et al.,
19
9 +1994). In a study by Green & Paller (1994), excess Ca content in cells was 
associated with increased superoxide production via a calmodulin-dependent 
conversion of xanthine dehydrogenase to xanthine oxidase during I/R.
1.2.4. The role o f the endothelium in I/R
During ischaemia there is a marked reduction in energy metabolism that has a 
profound effect on tissue injury and necrosis under conditions of ischaemia, 
which is accelerated upon reperfusion. During this phase, endothelial cells 
produce a number of mediators involved in the inflammatory response to 
ischaemia, including ROS (superoxide) and lipid mediators (PAF). In contrast, 
the endothelium is also responsible for the production and release o f several 
factors that can reduce neutrophil attachment such as adenosine and prostacyclin 
(PGI2) (Forman et al., 1990). PAF antagonists have been demonstrated to reduce 
microvascular leakage produced by PAF in the coronary circulation (Stahl & 
Lefer, 1987), and thereby prevent fluid leakage (Ma et al., 1991).
NO is an important mediator o f I/R injury as indicated by the exacerbated injury 
seen after nitric oxide synthase (NOS) inhibition, and the increased recovery 
from I/R after treatment with NO donors (Bolli, 2001). As yet there is no clear 
explanation for the protective role of NO, but a number o f hypothesised effects 
including antagonism of p-adrenergic stimulation and reduced contractility 
(Balligand et al., 1993), and opening o f Katp channels (Shinbo & Iijima, 1997) 
have been suggested. The use of NO donors has been shown to bring about a 
marked increase in the preservation of endothelial function after I/R (Siegfried et 
al., 1992). There are disputing reports about the involvement o f NO in the control 
of adhesion molecule expression. NO inhibition results in an increased leukocyte 
adherence (Kubes et al., 1991). There is also evidence of a reduced adhesion 
response to various inflammatory mediators in the presence of NO or NO donors 
(Kurose et al., 1994, Lefer et al., 1993) and neutrophil accumulation (Lefer et al., 
1993). Furthermore, a study by Matheis et al., (1992), indicates that NOS 
inhibition prevents both the contractile dysfunction and lipid peroxidation 
normally associated with I/R. The damaging effects o f NO are thought to be
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caused by the production of the peroxynitrite anion from the combination of 
superoxide and NO (Beckman et al., 1990).
Prostanoids also appear to be important in the pathogenesis o f I/R. In the 
ischemic myocardium there is a fine balance between PGI2 and TxB2 release, 
with significant increases in TxB2 being related to increases in arrhythmia 
formation (Coker et al., 1981). In addition, a study by Karmazyn (1986) suggests 
that reperfusion is a stimulus for prostaglandin release in the rat heart, and that 
this may be related to the failure o f ventricular recovery following I/R. In 
contrast, a reduction in PGI2 production has been observed after I/R, and 
supplementation o f PGI2 increases the preservation o f myocardial tissue from 
necrosis. The use o f a thromboxane antagonist reduces I/R-induced arrhythmia 
formation, suggesting that TxA2 may be arrhythmogenic (Coker & Parratt, 
1985). The major actions o f the prostanoids -  namely, coronary vasoconstriction 
and platelet aggregation are induced by TxA2, which will further decrease blood 
flow to the ischaemic area. Under normal physiological conditions, PGI2 would 
act to counteract these effects, but this response is disrupted by endothelial 
dysfunction in ischaemic-reperfused tissue.
Endothelial cells are also responsible for the metabolism of adenine molecules 
and the circulating level o f adenosine in the coronary circulation. Adenosine is 
an important mediator involved in vasodilation and coronary autoregulation. It 
also has the ability to disaggregate platelets and prevent the release o f the 
constrictor TxA2. In addition, adenosine can prevent the activation o f neutrophils 
and the damage associated with neutrophil accumulation. This is demonstrated in 
a canine model of I/R, where perfusion with adenosine prevents the accumulation 
o f neutrophils, and thus brings about a reduction in infarct size (Olafsson et al.,
1987). Furthermore, adenosine and its analogues can reduce superoxide 
generation by neutrophils and inhibit their adhesion to endothelial cells 
(Cronstein et al., 1986).
I/R-induced endothelial damage may encourage procoagulant pathways due to 
disruption o f the control mechanisms involved in coagulation. After ischaemic 
insult, synthesis of procoagulant enzyme tissue factors such as PAF and TxA2,
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are upregulated in the endothelium. The balance o f these effects after I/R injury 
appears to favour thrombosis (Virmani et al., 1990).
There is speculation as to the role o f heat shock proteins in the ischaemic heart. 
Heat shock proteins (HSPs) are a family o f proteins with varying molecular 
weight that are expressed under conditions of stress and have been shown to have 
a protective effect in cells under attack. There are a number o f important family 
members, such as HSP 70 and HSP 32 (more commonly known as 
haemoxygenase and discussed in length from 1.4 onwards). As regards cardio- 
protection, HSPs are expressed after ischaemic insult, hypoxia, haemodynamic 
overload and myocardial stretch (Black & Lucchesi, 1993). The extent of the 
protection available has been demonstrated in whole body experiments involving 
heat-stressed hearts exposed to ischaemia, where post-ischaemic left ventricular 
functional recovery is increased and enzyme loss is decreased (Yellon et al.,
1992). There appears to be a direct correlation between HSP expression and 
protection against ischaemic damage (Yellon et al., 1992). It is possible that this 
may be related to an effect on neutrophil activity. Heat-induced expression of 
HSPs inhibits neutrophil NADPH oxidase activity, which may contribute to a 
reduction in superoxide production and the accompanying tissue damage 
(Maridonnaeu et al., 1988).
1.3. The role of pre-conditioning in the prevention o f I/R-mediated damage
Pre-conditioning is a phenomenon that involves the induction of short periods of 
ischaemic stress in the myocardium that do not produce irreversible cellular 
damage, but rather activate an adaptive mechanism within the heart producing a 
resistance to further ischaemic insult. It generally consists o f two phases, a 
transient early phase that occurs within minutes and a later or delayed phase that 
takes place several hours before activation and can last for days. There are major 
differences between the two phases, which is demonstrated by the different time 
courses involved in the responses. The early phase o f the preconditioning 
response is mediated primarily by post-translational modifications of pre-existing 
cellular proteins. The later phase depends upon the upregulation o f particular 
gene expression (Williams & Benjamin, 2000). It has been demonstrated that
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preconditioning prior to full ischaemic insult decreases the extent o f the 
myocardial injury inflicted in the coronary artery, as illustrated by a reduction in 
infarct size (Murry et al., 1986). Furthermore, preconditioning can increase the 
recovery o f contractile function after I/R (Murry et al., 1986). Short periods of 
ischaemia prior to I/R can prevent the formation o f life-threatening arrhythmias 
during I/R (Reimer et al., 1990). This important response may provide greater 
protection from ischaemic insult than the accompanying reduction in infarct size. 
The exact mechanism responsible for the protection from I/R injury by 
preconditioning is as yet unknown. A major candidate for involvement in this 
cardio-protective response appears to be adenosine. Several pieces of 
experimental evidence support this assertion: firstly, inhibition o f adenosine 
receptors abolishes the protective effect o f preconditioning in the post-ischaemic 
heart (Liu et al., 1991); secondly, the use of an adenosine Ai agonist mimics the 
effects observed after preconditioning in the ischaemic heart (Downey et al.,
1993); thirdly, adenosine has been suggested to protect the heart from ischaemia 
by increasing myocardial energy production from an increase in glucose 
transport induced by preconditioning. Another mediator thought to be involved 
in the protective mechanism of preconditioning is NO. The inhibition o f NO 
generation has been demonstrated to reduce the protection evolved from 
preconditioning and prevent the antiarrhythmic effects of preconditioning (Vegh 
et al., 1992).
There is mounting evidence for the involvement of K a t p  channels in ischaemic 
preconditioning. For example, the administration o f K a t p  inhibitors has been 
demonstrated to reverse the protective effect o f ischaemic preconditioning in the 
myocardium (Auchempach et al., 1992). It has been postulated that the opening 
of K a t p  channels prior to ischaemia results in the generation o f ROS, which act 
as a trigger for the preconditioning response (Pain et al., 2000). The K a t p  
channel appears to be a downstream effector o f adenosine as demonstrated by 
Van Winkle et al., (1994), where blockade o f the K At p  channel prevented the 
reduction o f ischaemic injury by adenosine. Specifically, mitochondrially- 
expressed K a t p  channels have been demonstrated to be important in ischaemic 
preconditioning. For instance, the opening o f mitochondrial K a t p  channels 
appears to be important in the response to I/R, as the K+ channel opener
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diazoxide has been demonstrated to be protective due to the induced production 
o f ROS, and o f volume regulatory actions that preserve the structure function o f 
the intermembrane space (Dos Santos et al., 2002). Furthermore, the role o f 
mitochondrial K a t p  has been directly demonstrated in ischaemic preconditioning, 
as the use o f a selective mitochondrial K a t p  channel antagonist abolishes the 
cardioprotection induced by ischaemic preconditioning (Fryer et al., 2001). The 
late preconditioning effect that can be induced by adenosine A3 receptor 
activation involves not only iNOS and NF-kB, but also requires the opening of 
the mitochondrial K Atp  channel (Zhao & Kukreja, 2 0 0 2 ). Finally, the 
mitochondiral K a t p  channel’s involvement in the preconditioning response to 
ischaemia requires protein kinase C activation and translocation to the 
mitochondria (Wang et al., 1999).
Protein kinase C is another downstream effector thought to be involved in 
ischaemic-preconditioning. Activation of protein kinase C involves its relocation 
to the sarcolemma where it can phosphorylate a protein target to induce the 
response observed. However, Valhaus et al., (1996) have suggested that protein 
kinase C may not be involved in ischaemic preconditioning since protein kinase 
C blockade using staurosporin does not prevent the induction o f ischaemic 
preconditioning. Therefore, the degree of involvement o f protein kinase C in 
ischaemic preconditioning is as yet unclear, but it may be possible that protein 
kinase C is a secondary effector in ischaemic preconditioning.
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1.4 The enzyme haemoxygenase-1 fHO-O
Haemoxygenase (HO) is an important enzyme involved in the degradation of 
haem molecules. Free haem occurs within the cell as a result o f the breakdown of 
haemoglobin. As reviewed by Maines (1997), HO was first characterised in 1974 
and is mainly located in the smooth endoplasmic reticulum (ER). A hydrophobic 
region in the carboxy terminus of the protein anchors it to the ER. HO is present 
in three isoforms of which HO-1 is the 32kDa inducible form of the enzyme, 
HO-2 is the 36kDa constitutive form, and HO-3 is the 33kDa constitutive form, 
o f which only a little is known. Under normal physiological conditions, HO-2 is 
the major isoform and is expressed in a 2:1 ratio to HO-1. However, in the spleen 
HO-1 is constitutively expressed due to the large turnover o f haemoglobin as this 
organ is the primary site o f erythrocyte degradation. HO-1 and HO-2 are 
products of two different genes; whereas a single 1.8kb transcript codes HO-1, 
HO-2 is coded by two transcripts o f 1.3 and 1.7-1.9kb. HO-1 and HO-2 both act 
via a similar mechanism to catalyse haem, whereas HO-3 has little catalytic 
activity but rather acts as a haem sensing/binding protein due to the lack o f a 
completely conserved HO signature. The HO signature is a 24-amino acid 
segment also known as the haem pocket. Its main function is to bind the haem 
molecule via a hydrophobic bond with pyrrole rings 1 and 2 , resulting in the 
isomer specific cleavage o f the a-methene carbon-bridge. It has been 
demonstrated that a histidine residue within the pocket o f HO-1 (His 132) or HO- 
2 (Hisl51) is essential for enzymatic activity. The pocket recognises the side 
chains o f the porphyrin ring rather than the metal moiety, which means that it can 
be competitively inhibited by other protoporphyrins such as tin protoporphyrin 
(SnPP) and zinc protoporphyrin (ZnPP), as opposed to the natural substrate, 
FePP (haem). These molecules are commercially available as inhibitors o f HO, 
although they cannot discriminate between isoforms.
Under normal conditions the substrate haem becomes available from a freshly 
synthesised haem pool prior to its incorporation into various proteins, such as 
haemoglobin, haem-haemopexin complexes and various cytochrome P450s 
(Willis, 1999). Under patho-physiological conditions, ROS and reactive nitrogen
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species (RNS) generated during oxidative stress damage haemoproteins and 
cellular membranes, resulting in the release o f haem within the cell. Therefore 
under these conditions it is essential that haem molecules be removed to recycle 
the central iron molecule and reduce the production o f ROS, thus preventing 
further cellular oxidative stress (Maines, 1997).
The induction o f HO-1 is highly sensitive to a number o f stimuli that increase 
oxidative stress or decrease glutathione levels including heat shock (Okinga et 
al., 1996), ischaemia (Maulik et al., 1996b), hypoxia (Maines, 1997), 
inflammation (Willis, 1999), cytokines (such as TN F-a and IL-1 (Terry et al.,
1998), IL-6 (Rizzardini et al., 1993) and interferon-y (Willis, 1999), haemin 
(Clark et al., 2000) and a number o f metal ions (Co, Fe etc) (Maines, 1997). In 
contrast, only adrenal glucocorticoids have been identified as chemical inducers 
of HO-2 (Maines, 1997). The selectivity of HO-1 is also shown by the presence 
of various promoter elements in the HO-1 gene, such as heat shock elements 
(HSE-1 and -2 ) (Willis, 1999), AP-1 (Lavrovsky et al., 1994), NFkB (Lavrovsky 
et al., 1994), hypoxic responsive elements which can bind H IF -la  (hypoxia 
inducible factor)(Lee et al., 1997) and metal regulatory elements (MREs) (Willis,
1999).
The catalysis of haem requires NADPH-cytochrome P450 reductase as a 
cofactor, and utilises two molecules of oxygen. This oxidative reaction results in 
the release of equimolar levels o f biliverdin (further converted into bilirubin by 
biliverdin reductase), carbon monoxide and free iron (see diagram 4). The 
degradation of haem is required for the re-utilisation o f iron from haemoglobin, 
and further prevents the generation of free radicals induced by free haem 
(Maines, 1997). In reducing oxidative damage caused by haem, HO-1 by­
products have been demonstrated to have cellular functions of their own. For 
example, bilirubin is a potent anti-oxidant, carbon monoxide (CO) has 
vasodilator properties and free iron stimulates the induction of ferritin and the 










Diagram 4: HO catabolism of haem.
The function of HO-1 in physiological iron homeostasis systems has been 
investigated in HO-1 knockout mice. In general, the mice were smaller, thin and 
poorly groomed and there was also a high risk o f premature fatalities. HO-1 
knockout mice demonstrated a decrease in red blood cell number and size, and a 
decrease in serum iron accompanied by an increase in serum ferritin. There was a 
high proportion o f kidney and liver non-haem iron accumulation. Further studies 
of the kidney and liver indicated increased oxidised proteins and lipid 
peroxidation, progressive chronic inflammatory disease and glomerulonephritis. 
Thus, an absence of HO-1 produced a defect in iron reutilisation, i.e. decreased 
delivery of tissue iron stores to the blood and decreased protection against free 
radical tissue damage. There is also evidence o f the important role o f HO-1 to 
prevent the induction o f inflammatory disease states (Poss & Tonegawa, 1997a 
& b). A further, human, study of a 6-year old boy bom with a HO-1 deficiency 
has demonstrated the potential role of HO-1 in the human body. This study 
reported a marked growth retardation and developmental delay associated with 
erythrocyte fragmentation and persistent intravascular haemolysis. Haemin -  
induced cell injury from the patient was increased, indicating that the presence of 
HO-2 did not confer protection. Therefore, this study indicates the critical
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importance of HO-1 rather than HO-2 in iron metabolism and cell protection 
from oxidative damage (Yachie et al., 1999). In contrast, mice with an absence of 
the HO-2 enzyme demonstrated an increased mortality upon exposure to chronic 
hyperoxic exposure and increased evidence o f lung oxidative injury. The results 
of this study indicate that abolition o f HO-2 is associated with HO-1 induction 
and increased oxygen toxicity due to the accumulation o f iron in the mouse lung 
(Dennery et al., 1998)
1.5 HO-1 Products (D: Bilirubin
The enzyme biliverdin reductase, which is co-expressed with HO-1, converts the 
breakdown product biliverdin to the bile pigment bilirubin. An interesting 
example o f this reaction is demonstrated in the bruising o f the skin. Initially the 
bruise is black, an indication of the release o f haem, but after a couple of days 
this changes to a “greenish” colour after the conversion to biliverdin. Finally the 
fading bruise becomes a yellow colour as biliverdin is reduced to bilirubin. 
Bilirubin appears to act in an anti-oxidant capacity within the cell; it can inhibit 
lipid peroxidation (Willis, 1999), and at low O2 tensions, it has been shown to be 
a more successful inhibitor of lipid peroxidation than vitamin E (Wu et al., 
1991). A number of studies have indicated an anti-inflammatory role for 
bilirubin; for example, bilirubin increases the anti-inflammatory effect o f low 
dose dexamethasone in a model of I/R injury in the mouse paw (Oyanagui, 
1997). A further feature o f both bilirubin & biliverdin may involve anti­
complement effects in vitro  (Nakagami et al., 1993). Bilirubin may have a more 
widespread anti-inflammatory effect, as it can inhibit the cytotoxic activity and 
IL-2 production from human T-lymphocytes (Haga et al., 1996).
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1.6. HO Products fir): Free Iron
Iron released from the cleavage of haem may have both protective and 
detrimental activity within the cell. The expected response to iron release would 
involve the production of reactive oxygen species as a result o f the Fenton and 
Haber-Weiss reactions, both catalysed by free iron (Maines, 1997). A potential 
protective mechanism resulting from iron release may include the induction of 
the synthesis of ferritin, which can sequester the pro-oxidant iron (Vile et al., 
1994). In HO-1 knockout cells, iron accumulation was increased and iron efflux 
decreased, thus providing further evidence o f the importance o f HO-1 in the 
regulation o f iron mobilisation (Ferris et al., 1999). Hyperoxia-induced HO-1 
expression was potentiated due to the co-release o f free iron (Fogg et al., 1999). 
This is also demonstrated in a study by Ryter et al., (2000), where HO-1 
expression was increased after hypoxia and reoxygenation, but this response was 
dependent upon the release of chelatable iron. Therefore, the release o f iron may 
be an important response in terms o f acting to potentiate the expression of HO-1 
and the protection induced thereby.
The pro-oxidant activity o f HO occurs as a result o f the release o f iron. In a 
comparison of cell lines transfected with low, medium and high expression of 
HO-1, cells with high HO-1 expression demonstrated a reduced viability 
accompanied by an increased release o f iron and an increased generation of ROS. 
The high level o f HO-1 expression appeared to perturb the cell cycle and 
increase ferritin expression, and so did not successfully remove all iron present. 
Furthermore, the increase in iron also served to inhibit HO activity (Suttner & 
Dennery, 1999).
1.7 HO-1 Products fin): Carbon monoxide (CO)
The catalysis of haem by HO results in the generation o f endogenous CO. CO 
has an important physiological role due to its ability to activate guanylate cyclase 
(GC), and so bring about an increase in cGMP levels (Morita et al., 1995). It also 
has further properties including the ability to produce vasodilation and reduce the 
proliferation of vascular smooth muscle (Durante & Schafer, 1998). The release
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of CO by vascular cells has both autocrine and paracrine effects on both vascular 
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Diagram 5: The paracrine & autocrine effects o f CO in the healthy blood vessels.
A number o f studies have indicated a role for CO in regulating vasomotor tone. 
In the chronic hypoxic rat, signalling through endothelium-derived CO has been 
suggested as a candidate for the reduced vasoreactivity of rat aortic rings (Caudill 
et al., 1998). In contrast, Wang et al. (1997) have shown that CO acts 
independently o f intact endothelium in the rat de-endotheliumised tail artery. 
There are other mechanisms o f action by which CO may regulate vascular tone 
apart from a direct effect on guanyl cyclase. CO-induced vasorelaxation may be 
contributed to (albeit partially) by an indirect effect o f prostaglandins or 
adrenergic effects (McFaul & McGrath, 1987). Coceani et al., (1997) proposed 
that the CO-induced dilation o f the lamb ductus arteriosus was produced by a 
reduction in the formation o f the constrictor endothelin-1 (ET-1). Johnson et al., 
(1996) reported the possible involvement of HO-derived CO as an influential 
factor in the pressor mechanisms controlled by the autonomic nervous system; 
thus, rats pre-treated with the HO inhibitor ZnPP demonstrated an increase in 
arterial pressure. This was also confirmed in isolated vessels, where the 
administration of the HO-inhibitor chromium mesoporphyrin (CrMP) caused a
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sustained reduction in the internal diameter o f gracillis muscle arterioles (Kozma 
etaL, 1999).
There is strong evidence for the involvement o f Kca channels in CO-induced 
vasodilation (Wang & Wu, 1997). In the cerebral microcirculation, CO acts as a 
potent vasodilator agent by acting on Kca channels (Leffler et al., 1999). Wang & 
Wu, (1997) discovered that CO increases the open probability o f Kca channels, 
which may significantly affect vascular tone. CO appears to achieve this 
response by interacting with a particular histidine residue present in the Kca 
channel, thereby modulating the channel’s gating mechanism. CO also appears to 
be very important in the regulation of cellular proliferation. For example, 
VSMC-derived CO has been demonstrated to modulate hypoxia-induced VSMC 
proliferation by suppressing the gene expression o f the growth promoters ET-1 
and PDGF-B (platelet derived growth factor-B) (Morita & Kourembanas, 1995). 
HO-1-induced CO release has also been shown to have a negative feedback 
effect on the proliferation of VSMCs, which is linked to a reduction in growth 
factor activity (Peyton et al., 2002). This has also been demonstrated in a study 
of neo-intimal development, where increased HO expression (induced by 
haemin) reduced neo-intimal formation as produced by balloon injury. This 
involved a NO-independent increase in cGMP, implicating the involvement of 
CO in the regulation of VSMC proliferation (Togane et al., 2000). However, 
there is some evidence that implies the involvement o f CO in a pro-proliferative 
capacity due to prolonged exposure to CO. CO may be protective at lower doses, 
but after chronic exposure (for example, in long-term smokers) there may be a 
detrimental effect on vascular proliferation (Carraway et al., 2002).
CO has also been implicated in the protection o f various organ cells from 
apoptosis, which is a prominent feature of a number o f inflammatory diseases 
such as arteriosclerosis and I/R injury. Brouard et al., (2000), report that HO-1- 
derived CO prevents the apoptosis of endothelial cells stimulated by TN Fa in a 
guanyl cyclase- independent manner. In addition, angiotensin II-induced 
hypertension increased renal cell apoptosis, which was increased by ZnPP and 
reduced by haemin, indicating the involvement of HO-1 in the protection of renal
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cells in hypertension (Aizawa et al., 2001). This was confirmed when exposure 
o f TNFa-treated fibroblasts to low levels of CO was shown to inhibit apoptosis 
via a guanyl cyclase-dependent mechanism (Petrache et al., 2000). The full 
extent of this protective response may involve the protection o f other non-HO-1- 
expressing cells by CO generated by HO-1 expressing cells, such as 
neighbouring cells and infiltrating leukocytes (Brouard et al., 2000).
Johnson et al., (1996) observed that in rats subject to increased blood pressure 
(spontaneously hypertensive rats, DOCA-salt and phenylephrine-induced 
hypertension), addition of HO substrates (haem-L-lysinate and haem-L-arginate) 
induced an acute decrease in blood pressure through the production of CO. It has 
also been established that CO may also be responsible for the control o f synaptic 
neurotransmission in the hypoxic lungs and airways in an in vivo guinea-pig 
model (Cardell et al., 1998). The application o f exogenous CO ameliorated the 
degree o f inflammation in the ovalbumin-induced inflammation model as 
measured by the amount of eosinophil accumulation (as seen in asthma), due to a 
decrease in the level of IL-5 production (Chapman et al., 2001). Similarly, in a 
model o f hyperoxia-induced inflammation, exposure to exogenous CO provided 
protection against oxidative stress by the reduction o f airway neutrophil influx 
(Otterbein et al., 1999). These data provide evidence o f the important role CO 
may play in a number o f situations, particularly in relation to human disease 
states such as atheroslerosis, hypertension, asthma and ARDS (adult respiratory 
distress syndrome).
32
1.8. Interaction o f HO with NO and prostaglandins
It is interesting that HO, NO synthase and cyclo-oxygenase (COX) are all 
expressed in the same cell types and it is possible that there may be co-ordinated 
and complementary roles for these mediators. One o f the main documented 
interactions of HO with other mediators appears to be the interaction between 
CO and NO. This may be due to the number o f similarities between the two 
molecules. Both CO and NO share affinity for the haem molecule and both 
mediate a number o f their actions via the upregulation o f cGMP (Maines, 1997). 
However unlike NO, CO is not a free radical and cannot inflict tissue damage 
such as that caused by the production of the peroxynitrite radical associated with 
inflammation or cytotoxicity. Furthermore, HO-1 and iNOS are induced by 
similar stimuli such as bacterial endotoxins, cytokines and ROS (Nathan, 1992).
The interaction between CO & NO is demonstrated by the ability o f each to 
influence the production and actions of the other. For example, it has been shown 
that NO and NO donors can influence the expression o f HO. HO-1 mRNA or 
protein can be induced by the NO donors: sodium nitroprusside (SNP), S-nitro- 
N-acetyl penicillamine (SNAP) and 3-morpholinosyalnomine (SIN-1) in a 
number o f cell lines (Willis, 1999). The exact mechanism of action by which NO 
may induce HO-1 expression is not fully known. HO-1 induction in vascular 
smooth muscle cells by the NO donor SIN-1 appears to be dependent on 
production o f ROS (Durante et al., 1997). However in the same cell line treated 
with the NO donor SNAP-1, HO-1 induction was independent of ROS. This 
indicates that HO-1 induction by NO is not purely due to a change in redox state. 
This is further supported by the regulation o f HO-1 induction at the 
transcriptional level by NO (Hartsfield et al., 1997). HO-1 induction in VSMCs 
by NO donors appeared to be independent o f cGMP but dependent upon ROS 
(Hartsfield et al., 1997, Alcaraz et al., 2000), although it is interesting to note that 
in VSMCs treated with the peroxynitrite ion, HO-1 expression could not be 
induced (Hartsfield et al., 1997). Alternatively, recent evidence indicates that 
HO-1 induction may occur as a result of glutathione depletion by NO (Yee et al.,
1996). NO may also regulate HO-1 activity by an indirect effect on iron 
metabolism, as NO is reported to regulate iron response element (IRE) binding
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and ferritin synthesis (Weiss et al., 1993). A further mechanism of action may 
involve the release o f free haem from haem proteins (Lipton et al., 1993) by NO, 
as HO can be induced by the presence o f free haem. In conclusion, it is possible 
that the release of CO as initiated by NO may be a further mechanism by which 
NO can activate guanylyl cyclase and regulate vascular tone (Durante et al., 
1997).
HO-1 can regulate the production o f NO by a number of mechanisms. Firstly, 
increased HO-1 activity results in increased haem degradation and hence, 
impaired synthesis o f the hemoprotein NOS. Secondly, due to the haem nature of 
NOS it is a substrate for HO-1 and therefore, increased HO activity results in an 
increased turnover o f the enzyme (Maines, 1997). Furthermore, CO produced by 
HO can bind to NOS and effectively inactivate it (White & Marietta, 1992). 
Finally, iron released from the degradation o f haem can inhibit the nuclear 
transcription o f NOS (Weiss et al., 1994).
The interaction between CO and NO may have a significant influence in 
therapeutic situations, for example, in the ischaemic heart. NO production from 
L-arginine reduces the damage produced by I/R, and this reduction is 
accompanied by a HO-1 sensitive increase in cGMP. This suggests that although 
NO may be the major protective factor in this situation, CO generation is also 
involved in the signalling process and may potentiate the response to NO (see 
diagram 6) (Maulik et al., 1996).
There is also evidence o f an interaction between HO and various COX products. 
In piglet pial arterioles, both prostanoids and NO have been shown to contribute 
to a CO-induced cerebrovascular dilation that is not mediated by cyclic 
nucleotides, but rather by activation o f Kca channels (Leffler et al., 2001). 
Similarly, macrophages treated with zymosan (which is derived from yeast cell 
walls) have increased HO-1 expression, which can be negatively modulated by 
exogenous leukotrienes (Vicente et al., 2001). In contrast, in a macrophage cell 
line treated with a NO donor, HO-1 induction was potentiated by the inhibition 
o f COX-2 (Alcaraz et al., 2001). Thus, the interaction between CO and NO or
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prostanoids in both a negative and positive capacity may be important in the 




















Diagram 6: A proposed interaction for CO and NO in the ischaemic myocardium 
(Maulik et al. 1996).
This diagram illustrates the mechanisms by which I/R could interact with 
NO/CO systems.
1.9 The role of HO in the cardiovascular system.
In the cardiovascular system, under normal conditions, HO-2 is the predominant 
form of the enzyme expressed in the endothelial and smooth muscle layers of 
blood vessels and in the carotid body chemoreceptors (Maines, 1997). Under 
conditions of stress, the HO-1 protein is upregulated in the atrioventricular node 
and the myocytes o f the heart, as well as in the kidney and the vasculature. This 
has been demonstrated in an in vivo model o f kidney I/R, which exhibits a 
significant increase in the expression of HO-1 in the heart and aorta (Raju & 
Maines, 1996). There is a high capacity in this system to generate CO, due to the 
high availability of the substrate haem. It is also possible that CO may contribute 
to cGMP generation in this system (Ewing et al., 1994).
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The involvement o f HO-1 in the protection of the heart and surrounding tissues 
has implications in a number of conditions and disease states. In inflammatory 
conditions such as anaphylaxis, haemin-induced HO-1 expression inhibits 
cardiac anaphylaxis by inhibiting the release o f histamine via a cGMP-dependent 
mechanism which is initiated by the generation o f CO (Ndisang et al., 2001). In a 
rat xenograft model, transplant of hearts that over-express HO-1 significantly 
increased the survival o f the xenograft, possibly due to the anti-oxidant effect o f 
bilirubin and the vasodilator capabilities of CO, which would increase blood flow 
to the new tissue (Soares et al., 1998).
HO-1 has also been implicated in the cardiovascular adaptation to hypoxic stress 
and in the resulting VSMC proliferation. For example, HO-1 knockout mice 
exposed to chronic hypoxia exhibited an increased mortality as a result o f the 
induction of right ventricular infarction (Yet et al., 1999). Therefore, the absence 
o f HO-1 produced a maladaptive response in cardiomyocytes to hypoxic insult, 
and to the resulting increase in pulmonary arterial pressure.
HO-1 may also play a role in other vascular diseases such as hypertension and 
atherosclerosis. In a rat model of angiotensin II-induced hypertension, HO-1 
mRNA and protein was upregulated in the medial smooth muscle and adventitial 
cells o f the aorta. It was also shown that angiotensin II had both pressor- 
dependent and pressor-independent effects on HO-1 regulation (Ishizaka et al.,
1997). A further study o f chronic angiotensin II-induced hypertension presented 
evidence for the expression of HO-1 in granular tissue, in inflammatory cells 
infiltrating the area, and in fibrous tissue deposition. The induction of HO-1 
expression was found to be pressor-independent and was augmented by pressure 
overload (Ishizaka et al., 2000). A major feature o f the progression of 
atherosclerosis is the induction of monocyte transmigration by mildly oxidised 
low-density lipoprotein (LDL). In a coculture system o f human aortic endothelial 
cells and smooth muscle cells, LDL significantly induced the expression of HO- 
1. However, in haemin-treated cells the induced expression o f HO-1 significantly 
attenuated LDL-induced chemotaxis of monocytes (Ishikawa et al., 1997).
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It is postulated that, as increased ROS generation and complement activation 
contribute to I/R injury, the anti-oxidant and anti-complement actions o f 
biliverdin and bilirubin could afford a protective effect (Willis, 1999). 
Furthermore, the release of CO may counteract the hypoxia experienced during 
ischaemia by relaxing coronary and aortic smooth muscles and dilating coronary 
arteries (Katayose et al., 1993). Maulik et al., (1996b) have described an increase 
in HO-1 mRNA that is dependent on the formation o f ROS, upon reperfusion of 
the ischaemic rat myocardium. This may be due to the fact that ROS released 
from mitochondria during brief hypoxia have been shown to activate signalling 
pathways essential for the protection o f cardiomyocytes against I/R injury 
(Foresti et al., 2001). This indicates that HO is not inducible by ischaemia itself, 
but rather by the oxidative stress caused during reperfusion of the ischaemic area. 
A number of cytokines that can induce the expression o f HO have also been 
measured during cardiac by-pass surgery (Maulik et al., 1996b), and may be 
involved in the up-regulation of HO under these circumstances.
In an in vivo  model of I/R injury, expression o f HO-1 protein was not 
significantly upregulated until 24 hours post-insult and peaking at 48 hours 
(Hangaishi et al., 2000). HO-1 was primarily measured in the migrating 
leukocytes, and in cardiomyocytes adjacent to the infarct zone. Haemin pre­
treatment also significantly reduced the infarct size compared with control 2 
hours post-ischaemia (Hangaishi, et al., 2000). In contrast, in an isolated rat heart 
model, pre-treatment with haemin produced a significant increase in recovery 
from ischaemic insult due to an increase in tissue bilirubin levels that was also 
seen in the presence o f exogenous bilirubin (Clark et al., 2000). There are a 
number of studies that demonstrate that HO-1 expression may provide a 
protective effect against I/R by an antiapoptotic effect on myocytes and 
endothelial cells in the affected area (Katori et al., (2002), Vulapalli et al., 
(2002)). Another study by Yet et al., (2001), investigated the effect of cardiac- 
specific expression of HO-1 on recovery from I/R injury in both in vitro  and in 
vivo  models. HO-1 over-expression increased recovery from I/R injury, 
indicating a role for HO-1 in myocardial homeostasis by protecting 
cardiomyocytes from the oxidative stress induced by I/R injury. On a cellular 
level, cardiomyocytes exposed to hypoxia-reoxygenation showed an increase in
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HO-1 protein, which did not appear to involve ROS activation. Bilirubin 
production also increased after hypoxia, but not to the same extent as HO activity 
indicating that haem availability may be a limiting factor in the recovery o f the 
tissue. This effect was augmented in cells treated with haemin (Foresti et al., 
2001).
From the evidence discussed above, it is apparent that induction o f HO-1 by I/R 
injury is an important mechanism involved in the protection o f tissues from 
damage produced by ROS. Therefore, a study by Melo et al., (2002) has 
determined a gene therapy strategy for long-term protection o f the myocardium. 
For example, rats subjected to intramyocardial delivery o f a viral vector 
containing HO-1 exhibited reduced inflammation, necrosis and infarct size from 
ischaemic insult. This was shown to be a result o f decreases in both lipid 
peroxidation and oxidative myocardial damage as a result o f increased 
antiapoptotic mediator activity, accompanied by decreases in activity o f pro- 
apoptotic mediators and pro-inflammatory cytokines. In conclusion, HO-1 
expression is important in the protection of the myocardium from many different 
oxidative insults.
1.10 HO-1 in the kidney.
The kidney is an important organ involved in the regulation o f blood pressure 
and blood purification. As HO-1 has been implicated in the control of blood 
pressure and the regulation of vascular tone, it is possible that endogenous HO-1 
may have an influence on the regulation of kidney function (Da Silva et al., 
2001). However, systolic blood pressure was not increased in a HO-1 knockout 
mouse model compared with wild-type, suggesting a role for HO-2 in blood 
pressure regulation (Wiesel et al., 2001).
A study on the distribution of isoform-specific HO expression in the kidney has 
determined that HO-2 is the predominant isoform under basal conditions. In HO- 
2-inhibited tissues, HO-1 expression increased and this was particularly noted in 
tubular and arteriolar compartments. In the cortex, HO-1 expression was 
observed in the proximal and distal tubules, while in the medulla HO-1 was
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measured in the collecting ducts and loop o f Henle (Da Silva et al., 2001). 
Further data have indicated a role for CO release in the control o f renal 
haemodynamics. HO-2-derived CO has been shown to inhibit the reactivity o f 
small renal arteries to phenylephrine (Kalab et al., 1999), and HO-1 activity is 
also regulated by angiotensin II in a flow-dependent manner (Ishizaka et al., 
1997b). Therefore, it is possible that HO-2 released CO may influence the effect 
o f other endogenous autacoids on the control o f renovascular tone under basal 
conditions. A further effect o f HO may involve the influence of CO on the 
modulation o f ion transport and salt homeostasis in the thick ascending limb of 
the kidney (Dos Santos et al., 1998).
In a model o f angiotensin II-induced renal cell apoptosis, HO-1 induction 
decreased the amount of cellular apoptosis (Aizawa et al., 2001). Therefore, HO- 
1 may exert a protective effect by controlling renal cell proliferation and 
apoptosis in the kidney. There is also evidence for the involvement o f HO-1 in 
the regulation o f vascular tone in the kidney through the release o f CO. For 
example, renal arterial vessels release CO, and this can reduce the effect of 
constrictor agonists such as phenylephrine and vasopressin on smooth muscle by 
a mechanism involving activation of the Kca channel (Kaide et al., 2001). Under 
conditions o f chronic hypoxia, HO activity is increased resulting in increased CO 
production and the exertion o f an overall vasodilatory influence in the renal bed 
(O’Donaughy & Walker, 2000).
In I/R o f the kidney, HO-1 expression is upregulated in response to a number of 
events such as reduced glutathione levels and increased ROS (Maines et al., 
1993). A further study o f this cellular response indicated that whilst HO-1 is 
upregulated in the kidney there is also an accompanying increase in HO-1 in the 
heart and aorta. This may be a response to stress induced by the increase in fluid 
volume and pressure upon reperfusion, resulting in increased expression o f HO-1 
in the stretch receptors o f the heart and baroreceptors o f the aortic arch (Raju & 
Maines, 1996). In the ischaemic kidney, HO-1 induction using a “spin-trap” was 
found to be beneficial due to the prevention of peroxidation o f kidney tissue 
lipids. The associated preservation of the tissue structure in the cortical and
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medullary regions (the areas most prone to tissue damage) was associated with 
high levels o f HO-1 and biliverdin reductase expression (Maines et al., 1999).
1.11. Aims and Objectives
As I/R is a common pathological response in coronary heart disease, myocardial 
infarction and coronary bypass surgery, it is important to address the mechanisms 
involved and provide solutions to this problem. Therefore, the properties o f HO- 
1 discussed earlier make it a prime candidate for further investigation as a 
solution to this disease.
In tissues overexpressing HO-1, it can be postulated that increased haem 
breakdown will result in an increase in bilirubin, CO and iron release. We 
hypothesised that increased HO-1 expression will facilitate increased recovery in 
cardiac function from I/R due to the anti-oxidant properties of bilirubin and 
vasodilator effects of CO, which could increase perfusate delivery to infarcted 
tissue. The overall aim o f this study is to investigate the involvement o f haemin- 
induced HO-1 in a rat heart model o f I/R.
The Langendorff rat heart model provides a useful model for the investigation of 
the in vitro  effects o f HO-1 in I/R injury. The heart can be perfused using two 
methods; the constant-flow-perfused heart (10 ml/min) allows the maintenance 
o f coronary flow whilst providing a model to investigate the effect o f HO-1 on 
coronary perfusion pressure; and the constant-pressure-perfused heart (70 
mmHg) maintains the perfusion pressure and allows the investigation o f the 
effect o f HO-1 on the coronary flow rates during I/R. The investigation o f the 
effect o f various treatments in response to I/R injury will be measured according 
to recovery from contractile dysfunction.
To investigate the effect o f HO-1 expression in a model o f I/R it is important to 
be able to induce increased expression of HO-1 in the rat heart using haemin and 
to measure HO-1 expression using immunoblot analysis. Further information on 
the mechanisms of action involved in the response to haemin under conditions of 
I/R, can be achieved by establishing a method to measure at least one o f the
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products o f the HO/Haem reaction, such as bilirubin. Thus, bilirubin will be used 
as a biochemical marker of HO activity. The involvement o f HO-1 in the 
response to I/R can also be determined using the HO inhibitor, SnPP.
The different methods of perfusion allow the investigation o f different flow- 
related parameters, thus the comparison o f the effect o f increased HO-1 
expression in both the constant-flow and constant-pressure heart models may 
produce important information regarding possible mechanisms involved in the 
response to I/R injury. Furthermore, as the degree o f injury produced by I/R is 
proportionally related to the duration o f ischaemic insult, examining the effect of 
haemin pre-treatment on recovery o f cardiac function in the constant-flow and 
constant-pressure models over increased periods o f ischaemia, (20, 30 and 40 
min) can indicate the effectiveness o f HO-1 expression in a more severe injury. 
The pro-oxidant effects of iron may also influence the protective effect of 
haemin-induced HO-1 expression, and to remove this factor the recovery from 
I/R can be further investigated in the presence o f DFO.
Finally, the effect o f haemin pre-treatment on the vascular reactivity in other 
vascular beds, such as the isolated kidney and the perfused mesenteric vascular 
bed can be investigated using tissues from previously treated rats to demonstrate 




CHAPTER 2 : Materials and Methods
2.1 Solutions
In  vitro  perfusion solutions
The Krebs-Henseleit solution for heart perfusion consisted o f the following 
(mM): potassium chloride 2.8, potassium dihydrogen phosphate 1.2, calcium 
chloride 1.25, magnesium sulphate 1.2, sodium chloride 118, sodium bicarbonate 
25 and glucose 11.1 at a pH 7.4 gassed with 95%02/5%CC>2.
Heparin solution
The heparin solution for use in the isolated tissue preparations was produced 
from heparin sulphate (bovine) dissolved in 0.9% w/v saline at a final 
concentration o f 1000 U/ml and stored at 4°C.
SDS-PAGE (Western blotting) solutions
Lysis buffer : 50 mM Tris HC1 (pH 7.5), 150 mM NaCl, 1% Nonidet P40, 10% 
glycerol, 5 mM EDTA (pH 8.0), 1 mM sodium orthovanadate, 1 mM sodium 
molybdate, 10 mM sodium fluoride, 40 jig/ml phenylmethylsulphonyl fluoride 
(PMSF), 0.7 pg/ml pepstatin A, 10 pg/ml aprotinin, 10 p.g/ml leupeptin, and 10 
p,g/ml soyabean trypsin inhibitor.
10X Tris/glycine: 30 M Tris HC1 and 144 M glycine in 1L distilled water. 
Running buffer: 10% v/v 10X Tris/glycine and 10ml 10% SDS.
Transblot buffer: 10% v/v 10X Tris/glycine and 20% v/v methanol.
SDS sample buffer : 0.5% w/v SDS, 50%v/v glycerol, 0.25 M Tris HC1 (pH 6.8), 
2-mercaptoethanol and 0.001% w/v bromophenol blue in 50ml distilled water.
IX  blocking buffer : 5% w/v Marvel (powdered milk) in PBS.
4% Stacking g e l : 1.33 ml acrylamide, 6.36 ml deionised water (Milli Q), 1.25 ml 
1M Tris pH6.8, 0.15 ml 10% SDS.
10 % Running gel : 5 ml acrylamide, 4.35 ml deionised water (Milli Q), 5.6 ml 
1M Tris pH 8.8, 0.25 ml 10% SDS.
PBS (pH 7.4): 8M NaCl, 2.9M Na2H P04.12H20 , 0.2M KC1, 0.2M KH2PC>4 in 
deionised water (Milli Q).
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2.2 The effect o f haem in-induced HO-1 expression in the constant-flow-
perfused rat heart model.
2.2.1. Experimental conditions for the perfusion o f the constant-flow-and 
constant-pressure-perfused rat heart model.
This model was first described by Langendorff (1895), where the basis of the 
model involved the cannulation of the aorta, connecting it to a reservoir 
containing oxygenated perfusion fluid. This model can be used with both 
constant-flow and constant-pressure perfusion methods. In the constant-flow 
model, a flow rate of lOml/min was selected. The main disadvantage to this 
system is that autoregulatory mechanisms are overridden and therefore the 
amount of perfusate delivered does not alter. In contrast, in the constant- 
pressure-perfused heart, the heart was perfused at a pressure of 70mmHg. This 
model was used for comparison due to its more physiological nature.
Distance between top of 
fluid in reservoir & tip of 
cannula is 100cm H ,0 . 
Therefore, producing a 
constant head o f 70mmHg 
pressure
Perfusion pressure 
transducer or flow 






Reservoir filled with 
Krebs aerated with 9? 
0 2/C 0 2, from 
peristaltic pump
%
Perfusion with Krebs @ 
constant flow o f 1 Oml/min 
by peristaltic pump
Hook into Left 
Ventricle for LVDT
Isometric transducer for 
measurement o f LVDT
Diagram 2.2.1: The Langendorff heart perfusion system.
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All animal experiments were carried out under Home Office project and personal 
licence specifications.
Male Wistar rats (270 - 320g -  Bred in house) were anaesthetised with an 
injection o f 100 mg/kg sodium pentobarbitone i.p. and given 500 U heparin i.v 
(via the rat tail vein). The heart was rapidly removed and immediately immersed 
in a small crucible of ice-cold Krebs to prevent spontaneous contraction. The 
heart was set up and perfused in the Langendorff mode via a cannula through the
aortic stump at a constant flow rate o f 10 ml/min using a peristaltic pump
+
(Watson-Marlow H.R. Flow Inducer) with a Krebs solution containing 4 mM K 
(see diagram 2.2.1). The composition o f the Krebs solution used throughout the 
study is described in section 2.2 and was aerated with 95% O J5 %  C 0 2- In the
constant-flow model, the heart was perfused at 10 ml/min for a total o f 30min. In 
the constant-pressure experiments, the heart was perfused at constant flow for 10 
min before switching to a constant pressure o f 70 or 130 mmHg for the 
remainder o f the 30 min.
The coronary perfusion pressure (CPP) was measured using a Druck pressure 
transducer (Model PDCR) attached to the side arm o f the aortic cannula with 
polyethylene tubing in the constant flow perfused heart. In the constant pressure 
model the coronary flow rate (CFR) was determined using a flow probe 
(Transonic) connected to the perfusion system before the aortic cannula. 
Measurements were recorded using Mac Lab version 3.5 on a Mackintosh 
Performa 5400/160. A hook attached to the left ventricle, and connected to an 
isometric transducer (Dynamometer UFI), was used to measure the left 
ventricular developed tension (LVDT). The resting tension of the heart was 
adjusted to 2g. The isometric transducer also triggered the measurement o f heart 
rate (HR) via a rate meter (Lectromed). The CPP, LVDT and HR were measured 
using either a 4-channel chart recorder (Lectromed Multitrace) or MacLab 
version 3.5.
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2.2 .2  Investigation o f  the expression o f  H O -1 on ischaem ia-reperfusion (I/R) 
in jury in the constant-flow  L a n g en d o rff heart model.
The enzyme HO-1 has been previously reported to be expressed as a result o f I/R 
injury (Maulik et al., 1996b), and may be protective due to the release of CO and 
biliverdin from haem breakdown. The over-expression o f HO-1 was induced in 
Wistar rats via an i.p. injection o f haemin (dissolved in 0.1 M NaOH and 
adjusted to pH 7.4) at a dose o f either 40 |imol/kg (Hangaishi et al., 2000) or 75 
|Limol/kg (Clark et al., 2000), for 18 to 24 hours respectively prior to removal of 
heart tissue. The HO inhibitor SnPP, when used, was administered at 40 (imol/kg 
i.p. 1 hour before culling the animals.
The heart was set up in the Langendorff mode and there was a stabilisation 
period o f 30 min at either a constant-flow o f 10 ml/min or a constant-pressure o f 
70 mmHg. The perfusate was collected for 1 min at 5, 10 and 15 min before 
ischaemia for the analysis of nitrite release in the constant-pressure model. The 
experiment followed either protocol 1 or 2 as illustrated in diagram 2.2.2, 
depending upon the duration o f ischaemia (i.e., 20, 30 or 40 min ischaemia). 
During the first 5 min o f reperfusion, the perfusate was collected for analysis o f 
lactate release (and nitrite levels in the constant pressure heart model). At the end 
o f reperfusion, the tissue was snap-frozen using liquid N2 for the analysis o f HO- 
1 protein levels and tissue bilirubin content.
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Protocol 1:
30min Stabilisation 20min Ischaemia 30min Reperfusion
f  t i t  Tissue superfused
j  i  a
Drug Perfusate collected with anoxic Krebs Collection o f  perfusate for
Addition 5 ,10  15 min pre- lactate and nitrite analysis
ischaemia
Protocol 2:
30min Stabilisation 30min Ischaemia 30min Reperfusion
I I I  Tissue superfused
k i
Perfusate collected with anoxic Krebs Collection o f  perfusate for
5, 10 15 min pre- lactate and nitrite analysis
ischaemia
Diagram 2.2.2
Schematic representation of the protocols employed in the constant flow and 
constant pressure heart model.
To investigate the effect of NOS or COX inhibition in the constant-flow model, 
the perfusate was changed to a Krebs solution containing 100 pM L-nitro- 
Arginine (NOS inhibitor) or 10 pM indomethacin (COX inhibitor) after the 
initial stabilisation period o f 10 min. To investigate the effect o f iron removal in 
the constant-pressure model, the heart was perfused with Krebs containing 50 
pM desferrioxamine (iron chelator) throughout the course o f the experiment.
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2.2.3. D eterm ination o f  the e ffect o f  haem in-induced H O -1 expression on 
autoregulation m echanism s o f  vascular tone in the constant-pressure rat heart.
In the constant-flow model, the flow rate cannot automatically alter the amount 
o f perfusate delivered to the heart. However in the constant-pressure model, the 
CFR can be altered and is controlled by autoregulation mechanisms.
Male Wistar rats were treated with 75 pmol/kg haemin or saline (24 hours) in the 
presence or absence o f SnPP (1 hour). The hearts were removed, cannulated in 
the constant-flow mode and perfused at constant-flow for 10 min. The perfusion 
pressure was switched to a level similar to the pressure at the end o f 10 min 
stabilisation. Therefore, control and SnPP-treated hearts were perfused at 
130mmHg constant-pressure and haemin treated hearts were perfused at 100 
mmHg constant-pressure. The pressure was increased or decreased to 120, 100, 
80 and 60 mmHg and stabilised for 1 Omin at each pressure. During the course of 
the experiment, the tissue temperature was maintained by superfusion with Krebs 
warmed to 37°C; LVDT, CFR and HR were measured throughout the 
experiment.
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2.3 Immunoblot analysis (SDS-PAGE)
The separation o f proteins on the basis of molecular size was obtained using the 
principle o f SDS-PAGE as described by Laemmli (1970).
2.3.1 Protein  extraction fro m  whole tissue
Whole heart tissue samples were homogenised using 0.1 ml-lysis buffer per 100 
mg tissue using a glass-Teflon homogeniser on ice. The resulting suspension was
centrifuged at 14,000g for 3 min. The supernatant was transferred to a sterile 1.5
0
ml tube and stored at -70 C.
2.3.2 Q uantification o f  to ta l pro tein
The protein assay o f choice was based on the Bradford dye binding principal 
(Bradford 1976). A standard curve was obtained using a stock solution o f 1 
mg/ml BSA diluted with PBS (pH 7.4) to a concentration range o f 1 pg/ml to 20 
|LLg/ml. The samples were prepared by adding 10 pi sample to 0.5 ml Bradford 
reagent and adding 200 pi o f the diluted sample or standard in duplicate to a 96 
well plate. The optical density was measured using a microplate reader at a 
wavelength o f 450 nm.
2.3.3 Sam ple Preparation
Protein from the supernatant of the tissue extract (10 pg) was transferred to a 
fresh 1.5 ml tube and resuspended in 15 pi of sample buffer. The samples were
o
heated to 85-90 C for 15 min and cooled on ice.
2.3 .4  G el production
This was carried out using the Protean II xi gel system (Bio-Rad). A minigel 
consisting o f 5 % w/v stacking gel and 10 % w/v acrylamide running gel was 
prepared by firstly pouring the running gel so that it filled about 3/4 o f the gel 
forming equipment. Once this had set, the stacking gel was poured and wells 
formed using a 9 well comb. When this had set, the gel was placed in a tank 
filled with running buffer. A molecular weight marker was prepared by adding 1 
pi broad range molecular weight marker to 19 pi o f sample buffer and loaded
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onto each gel. The total volume o f the sample to give 10 jug protein was loaded 
into each well. The gel was run at 50 V (room temperature) for approximately 30 
min, or until the bromophenol blue dye front had run into the running gel. At this 
point, the voltage was increased to 150 V for a further 30 min or until the 
bromophenol blue dye front had run to the end o f the gel.
2.3.5 Protein  transfer
Four pieces o f filter paper and a piece o f nitrocellulose membrane were cut to the 
size o f the gel. The gel, filter paper, membrane and nylon pads were assembled 
into a sandwich and soaked in transblot buffer to prevent shrinkage during the 
transblot procedure. The entire assembly was then placed inside a transblot 
cassette, which was immersed in a tank filled with cold transblot buffer, with the 
membrane adjacent to the anode. Transfer o f proteins onto membrane was 
carried out using transblot electrophoretic equipment (Biorad) at 100 V for 1 
hour. Following this, the membrane was soaked in Ponceau stain to determine 
successful transfer o f protein onto the membrane. The Ponceau was removed by 
briefly washing with water followed by washing with PBS + 1% Tween. The 
membrane was then incubated overnight in IX  blocking buffer (as described in 
section 2.2) to prevent non-specific binding.
2.3 .6  Im m unoblo t analysis f o r  the presence  o f  H O -1 p ro te in
The following washes were carried out at room temperature with gentle shaking. 
The membrane was washed in PBS + 1% Tween for two periods o f 10 min 
followed by three periods o f 10 min in PBS alone. The membrane was incubated 
with mouse anti-rat HO-1 antibody (diluted 1:1000 in blocking buffer) for 2 
hours at room temperature. A further washing period (as described earlier) was 
followed by the addition of a goat anti-mouse secondary antibody conjugated to 
horseradish peroxidase (diluted 1: 2000 in blocking buffer). After a further 
washing period, the membrane was incubated with ECL reagent for one minute. 
The membranes were drained and wrapped in cling film before exposure to 
Kodak Xomat AR5 X-ray film for between 1-4 hours.
50
2.4 Determination of tissue bilirubin content using a spectrophotometric
method based on the measurement of azobilirubin.
The measurement o f tissue bilirubin content was carried out using an adapted 
method from Van Roy et al., (1971) based on the conversion o f bilirubin to 
azobilirubin and spectrophotometric analysis at 530 nm.
2.4.1 Preparation o f  tissue hom ogenates and  bilirubin standards.
A sample o f the frozen tissue taken at the end of each experiment was weighed 
and cut up into smaller pieces. The tissue was homogenised for 2 min using 0.1 
ml-0.1 M NaOH per 100 mg tissue using a glass-Teflon homogeniser on ice. The 
resulting suspension was centrifuged at 14,000g for 3 min. The supernatant was 
transferred to a sterile 1.5 ml tube and used immediately.
Bilirubin standards were diluted from an initial stock solution of 1 mg/ml 
bilirubin made up using 0.1 M NaOH. The dilutions were made using 0.1 M 
NaOH and were kept out o f direct contact with light.
2.4.2 Preparation o f  the so lu tions required fo r  the fo rm a tion  o f  azobilirubin  
The formation o f nitrous acid requires the addition o f 0.15 ml of 100 mg/ml 
sodium nitrite to 4 ml 2M p-toluene-sulphonic acid in a sterile glass tube. The 
production of the diazo reagent involves the addition o f 2 ml o f nitrous acid to 1 
ml 100 mM 4-iodoaniline. The reaction mixture was left for 1 min at room 
temperature. After further additions o f 5 ml of distilled water, followed by 0.1 ml 
o f 1.5 M ammonium sulphamate, the reaction mixture was mixed well. The 
resulting mixture was left on ice for 5 min and used immediately.
2.4.3 The fo rm a tion  o f  azobilirubin  fro m  standard  or sam ple bilirubin.
0.1 ml o f sample or standard was added to 15 ml centrifuge tubes (Falcon) and 
followed by 0.4 ml of an acetone-ethanol (1:1 v/v) mixture. Finally, 0.1 ml o f 
diazo reagent was added to the reaction mixture and mixed well. The tubes were 
kept on ice and out o f direct light for 60 min. The reaction was stopped by 
adding stopping reagent: 0.6 ml o f 0.1 M NaCl containing 10 mg/ml ascorbic 
acid. At the same time, control samples were produced in the same way as 
reaction mixtures except that diazo reagent addition was followed immediately
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by addition o f the stopping reagent. n-Butyl acetate (1 ml) was then added to 
each tube and samples were shaken vigorously using a whirlimix (Gallenkamp) 
for 2 min. The upper layer was separated by centrifugation for 10 min at 6000 g 
and collected into cuvettes. The absorbances of samples and controls were read 
at 530 nm.
Bilirubin content was measured using the extinction coefficient (e) o f bilirubin in 
n-butyl-acetate (40 m M '1.cm'1) and the dilution factor. The results are expressed 
as pmol/g wet weight tissue.
2.5 Measurement of L-(+) lactate content in the coronary effluent of I/R rat
hearts
The method chosen for the analysis o f lactate content is based upon the method 
described by Hohorst (1965). The principle of the assay is based upon the 
following reaction:
L-(+)-lactate + NAD+ + hydrazine -(LDH) —> pyruvate hydrazone + NADH
The reaction mixture was formed as follows:
E xperim enta l Cuvette:
450 pi 0.4 M hydrazine + 1 M glycine buffer (pH 9.5), 550 pi distilled water,
50 pi Coronary effluent sample, 50 pi (5-NAD solution (40 mg/ml) and 50 U 
LDH (1,145 U/mg protein).
C ontrol Cuvette:
450 pi 0.4 M hydrazine + 0.1 M glycine buffer (pH 9.5), 600 pi distilled water,
50 pi P-NAD solution (40 mg/ml) and 50 U LDH.
The lactate content of each sample was determined by the measurement of 
NADH production at 340 nm, after an incubation o f 20 min at room temperature. 
The total lactate amount based on an extinction coefficient of 6.22 x 103 M was 
calculated as follows:
Vol. O f Sample X Absorbance @ 340 nm X 3.55 = Lactate pmol/min
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2.6 The determination of nitrite release from the perfusate of ischaemic-
reperfused rat hearts.
The method chosen for the measurement o f NO involves determination o f nitrite, 
the stable break-down product of NO. The nitrite assay selected is based upon the 
method o f Misko et al. (1993), and detects the formation o f fluorescent 1-(H)- 
napthotriazol from the reaction with 2,3 diaminonaphthalene.
2.6.1. Sam ple preparation.
The perfusate from rat hearts was collected at 5, 10 and 15 min pre-ischaemia 
and 1-5 min post-ischaemia. The samples were stored at -20°C  for no longer 
than one week before use. The samples were completely thawed at room 
temperature before use in the nitrite assay.
2.6.2 P reparation o f  S tandard  Curve
A lmM  sodium nitrite stock solution was prepared and stored in aliquots at -  
20°C prior to the start o f the assay. This stock solution was diluted with Krebs 
solution to give a final concentration range o f 0.4-3 jliM. Finally, a zero standard 
was prepared using Krebs solution alone.
2.6.3 Preparation o f  diam inonaphthalene (DAN)
A solution of 1 mg/ml of 2,3 diaminonaphthalene was made up in 0.62 M HC1, 
sonicated to dissolve and wrapped in aluminium foil. This solution was diluted in 
0.62 M HC1 to give a final concentration o f 50 |Lig/ml. The solution was then 
stored at room temperature in the dark until use.
2.6.4 P reparation o f  sam ples and  standards f o r  n itrite  assay.
For each reaction mixture, 1ml o f sample or standard was added to a disposable 
cuvette (Elkay). 100 pil o f 50 jig/ml DAN was added to each sample and mixed. 
The cuvettes were stored in the dark for 10 min to allow the reaction to occur. 
Adding 1 ml o f 0.28 M NaOH stopped the reaction. Finally, the samples were 
read using a fluorimeter (Photon Technology International, Deltascan), 
(excitation 365 nm, emission 405 nm) at room temperature. The total nitrite was 
calculated by reference to the standard curve and dilution factor, and expressed 
as pg/ml.
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2.7 The determination of the role of HO-1 expression in other vascular beds.
2.7.1 The rat iso la ted  p erfu sed  m esenteric vasculature and  p erfu sed  kidney.
Male Wistar rats (270-320 g) were pre-treated with 75 jimol/kg haemin or saline 
(24 hours) in the presence and absence o f 40 jumol/kg SnPP (1 hour all given i.p). 
The animals were anaesthetised with an injection o f 100 mg/kg sodium 
pentobarbitone i.p. and administered with 500 U heparin i.v. The abdomen was 
opened by a midline incision. For the preparation o f the perfused mesentery the 
colic artery was tied o ff and the cannulation of the superior mesenteric artery was 
achieved via the descending aorta using a Portex cannula (size 3FG). For the 
preparation o f the perfused kidney, the left kidney was cleared prior to 
cannulation o f the renal artery via the descending aorta with a Portex cannula 
(size 3FG). The mesentery and kidney were carefully separated from the 
intestines and mounted vertically in a heated water jacket at 37°C. The mesentery 
and kidney were perfused at a constant-flow o f 6  ml/min and 5 ml/min 
respectively by a peristaltic pump (Watson-Marlow 501) with Krebs-Henseleit 
solution containing 4 mM K+ (warmed to 37°C and aerated with 95% O f 5%  
CO2). The perfusion pressure was measured using a Druck PDCR75 pressure 
transducer and recorded using MacLab version 3.5 on a Macintosh Performa 
5400/160.
A stabilisation period o f 30 min was allowed before the start o f the experiments. 
All drugs were administered as a bolus injection of no more than 50 pi via an 
injection approximately 5 cm from the preparation. For the investigation of 
vasodilator substances ACh and histamine, the mesentery and kidney were pre­
contracted using 10 pM phenylephrine (PE) dissolved in Krebs solution or Krebs 
solution containing 30 mM K+ respectively, perfused for 30 min prior to the start 
of the experiment. For the investigation of the vasoconstrictor agents PE, 
endothelin-1 (ET-1) and sarafotoxin-6 C (SX6 C) (only recorded in kidney), each 
dose followed a dose cycle time o f approximately 5 min and at least 10 min 
between each dose response curve in the above order.
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Stock solutions o f PE, histamine, ET-1 and noradrenaline (Krebs solution + 
ascorbic acid) were made up using Krebs solution at a concentration o f 10 mM 
and stored at -20°C. Further dilutions were made using Krebs solution for use 
during the experiment.
2,8 Statistical analysis
All values are expressed as mean ± standard error o f the mean (SEM).
Statistical differences were compared by either Student’s t-test for comparison 
between two groups, or ANOVA (one-way) and a comparison o f means using 
Tukey’s Honestly Significant difference test when more than two groups were 
involved. Significance was measured as P<0.05.
The recovery o f cardiac function after I/R was expressed as % of the original pre- 
ischaemic value compared with the post-ischaemic value.
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2.9 Materials
Male Wistar rats (270 - 340 g) were bred in house.
Sigma supplied: acetone, acetylcholine chloride, ammonium persulphate, 
aprotinin, ascorbic acid, bilirubin, bovine serum albumin (BSA), bradykinin, 
bromophenol blue, n-butyl acetate, calcium chloride, EDTA, endothelin-1, 
glycerol, glycine, haemin sulphate, histamine, lactic dehydrogenase (LDH), 
lauryl sulphate (SDS), leupeptin, magnesium sulphate, maleic acid, 2- 
mercaptoethanol (2-ME), nonidet P40, noradrenaline, pepstatin A, 
phenylephrine, phenylmethylsulphonyfluoride (PMSF), ponceau, sodium acetate, 
sodium fluoride, sodium hydroxide, sodium molybdate, sodium nitrite, sodium 
orthovanadate, soyabean tetramethylethylenediamine (TEMED), trizma base, 




Ethanol, glacial acetic acid, glucose, K C 1,  K H 2 P O 4 ,  methanol, NaCl, 
nitrocellulose membrane and sodium bicarbonate (BDH).
Acrylamide (National Diagnostics).
Bradford protein assay reagent and broad range molecular weight marker 
(Biorad).
Mouse anti-rat HO-1 monoclonal antibody (Stressgen).
Goat anti rat conjugate antibody (Dako).
Chemiluminescent (ECL) reagent (Amersham International).
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CHAPTER 3: The role of HO-1 in the constant flow perfused rat
heart
3.1. The development of methods used throughout the investigation.
3.1.1 The determination of the effect of haemin and SnPP treatment on HO-1 
expression in the rat heart
HO-1 expression can be induced by a number of stimuli such as cytokines, 
hypoxia, metal ions, glutathione removal and haemin. For the purpose of this 
study, HO-1 expression was induced using an i.p. injection of haemin. A 
previous study comparing the effects of 40 (imol/kg haemin (18 hours) and 75 
pmol/kg haemin (24 hours) (Data not shown) on HO-1 expression in the rat heart 
found the higher dose of 75 pmol/kg haemin produced a larger increase in HO-1 
expression. The effect of the HO inhibitor SnPP on HO-1 expression was 
investigated using immunoblot analysis with an anti-rat HO-1 antibody (Fig 
3.1.1).
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Figure 3.1.1
The effect of haemin pre-treatment on HO-1 expression in the rat heart.
Rats were treated with saline (1 & 2), 75pmol/kg haemin (24hours) (3 &4), 75 gmol/kg haemin +
40|imol/kg SnPP (5 &6) and 40pmol/kg SnPP alone (7 & 8).
Hearts were frozen using liquid nitrogen after 30min perfusion followed by 20min global
ischaemia and finally 30min reperfusion.
The results clearly demonstrate that 75 pmol/kg haemin produces an increase in 
HO-1 expression (3 & 4) compared with control (1 & 2). However, SnPP 
treatment (in the presence of haemin, 5 & 6 ) did not affect HO-1 protein levels. It 
is also important to note that SnPP alone did not induce HO-1 protein expression 
(7 & 8 ). The data presented in figure 3.1.1 are representative of the increase in 
HO-1 expression observed throughout the study. Analysis of HO-1 protein levels 
was carried out after each experiment with the same result.
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3.1.2 The evaluation of the method selected for the determination o f tissue
bilirubin levels.
The initial experiment involved the determination o f a standard curve o f bilirubin 
over a range of 0-100 Jig/ml. This was achieved by following the protocol 
described by Van Roy et al. (1971). Bilirubin was extracted from the sample and 
converted into azobilirubin, whose absorbance could be measured 
spectrophotometrically at 530 nm. The bilirubin was dissolved in 0.1 M NaOH at 
an initial concentration of 1 mg/ml, and further dilutions were made to cover a 
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Figure 3.1.2
A standard curve for bilirubin over a range of 0-100 pg/ml.
A series of bilirubin solutions covering the range of 0-100 fig/ml were converted into azobilirubin 
and measured at 530 nm. Values were measured mean ± SEM after conversion to azobilirubin, 
where n=4. Note: some errors fall within symbol size.
This initial experiment demonstrated that the bilirubin concentration o f a stock 
solution could be determined using the method selected. The next step was to 
determine if  bilirubin could be measured from a homogenised tissue sample. The 
original data (not shown) demonstrated that bilirubin was not detected in spleen 
tissue, although this tissue is reported to have a high level of HO-1 expression 
(Maines, 1997). The following experiment was used to compare the effect o f a
59
bilirubin stock solution dissolved either in lysis buffer and 0.1M NaOH on the
detection o f bilirubin levels (Figure 3.1.3).
0.9 - Lysis Buffer A 
-B -  Lysis Buffer B 
-e -N a O H A  












Concentration of Bilirubin (pg/ml)
Figure 3.1.3
The comparative effect of lysis buffer or 0.1 M NaOH on bilirubin measurement.
Values are expressed as mean ± SEM (errors fall within size of symbol), on two separate 
occasions denoted as A and B, (n=4).
The data described in figure 3.1.3 demonstrates that bilirubin may dissolve more 
readily in NaOH than lysis buffer or that other elements of the lysis buffer 
affected absorbance. Furthermore, the data is also fairly reproducible as indicated 
by similar results achieved on two separate occasions (A and B). Therefore, in all 
subsequent test, tissues were homogenised in 0.1 M NaOH.
The final experiment investigated the efficiency o f the assay by measuring a 
known concentration o f bilirubin added to a homogenised tissue sample (Figure 
3.1.4). The “spike” test demonstrates the accuracy of the assay, by measuring a 
known amount o f bilirubin extracted from a tissue sample. A bilirubin solution of 
100 |Lig/ml bilirubin produced an absorbance o f 0.382±0.05 (n=4), compared with 
0.586±0.01 (n=4) in samples containing spleen and bilirubin, and 0.262±0.04 
(n=4) for spleen alone (see methods pg 51). Therefore, extraction of bilirubin 
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□  Spleen Alone____________
Figure 3.1.4
The accuracy of the Azobilirubin assay as measured by the extraction of a known bilirubin 
concentration from a tissue sample and compared with the absorbance of the tissue sample alone. 
Values are expressed as mean±SEM, (n=4).
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3.2 The effect of haemin pre-treatment on the recovery from I/R in the
constant-flow perfused rat heart.
The effect o f haemin on the recovery o f cardiac function after I/R was 
investigated to determine whether any potential increase in HO-1 activity might 
offer protection. It is possible that the increase in haem breakdown and the 
accompanying increase in HO by-products may act to “pre-condition” the tissue, 
and thereby improve the recovery from I/R in the constant-flow-perfiised rat 
heart model. In addition, the effect o f haemin-induced HO-1 expression was also 
measured in the pre-ischaemic heart.
3.2.1 A representative description of the experimental procedure and 
observations / measurements made during procedure.
The traces shown in Figures 3.2.1 A and 3.2. IB are representative o f the standard 
I/R (20 min ischaemia/ 30 min reperfusion) experiment under constant-flow 
conditions in haemin-treated and control hearts respectively. The hearts were set 
up as described in section 2.2; during the initial 30 min o f perfusion, the CPP 
increased and eventually stabilized at around 100 mmHg (section A-trace). The 
heart rate remained relatively constant throughout initial perfusion stage even 
during the adjustments to basal tension (section B-trace). Finally, the developed 
tension remained low for about 5-10 min and basal tension was adjusted until at 
the 30 min stage developed tension stabilized at around 6 -8 g (section C-trace). 
During zero flow global ischaemia there were no measurements o f CPP. There 
were some small contractions that triggered the rate-meter during the first 2-3 
min of ischaemia. After 20 min ischaemia, the perfusate was re-introduced and 
contractions developed within the first two min. As this is a haemin-treated heart 
the contractions are large enough to trigger the rate-meter. Unfortunately, 
contractile recovery is very poor in control hearts and the rate meter was not 
triggered making it difficult to compare HR data. The developed tension, CPP 




This trace is representative of the experimental conditions and observations in a haemin-treated heart perfused at a constant- 
flow of lOml/min. The CPP (section A), heart rate (section B) and LVDT (section C) were measured throughout the initial 




This trace is representative of the experimental conditions and observations in a control heart perfused at a constant-flow of 
lOml/min. The CPP (section A), heart rate (section B) and LVDT (section C) were measured throughout the initial 
stabilisation period, 20min ischaemic insult and 30 min reperfusion.
Ischaemia Reperfusion
3.2.2. Pre-ischaemia
After a stabilization period o f 30 min, CPP in control hearts was recorded as 
141.3±3.6 mmHg (n=5), compared with 131.3±7.2 mmHg and 99.8±13.5 mmHg 
after 40 pmol/kg and 75 pmol/kg haemin treatment respectively (figure 3.2.2A). 
Therefore, haemin pre-treatment reduced CPP in a dose dependent manner. 75 
pmol/kg haemin, the highest dose used, significantly decreased CPP compared 
with control (p<0.05, n=5). This suggests that there is a vasodilator component 
involved in the response o f the pre-ischaemic rat heart to haemin pre-treatment. 
The HO inhibitor SnPP abrogated the effect o f haemin on CPP, while having no 
effect on its own. Therefore, these data implicate HO in the vasodilator response 
to haemin. Haemin pre-treatment had no significant effect on the developed 
tension compared to control (5.65±lg) (Fig 3.2.2B). In contrast, SnPP alone 
significantly increased contractility, which implicates that HO-l/HO-2 may be 
involved in the control o f endogenous contractility o f the constant-flow-perfused 
rat heart.
At the end of the initial 30 min perfusion period, haemin pre-treatment at either 
dose did not significantly affect the heart rate (270±18 BPM after 40 pmol/kg 
haemin compared with 284.6±18 BPM for 75 pmol/kg haemin) o f the tissue 
compared with control (285.8±19 BPM) (Figure 3.2.3A). Interestingly, there was 
no variation in the response to haemin after SnPP treatment (272.5±12 BPM) but 
tissues exposed to SnPP treatment alone demonstrated a significant increase in 
HR compared with control (362.5±112 BPM, p<0.05, n=5). These data contrast 
with the results observed in figure 3.2.2B, where SnPP alone significantly 
increased LVDT compared with control levels. Therefore, there is strong 
evidence that HO has a significant influence on the contractility o f the rat heart in 
this system. At this stage it is unclear by which mechanism (s) HO may exert 
such an effect. The measurement of the basal tension is an indication o f potential
I
Ca overload. During the equilibration interval, haemin and SnPP pre-treatment 
did not significantly affect basal tension (Figure 3.2.3B). Therefore, these data 
suggest that after haemin and/or SnPP treatment, the heart is stable and viable for 







































1 -  
0
B  Control
□  4 0  M-mol/kg H aem in
□  75  nm ol/kg H aem in
□  7 5  nm ol/kg H aem in + 4Q im ol/kg  
S n P P
□  4 0  |im ol/kg S n P P
Figure 3.2.2
The effect of haemin and SnPP pre-treatment alone and in combination on CPP (A) and LVDT 
(B) in the pre-ischaemic rat heart. Haemin doses are as follows; 40 pmol/kg haemin (18hour) and 
75 umol/kg haemin (24hour), 40 pmol/kg SnPP (lhour) or 75 pmol/kg haemin + 40 pmol/kg 
SnPP. Values are expressed as mean±SEM, where * is p<0.05 compared with control (n=5).
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The effect of haemin and SnPP pre-treatment alone and in combination on Heart Rate (A) and 
basal tension (B) in the pre-ischaemic rat heart. Haemin doses are as follows; 40 pmol/kg haemin 
(18hours) and 75 umol/kg haemin (24hours), 40 pmol/kg SnPP (lhour) or 75 pmol/kg haemin + 
40 pmol/kg SnPP. Values are expressed as mean±SEM, where * is p<0.05 compared with control 
and ** p<0.05 compared with 75 pmol/kg haemin (n=5).
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3.2.2. The response o f  the rat heart to haemin pretreatment post ischaemia.
After a period of 30 min stabilization, hearts were subjected to 20 min ischaemia 
followed by 30 min reperfusion to investigate the effect o f HO-1 induction on the 
recovery of cardiac function after I/R. Haemin pre-treatment produced a dose 
dependent reduction in CPP throughout reperfusion compared with control. This 
confirms the data recorded prior to ischaemia, where the higher dose o f 75 
pmol/kg haemin significantly decreased CPP compared with control for the 
entire 30 min (see figure 3.2.4A) (p<0.05, n=5). In conclusion, haemin pre­
treatment significantly decreased CPP during reperfusion indicating a vasodilator 
response. The addition o f SnPP had no significant effect. These data indicate that 
the vasodilator effect is not dependent upon ischaemic insult as it was 
demonstrated in both the pre- (Fig 3.2.2A) and post-ischaemic periods. It is 
possible that a HO-1-mediated reduction in CPP may not be the only mechanism 
involved. The CPP values o f SnPP and control hearts during reperfusion did not 
significantly differ, indicating that endogenous HO is unlikely to be involved in 
the pathological response to I/R.
The recovery o f cardiac contractility during reperfusion was measured as the %  
recovery of the contractility o f the tissue (after 30 min reperfusion) compared 
with the pre-ischaemic value. Haemin pre-treatment increased the recovery of 
cardiac contractility during reperfusion in a dose-dependent manner (20 ± 6 .7%  
after 40 pmol/kg haemin, and 45.3 ± 8.7% after 75 pmol/kg haemin) compared 
with control (14.3 ± 4.5%) (figure 3.2.4B). The highest dose of haemin 
significantly increased recovery compared with control (p<0.05, n=5). SnPP 
treatment did not significantly affect the recovery o f contractility in either the 
presence or absence of haemin (27.3 ± 13.8% and 7.2 ± 3.3% respectively). In 
conclusion, HO-1 induction significantly increases recovery o f cardiac function 
after I/R, but it is as yet unclear if  HO-l/HO-2 is involved in the endogenous 
response to I/R. The effect of I/R on HR could not be determined due to the lack 
of data from the rate meter, which was not triggered consistently by the 
developed tension recorded.
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Figure 3.2.4
The effect of haemin and SnPP pre-treatment alone and in combination on CPP (A) and recovery 
of LVDT (B) during reperfusion (30min).
Hemin doses are as follows; 40 |iimol/kg haemin (18hour) and 75 umol/kg haemin (24hour), 40 
|Limol/kg SnPP (lhour) or 75 pmol/kg haemin + 40 pmol/kg SnPP. Values are expressed as mean 
+ SEM, where * p<0.05 compared with control (n=5).
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Treatment with SnPP in the presence o f haemin significantly reduced basal 
tension compared with control and haemin alone. Thus, it is possible that in 
combination, haemin + SnPP treatment produces an additive effect. As this effect 
is not paralleled by the recovery o f cardiac function this may be an indirect effect 
of haemin and SnPP treatment, as opposed to being due to HO-1 induction and 
consequent inhibition (Figure 3.2.5A).
At the end o f reperfusion, the tissue was frozen using liquid N2 and stored at - 
80°C for the measurement o f tissue bilirubin levels (Figure 3.2.5B). 40 pmol/kg 
haemin did not have any effect on bilirubin production compared with control. In 
contrast, 75 pmol/kg haemin significantly increased bilirubin production (6.4 ± 
0.6 pmol bilirubin/g wet weight tissue) compared with control (3.5 ± 0.6 pmol 
bilirubin/g wet weight tissue, where * p<0.05, n=5). The addition o f 40 pmol/kg 
SnPP did not significantly reduce the amount o f bilirubin measured after haemin 
pre-treatment (5.1 ± 1.1 pmol bilirubin/g wet weight tissue). SnPP alone also 
failed to significantly reduce tissue bilirubin levels (2.5 ± 0.9 pmol bilirubin/g 
wet weight tissue) compared with control. Tissue bilirubin levels are an 
indication o f HO activity and provide a possible mechanism for the protective 
action o f HO-1. These data show that pre-treatment with high doses o f haemin 
significantly increased tissue bilirubin production. This is likely to be due to the 
increased availability o f substrate, as haemin is a known inducer of HO-1 
because it is the common substrate o f the HO-mediated reaction producing a 
1:1:1 ratio o f bilirubin, CO and iron.
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Figure 3.2.5
The effect of haemin and SnPP pre-treatment alone and in combination on basal tension (A) and 
tissue bilirubin levels (B) during reperfusion.
Rats were pre-treated with i.p. injections of saline, 40 pmol/kg and 75 pmol/kg haemin, plus 40 
pmol/kg SnPP (in the presence of haemin or alone). Values are expressed as mean ± SEM, * 
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Figure 3.2.6
The effect of 75 pmol/kg haemin pretreatment (24h) on lactate washout in the I/R rat heart during 
the first 5 min of reperfusion.
Rats were pre-treated with saline or 75 pmol/kg. Values are expressed as mean ± SEM (n=5).
During ischaemia, lactate accumulates extracellularly as a result o f increased 
anaerobic glycolysis and decreased wash out. Therefore, upon reperfusion lactate 
can be washed out, and measurement o f this release is an indication o f anaerobic 
glucose utilization. Hence, if  pre-treatment with haemin were to protect the heart 
by increasing anaerobic glycolysis and ATP production, one might expect an 
increase in lactate washout during the initial stages o f reperfusion. As shown by 
measuring the total amount o f lactate, and also by its rate of removal, the actual 
data from control and haemin-treated hearts suggest that haemin does not affect 
lactate production, as demonstrated by the rate o f removal and total lactate 
amounts. Therefore, the exact mechanism by which haemin can protect against 
I/R injury is as yet unclear, but it appears that it affects neither anaerobic 
glycolysis nor the production o f lactate during ischaemia.
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3,3 The effect of NOS inhibition on haemm-induced recovery in the I/R rat
heart.
3.3.1 The effect o f NOS inhibition in the pre-ischaemic heart.
We investigated the potential role o f other vasoactive mediators in the response 
to haemin pre-treatment in the pre-and post-ischaemic heart. The results from the 
experiments in 3.2 indicate that SnPP does not completely inhibit the response to 
haemin on CPP in the pre- and post-ischaemic heart. This may be due to 
insufficient inhibition o f HO-1 with the selected dose o f haemin or the possible 
involvement o f other factors in the CPP response to haemin. It is important to 
note that 3 o f the total 8  hearts pre-treated with haemin and further perfused with 
L-NO-Arg exhibited ventricular fibrillation after the initial 5-10 min o f exposure 
to L-NO-Arg.
L-NO-Arg was introduced to the perfusate after the initial 10 min of perfusion. 
Interestingly, L-NO-Arg did not have any significant effect on CPP in control 
hearts (Figure 3.3.1 A). This may suggest that there is very little basal NO 
production in this system. The addition of 100 jiM L-NO-Arg significantly 
increased CPP in haemin-treated tissues compared with those treated with 
haemin alone (p<0.05, n=5). The addition o f L-NO-Arg prior to ischaemia did 
not have any significant effect on LVDT compared with control or haemin 
treatment after 30 min stabilization (figure 3.3.IB). As L-NO-Arg did not alter 
CPP it is unlikely that changes in LVDT are caused by vasodilation.
Inhibition o f NO production by L-NO-Arg does not have any significant effect 
on heart rate compared with control (Figure 3.3.2A). Therefore, these data 
parallel the results in figure 3.3.IB, where L-NO-Arg had no effect on 
contractility. This is in agreement with the data in figure 3.3.2A, as NO does not 
appear to be involved in the control o f contractility and heart rate in control or 
haemin treated hearts perfused at constant-flow. The inhibition o f NOS in control 
and haemin-treated hearts did not significantly affect basal tension compared 
with control and haemin-treated hearts respectively (Figure 3.3.2B). This 
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F ig u re  3.3.1
The effect of ' “ r_1.1 L-NO-Arg on pre-ischaemic CPP (A) and LVDT (B) in control and haemin 
pre-treated rat hearts perfused at constant-flow.
Rats were treated with 75|imol/kg haemin and saline (24hours) and L-NO-Arg was introduced to 
perfusate after initial 10 min of perfusion. Values are measured at the end of the 30min 
stabilization period and expressed as the mean ± SEM. * p<0.05 compared with control and # 
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Figure 3.3.2
The effect of 1 OOfiM L-NO-Arg on pre-ischaemic heart rate (A) and basal tension (B) in control 
and haemin-treated rat hearts.
Rats were pre-treated with saline or 75 pmol/kg haemin (24hours) and L-NO-Arg was introduced 
to perfusate after the initial 10 min perfusion. Values were measured at the end of the 30min 
stabilization period and are expressed as mean ± SEM (n=5).
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3.3.2 The effect o f NOS inhibition on the recovery o f cardiac function after I/R 
in haemin-treated rat hearts.
The addition o f L-NO-Arg significantly reduced CPP in control hearts (see 
Figure 3.3.3A, where t= 6-10 min o f reperfusion). Haemin-treated hearts exhibit 
a significant reduction in CPP post-ischaemia. In the presence o f L-NO-Arg, the 
reduction in CPP produced by haemin treatment is significantly attenuated 
(p<0.05, where t= 2-26 min, n=5) to levels similar to those o f control samples. 
Consequently, there appears to be an element o f NO involvement in the 
vasodilator response to HO-1 in the rat heart perfused at constant-flow. The 
effect o f L-NO-Arg on the haemin-induced CPP was reduced after 26 min of 
reperfusion, suggesting that the mediator(s) involved in the response to haemin 
pre-treatment were washed out or had ceased to be produced by this stage of the 
reperfusion period.
Inhibition o f NOS did not have a significant effect on recovery o f contractility 
after I/R compared with control. Furthermore, inhibition o f NOS did not 
significantly affect the improved recovery o f LVDT associated with haemin pre­
treatment, although there are large error bars (Figure 3.3.3B). In conclusion, 
NOS inhibition with 100 pM L-NO-Arg does not prevent the protection of 
LVDT during reperfusion induced by haemin pre-treatment. There is a 
significant increase in CPP in haemin-treated hearts in the presence o f L-NO- 
Arg, which suggests that although NO is involved in the vasodilator response to 
haemin, this effect may not influence the degree o f recovery o f LVDT.
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Figure 3.3.3
The effect of 100p.M L-NO-Arg on CPP (A) and recovery of LVDT (B) post-I/R in control and 
haemin pre-treated rat hearts.
Rats were pre-treated with saline or haemin (24hours). Values are expressed as mean ± SEM. * 
where p<0.05 compared with control, # p<0.05 Haemin + L-NO-Arg compared with haemin 
alone and ** L-NO-Arg compared with control (n=5).
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Figure 3.3.4
The effect of 100|iM L-NO-Arg on post-ischaemic basal tension (A) and tissue bilirubin 
production (B) in control and haemin-treated rat hearts.
Rats were treated with saline or 75(J.mol/kg haemin (24hours). Values are expressed as mean ± 
SEM, where * p<0.05 compared with control and # p<0.05 compared with haemin (n=5).
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After I/R, L-NO-Arg did not significantly affect basal tension in control or 
haemin-treated hearts (Figure 3.3.4A). This suggests that inhibition o f NOS does
9-1-not have a significant effect on the induction o f Ca overload after I/R. 
Furthermore, these data, in combination with figure 3.3.3A, suggest that L-NO- 
Arg does not inhibit the protection conferred by haemin pre-treatment on I/R 
injury, as it does not significantly increase the basal tension. Calculation of tissue 
bilirubin levels indicates that L-NO-Arg does not appear to affect the increase in 
tissue bilirubin levels induced by haemin pre-treatment, although large errors are 
apparent (Figure 3.3.4B). This is in association with the finding that NOS 
inhibition does not significantly affect the degree o f recovery from I/R (Figure 
3.3.3B). The results from figure 3.3.5 indicate that inhibition of NOS has no 
significant effect on lactate washout after I/R as measured after each minute, 
compared with control or haemin hearts, but there is a significant reduction in 
total lactate release in the presence o f L-NO-Arg (p<0.05). Hence, inhibition of 
NO production significantly reduces the anaerobic glucose metabolism of the 
tissue after I/R, as shown by the reduction of total lactate levels.
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Haemin + L-NO-Arg: 20.3±7|imol
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Figure 3.3.5
The effect of 100(iM L-NO-Arg on lactate washout in the I/R rat heart.
Rats were pre-treated with saline or 75 pmol/kg haemin (24hours). The tissues were exposed to a 
20 min ischaemic period and upon reperfusion the perfusate was collected for the initial 5 min for 
lactate analysis. Mean ± SEM, * p<0.05 compared with control. Note: a negative value was 
observed at t=5 min in the presence of L-NO-Arg.
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3.4 Determination of the influence of COX products on haemin-induced
recovery of cardiac function post I/R.
3.4.1 The effect o f COX inhibition in the pre-ischaemic rat heart.
The initial experiments reported in section 3.3 suggested that factors other than 
NO might be involved in the vasodilator response observed in pre- and post- 
ischaemic rat hearts treated with haemin. The following experiment investigated 
the possible effect o f COX products on the response to haemin pre-treatment in 
the pre- and post-ischaemic rat heart.
Indomethacin treatment did not significantly affect CPP in pre-ischaemic control 
hearts. However, there did appear to be a small reversal o f the haemin-induced 
response in the presence o f indomethacin. Furthermore, the use o f indomethacin 
as a COX inhibitor did not induce any significant effect on the dilator response to 
haemin in the pre-ischaemic heart (Figure 3.4.1 A). In contrast to the CPP data, 
haemin-treated hearts perfused with 10 jiM indomethacin exhibited a significant 
increase in LVDT compared with hearts treated haemin alone, (p<0.05 and n=5, 
Fig 3.4.IB). This suggests that COX products may be involved in the control of 
contractility in haemin-treated hearts. As there was no significant effect on CPP, 
this is unlikely to influence the force o f contraction.
Indomethacin did not significantly affect HR in control hearts. COX inhibition 
after haemin pre-treatment significantly reduced heart rate compared with control 
and haemin-treated hearts (p<0.05, n=5, Figure 3.4.2A). The reduction in heart 
rate may be a response to an increase in contractility (Figure 3.4.IB) or vice 
versa. The data in figure 3.4.2B indicate that inhibition o f COX using 
indomethacin did not significantly affect basal tension in the pre-ischaemic heart 
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Figure 3.4.1
The effect of 10|iM indomethacin on pre-ischaemic CPP (A) and LVDT (B) in control and 
haemin-treated rat hearts.
Rats were pre-treated with saline or 75 pmol/kg haemin (24hour). Values were measured at the 
end of the 30 min stabilization period and are expressed as mean ± SEM, * p<0.05 compared 
with control and # p<0.05 compared with haemin alone (n=5).
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Figure 3.4.2
The effect of IOjiM indomethacin on pre-ischaemic heart rate (A) and basal tension (B) in control 
and haemin-treated rat hearts.
Male wistar rats were pre-treated with saline or 75 pmol/kg haemin (24hour). Values were 
measured at the end of 30 min stabilization and are expressed as mean ± SEM, where * p<0.05 
compared with control hearts and haemin treated hearts.
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3.4.2 The effect o f  COX inhibition on recovery o f  cardiac function in haemin-
treated rat hearts.
After a 20 min period o f global ischaemia, indomethacin significantly reduced 
the vasodilator component o f the response to haemin pre-treatment during the 
first 12 min o f reperfusion (Figure 3.4.3A). This is in contrast with the data 
recorded in the pre-ischaemic heart. Therefore, it is possible that COX products 
are only significantly involved in the vascular response to I/R, rather than under 
basal conditions, in this system. However, the profile is similar to that observed 
in the presence o f L-NO-Arg (Figure 3.3.3A), where the significant effect is the 
inhibition of a vasodilator mediator involved in the response to haemin pre­
treatment during the early response to I/R.
Indomethacin had no significant effect on the recovery o f control hearts, 
suggesting that this is a haemin-induced response, and that COX products may 
not be involved in the endogenous response to ischaemic insult in this system. 
The inhibition o f COX significantly abrogated the improved recovery of 
contractility after I/R conferred by haemin (Figure 3.4.3B). These data suggest 
that COX products are involved in the recovery o f contractility conferred by 
haemin pre-treatment. This confirms the pre-ischaemic data, as COX products 
appear to be involved in the regulation of contractility in haemin-treated hearts. 
Indomethacin treatment did not significantly affect the basal tension compared 
with either haemin or control (Figure 3.4.4A).
Indomethacin treatment did not significantly affect tissue bilirubin levels in 
control hearts (Figure 3.4.4B). The addition o f indomethacin to the perfusate of 
haemin treated hearts significantly increased tissue bilirubin levels compared to 
control and haemin alone. Hence, these data may implicate the involvement of 
COX products in the regulation o f tissue bilirubin levels in haemin-treated hearts. 
These data do not directly correlate with those seen in figure 3.4.3B, where 
indomethacin significantly reduces the recovery o f cardiac contractility conferred 
by haemin pre-treatment.
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Figure 3.4.3
The effect of COX inhibition using 10pM indomethacin on post-ischaemic CPP in control and 
haemin-treated rat hearts.
Rats were pre-treated with saline or 75pmol/kg haemin (24hour). Values are expressed as mean ± 
SEM. * where p<0.05 compared with control or # where p<0.05 compared with haemin alone 
(n=5). Note: some errors may within the symbol.
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(A) Basal tension during reperfusion
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Figure 3.4.4
The effect of COX inhibition using 10(iM indomethacin on basal tension (A) and tissue bilirubin 
levels (B) after I/R in control and haemin -treated rat hearts.
Rats were treated with saline or 75 pmol/kg haemin (24hour). Values are measured at the end of 
30 min reperfusion and expressed as mean ± SEM. * p<0.05 compared with control and # p<0.05 
compared with haemin (n=5).
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Figure 3.4.5
The effect of COX inhibition using 10|iM indomethacin on lactate wash-out during the first 5 
min of reperfusion in control and haemin-treated rat hearts.
Male wistar rats were treated with saline or 75 (imol/kg haemin (24hour). The perfusate was 
collected during the initial 5 min for the calculation of lactate content. Values are expressed as 
mean ± SEM (n=5). Note: some errors fall within symbol size.
The addition o f indomethacin did not significantly affect the rate o f lactate wash­
out or total lactate release during reperfusion after an ischaemic insult o f 20 min 
(Figure 3.4.5). The recovery of cardiac function throughout the series of data 
does not appear to be accompanied by any change in lactate levels.
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3.5. The effect of increasing ischaemic period on haemin-induced recovery of
cardiac function after 30mins I/R.
The effect o f haemin pre-treatment on the recovery o f cardiac function after an 
ischaemic insult o f 30 min was investigated to determine whether the protective 
effect post I/R is dependent upon the length o f ischaemic insult and thus to 
answer the following questions: firstly, does the dose o f haemin used offer 
sufficient protection after a more severe ischaemic injury where it is possible that 
irreversible injury may be caused? And secondly, could we repeat the result 
described by Clark et al. (2000), from which our dose o f haemin was selected, 
where haemin offered significant protection from 30 min I/R.
Interestingly, the CPP measured in control hearts is not different after 20 and 
30min ischaemia (Figure 3.5.1 A), whereas the increase in ischaemic insult 
significantly increases CPP in haemin-treated hearts compared with 20 min 
ischaemia. Therefore, it is possible that increasing ischaemia may affect the 
vascular responsiveness of the tissue, as illustrated by the abolition o f the 
vasodilator response to haemin treatment. In addition, the recovery of 
contractility does not significantly differ in control hearts exposed to 20 or 30 
min ischaemia followed by reperfusion (Figure 3.5.IB), while the recovery of 
contractility induced by haemin pre-treatment is significantly reduced after 
increasing the ischaemic period to 30 min. The reperfusion period is the same in 
both experiments, suggesting that the destructive element must by produced 
during ischaemia. After 30 min I/R there was a significant increase in basal 
tension compared with 20 min I/R in control hearts (Figure 3.5.2A), although 
there was no significant difference in haemin-treated hearts after 20 or 30 min 
ischaemia. This indicates that increasing ischaemia in control hearts potentiates 
Ca2+ overload as measured by basal tension. This result is as expected, as basal 
tension and Ca2+ overload would be expected to increase as the duration of 
ischaemic period increases. The data in figure 3.5.2B shows that after 30 min 
ischaemia, haemin pre-treatment does not significantly increase tissue bilirubin 
levels compared with control. It can be postulated that the reduced recovery of 
cardiac function after a lengthened ischaemic period may be due to a reduction in 
the levels o f bilirubin.
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Figure 3.5.1
The effect of increasing the ischaemic period on CPP (A) and recovery of LVDT (B) during 
reperfusion after a 20 or 30 min ischaemic insult in control and haemin-treated hearts.
Male wistar rats were pre-treated with saline or 75 fimol/kg Haemin (24hour). Values are 
expressed as the mean ± SEM, * where p<0.05 compared with control (0=5). Note: some error 
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Figure 3.5.2
The effect of increasing ischaemic period on basal tension (A) and tissue bilirubin levels (B) in 
control and haemin-treated hearts.
Male wistar rats were treated with saline or 75 pmol/kg haemin (24hour) prior to removal of 
heart. Values are expressed as mean ± SEM. * where p<0.05 compared with control and ** 
p<0.05 compared with haemin (20min I/R) (n=5).
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Figure 3.5.3
The effect of increasing ischaemic period on lactate washout during the first 5 min of reperfusion 
in control and haemin-treated hearts.
Male wistar rats were treated with saline or 75 |imol/kg haemin (24hour) prior to removal of 
heart. Values are expressed as mean ± SEM (n=5) and *p<0.05 compared with control hearts 
after 20mins ischaemia. Note: some errors fall within the symbol size.
The increase in duration o f ischaemic period did not significantly affect the 
washout o f lactate over each minute during the first 5 min o f reperfusion in either 
treatment group, but there was a significant increase in the total lactate amounts 
present in control hearts after 30 min I/R. Therefore, it is possible that haemin 
treatment may not affect anaerobic glycolysis as there is no increase in lactate 
production after 30 min I/R.
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3.6 Chapter 3: Summary
• 75jnmol/kg haemin pre-treatment successfully increased HO-1 protein 
expression in the rat heart
•  Haemin pre-treatment significantly reduced CPP in the pre-ischaemic rat 
heart; this is indicative o f a vasodilator response.
• SnPP alone significantly increased contractility and heart rate and SnPP 
significantly reduced basal tension in the presence or absence o f haemin.
« Haemin pre-treatment significantly increased recovery of cardiac function
after 20 min ischaemia and 30min reperfusion and also produced a significant 
reduction in CPP during reperfusion.
• SnPP did not completely inhibit the effect haemin pre-treatment in either the 
pre- or post-ischaemic rat heart.
• Haemin induced recovery o f contractility was linked to an increase in tissue 
bilirubin content.
• Increasing ischaemic period to 30 min significantly reduced recovery in 
control and haemin-treated hearts. This was associated a significant increase 
in tissue bilirubin content o f haemin-treated hearts and the complete abolition 
o f the vasodilator response during reperfusion o f haemin-treated hearts.
• L-NO-Arg significantly increased CPP in haemin-treated hearts, but did not 
affect CPP in control hearts.
• L-NO-Arg significantly increased CPP in haemin-treated hearts during the 
initial 20 min o f reperfusion, but this was not accompanied by a reversal of 
the improved recovery o f contractility in haemin-treated hearts.
• Indomethacin did not affect CPP but significantly increased contractility and 
reduced heart rate in pre-ischaemic haemin-treated hearts.
•  After 20 min ischaemia, indomethacin significantly reduced recovery of 




THE ROLE OF HO-1 IN THE CONSTANT- 
PRESSURE-PERFUSED RAT HEART
92
CHAPTER 4; The role of HO-1 in the constant pressure perfused
rat heart
4.1 The effect of haemin and SnPP pre-treatment on the pre-ischaemic rat 
heart perfused at a constant pressure of 70mmHg.
The following experiments were carried out to determine the vascular effect of 
haemin pre-treatment in the pre-and post-ischaemic rat heart perfused under 
conditions o f constant pressure. The constant pressure heart model allows 
investigation o f the effect o f haemin pre-treatment on the control o f coronary 
flow in a perfusion system where the endogenous coronary autoregulation 
mechanisms remain active.
4.1.1 A representative trace o f the experimental procedure and observations / 
measurements made during procedure.
The representative traces demonstrated in figure 4.1.1 A and 4.1.IB, indicate the 
procedure involved in the experiments at constant-pressure in haemin-treated and 
control hearts respectively. The hearts were set up and perfused at a constant 
flow of 10 ml/min for 10 min. The method of perfusion was then converted to a 
constant pressure o f 70 mmHg. Contractility/LVDT (A), heart rate (B) and 
coronary flow rate (CFR) were measured throughout the experiment.
After a total o f 30 min stabilization, the heart was subjected to 20 min zero-flow 
global ischaemia. In this section o f the experiment, there was a gradual reduction 
in LVDT during the first 3 min. Upon reperfusion, there was a rapid return to a 
relatively strong force of contraction and HR within 1 min o f reperfusion. HR 
showed a transient increase above the initial rate followed by a plateau after 
about 3-4 min. CFR increased upon reperfusion as part o f the reactive 








This trace is representative of the experimental conditions and observations in a haemin-treated heart perfused at a constant- 
pressure o f 70mmHg. The LVDT (section A), CFR (section B) and heart rate (section C) were measured throughout the 
initial stabilisation period, 20min ischaemic insult and 30 min reperfusion.
Ischaemia reperfusion
Figure 4.1.1B
This trace is representative of the experimental conditions and observations in a control heart perfused at a constant-pressure 
of 70mmHg. The LVDT (section A), CFR (section B) and heart rate (section C) were measured throughout the initial 
stabilisation period, 20min ischaemic insult and 30 min reperfusion.
HO-1 protein expression was induced in the rat heart using 75fimol/kg haemin 
(24 hour) as in the constant-flow perfusion experiments. The results were 
analysed using immunoblot analysis with an anti-rat HO-1 antibody.
As indicated in figure 4.1.2, 75|imol/kg haemin successfully increased HO-1 






The effect of haemin pre-treatment on HO-1 expression in the rat heart perfused at a constant- 
pressure of 70mmHg.
Rats were treated with saline, 40pmol/kg SnPP (1 hour), 75gmol/kg haemin, and 75jimol/kg 
haemin + 40fimol/kg SnPP respectively. HO-1 protein expression was measured at the end of 
20min ischaemia and 30 min reperfusion (n=2 in this particular blot).
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4.1.2. The effect of haemin and SnPP pre-treatment on basal flow and LVDT in
the pre-ischaemic rat heart perfused at 70 mmHg.
(A) CFR
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F ig u re  4 .1 .3
The effect of haemin and SnPP pre-treatment alone and in combination on CFR (A) and LVDT 
(B) in the pre-ischaemic rat heart perfused at a constant-pressure of 70mmHg.
Rats were pre-treated with saline, 75 |imol/kg haemin (24hour), 40 pmol/kg SnPP (1 hour) and 
haemin + SnPP. Values are expressed as mean ± SEM. * where p<0.05 compared with control 
and ** p<0.05 compared with haemin alone (n=5).
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Haemin pretreatment significantly reduced CFR from 6.2 ml/min in control 
hearts to 3.8 ml/min in haemin-treated hearts (p<0.05, n=5) (Figure 4.1.3A). This 
effect is indicative of a vasoconstrictor response to haemin pre-treatment. In 
contrast, SnPP had no significant effect on CFR in control or haemin-treated 
hearts, suggesting that endogenous HO-2 may not be involved in the control of 
CFR. In addition, haemin pre-treatment did not significantly affect contractility 
compared with control (6.6 ± 0.6g and 6.5 ± O.lg respectively) (Figure 4.1.3B). 
Thus, induction o f HO-1 expression did not appear to influence the force of 
contraction in the pre-ischaemic rat heart perfused at constant-pressure. In 
contrast, SnPP treatment significantly reduced the force of contraction regardless 
o f control or haemin pre-treatment (3.8 ± O.lg and 3.9 ± 0.4g respectively). Thus, 
this effect appears to be limited to SnPP treatment and may occur as a result o f a 
non-specific action. In contrast to its lack o f effect on LVDT, haemin pre­
treatment significantly reduced heart rate from 240.4 BPM in control hearts to 
196.4 BPM (p<0.05, Figure 4.1.4A). SnPP did not significantly affect heart rate 
in rat hearts treated with saline or haemin (260 ± 39 BPM and 210 ± 24 BPM 
respectively). This result parallels the effect on CFR, implicating a possible 
connection between the two events. For example, heart rate may be reduced as a 
result o f the vasoconstrictor effect o f haemin treatment. Haemin and SnPP-alone 
or in combination did not affect basal tension immediately prior to the start of 
ischaemia (Figure 4.1.4B).
98
(A) H eart Rate
B  Control 
□  Haemin 
^SnPP




□  S n P P
□  Haemin + S n P P
Figure 4.1.4
The effect of haemin and SnPP pre-treatment alone and in combination on heart rate (A) and 
basal tension (B) in the pre-ischaemic rat heart perfused at a constant-pressure of 70 mmHg.
Rats were pre-treated with saline, 75 pmol/kg haemin (24hour), 40 pmol/kg SnPP (1 hour) and 
haemin + SnPP. Values are expressed as mean ± SEM. * where p<0.05 compared with control 
(n-5).
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4.1.3. The effect o f  haemin pre-treatment on the recovery o f  heart perfused at a
constant pressure o f  70 m mHg follow ing 20 min ischaemia / 30 m in reperfusion.
Haemin pre-treatment did not significantly affect CFR during reperfusion, 
compared with control (Figure 4.1.5A). The presence o f SnPP in haemin-treated 
hearts brought about a significant reduction in CFR (t=4-12 min) compared with 
haemin alone, and also compared with control and SnPP (t=2-24 min). Therefore, 
haemin and SnPP appear to blunt reactive hyperemia. A potential additive effect 
o f haemin + SnPP may be involved in the significant reduction o f CFR.
In contrast to the situation in constant-flow-perfused hearts, the recovery of 
contractility in the constant-pressure-perfused rat heart was not significantly 
increased in haemin-treated hearts (Figure 4.1.5B). This may be due to the high 
level o f recovery observed in control hearts (82.7 ± 5% compared with 73.5 ± 
19% in haemin-treated hearts). Recovery from I/R in hearts perfused at constant 
pressure is increased compared with data observed in the constant-flow perfusion 
model (Chapter 3), where control hearts recovered by 14 % and haemin-treated 
hearts recovered by 45 %, indicating that the constant-pressure model itself may 
confer protection after 20 min ischaemia. In addition, this result demonstrates 
that there is a very small therapeutic window in which to establish whether or not 
haemin can aid protection in this model. Furthermore, the recovery in 
contractility observed in control and haemin-treated hearts was significantly 
reduced in the presence of SnPP (21.8 ± 11 % and 29.3 ± 14 %  respectively). 
SnPP also reduced contractility in the pre-ischaemic heart (Figure 4.1.2A). As 
haemin treatment exerts little influence on the contractility o f the rat heart, it is 
likely that the reduction in recovery may be produced by a non-specific action 
from SnPP treatment. Alternatively, HO may be involved in the control and 
recovery o f contractility, but an increase in HO-1 expression may not potentiate 
the effect.
100
(A) CFR during reperfusion
Control
- ■ - H a e m in
- © - S n P P
- B -  Haemin + SnPP
2 4 6 8 10 12 14 16 18 20 22 24  26  28 30
Time (min)
(B) Recovery of LVDT
100
9 0  A
ED Control
□  Haemin
□  S n P P
□  Haemin + S n P P
Figure 4.1.5
The effect of haemin and SnPP pre-treatment alone and in combination on CFR (A) and recovery 
of LVDT (B) in the post-ischaemic rat heart perfused at a constant pressure of 70 mmHg.
Rats were pre-treated with saline, 75 pmol/kg haemin (24hour), 40 fimol/kg SnPP (1 hour) and 
haemin + SnPP. Values are expressed as mean ± SEM. * where p<0.05 compared with control 
and SnPP (t=2-24min for CFR) or # p<0.05 compared with haemin, (n=5). Note: some error bars 
may fall within symbol size.
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Figure 4.1.6
The effect of haemin and SnPP pre-treatment on basal tension (A) and tissue bilirubin levels (B) 
at the end of I/R in hearts perfused at a constant-pressure of 70 mmHg.
Rats were pre-treated with i.p. injections of saline, 75 fimol/kg haemin, and 40 pmol/kg SnPP (in 
the presence of haemin or alone). Values are expressed as mean ± SEM. * where p<0.05 





At the end o f reperfusion, the basal tension observed in control and haemin- 
treated hearts did not differ significantly from each other (Figure 4.1.6A), and 
were also not different to the measurements taken at the pre-ischaemic period. In 
contrast, SnPP treatment in control and haemin-treated hearts caused a 
significant increase in basal tension at the end o f the reperfusion period. After 
I/R, heart tissue was assayed for the quantity o f tissue bilirubin. Haemin 
treatment did not significantly affect tissue bilirubin levels (3.0 ± 1 jimol 
bilirubin/g wet weight tissue) compared with control (3.4 ± 1 pmol bilirubin/g 
wet weight tissue) (Figure 4.1.6B). In the constant-flow model, the same dose of 
haemin increased bilirubin levels to approximately 6.5 pmol bilirubin/g wet 
weight tissue, whereas at constant-pressure, haemin pre-treatment induced the 
production of approximately 3 jimol bilirubin/g wet weight tissue. In addition, as 
a similar amount o f bilirubin was detected in control tissues perfused at constant- 
flow and constant-pressure, it is likely that the protection observed under these 
conditions may be due to the method of perfusion itself rather than an increase in 
HO-1 activity or bilirubin production. The combination of haemin + SnPP 
significantly increased bilirubin production, which was surprising as SnPP 
actually reduced bilirubin production. Haemin and/or SnPP did not significantly 
affect the washout o f lactate during the first 5 min of reperfusion, although there 
was a significant increase in total lactate release in hearts treated with haemin + 
SnPP compared with those treated with haemin alone (Figure 4.1.7A), whereas 
the combination o f haemin + SnPP significantly increased total lactate release 
compared with haemin alone.
The release of nitrite in the pre- and post-ischaemic rat heart was measured to 
determine if the vasoconstrictor effect of haemin on CFR was due to an 
inhibitory effect on NO release. The results demonstrate that haemin has little 
effect on nitrite release in the pre-ischaemic heart compared with control (Figure 
4.1.7B). On reperfusion, there is a significant decrease in nitrite release in 
haemin-treated hearts during the first minute o f reperfusion compared with 
control. Interestingly, SnPP treatment significantly increased NO release in both 
the pre- and post-ischaemic heart (p<0.05 compared with control and haemin). 
This suggests that there may be further non-specific effects involving SnPP 
treatment on NO release.
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(B) Nitrite production in the pre- and post-ischaemic rat heart
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F ig u re  4 .1 .7
The effect of haemin and SnPP pre-treatment on nitrite release pre- and post- ischaemia in rat 
heart perfused at a constant-pressure of 70mmHg.
Rats were pre-treated with saline, 75 fimol/kg haemin (24hour), 75|imol/kg haemin and 
40|imol/kg SnPP or 40 fimol/kg SnPP (lhour) alone. Values are expressed as mean ± SEM. * 
where p<0.05 compared with control and haemin and # compared with control (n=5). Note: some 
error bars fall within symbol size.
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4.2 The effect of increasing the duration of the ischaemic period on the
recovery of cardiac function in the constant-pressure-perfused rat heart
The following experiments were used to compare the effect o f increasing 
ischaemic injury on the recovery o f control hearts. The effect o f haemin pre­
treatment on the recovery o f cardiac function after 30 min I/R was also 
determined. The data from these experiments helped to establish whether 
haemin’s protective effect post I/R remained after a more severe and potentially 
irreversible ischaemic injury.
4.2.1 The effect of differing ischaemic insults on the recovery o f control hearts 
perfused at 70 mmHg.
After an ischaemic period o f increased duration (30-40 min), CFR was 
significantly reduced during the initial 12 min o f reperfusion (Figure 4.2.1 A). 
Therefore, the increase in duration o f ischaemia is responsible for abolishing the 
reactive hyperaemia response to ischaemia. Consequently, it seems that there 
may be either a reduction in vascular responsiveness, or a decreased release of 
vasoactive mediators or disruption in the balance of vasoactive mediators during 
the first 10 min of reperfusion. Overall, this effect on reactive hyperemia is the 
most significant difference, as all 3 groups end with similar CFRs after 30 min 
reperfusion.
Recovery o f contractility is also significantly reduced after increasing the 
duration of the ischaemic periods (Figure 4.2.IB). There is very little difference 
between the recovery of hearts after 30 and 40min ischaemia (3.4 ± 1 %  and 3.9 
± 1 %, respectively). This suggests that the duration o f the ischaemic period is 
vital in determining the recovery of contractility during reperfusion.
The reduction in recovery o f contractility after 30 or 40 min ischaemia proceeded 
in parallel with an increase in basal tension (Figure 4.2.2A). There is a significant 
increase in basal tension after 30 and 40 min ischaemia. Increasing the duration 
o f ischaemic injury to 40min caused a significant increase in bilirubin production 
(Figure 4.2.2B). HO-1 activity may increase in response to a longer ischaemic 
time course.
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Figure 4.2.1
The effect of increasing ischaemic period on CFR (A) and recovery of LVDT (B) in the post- 
ischaemic control rat heart perfused at a constant-pressure of 70mmHg.
Rats were treated with saline (24hour) prior to heart removal. Values are expressed as mean ± 
SEM. * where p<0.05 compared with control heart after 20 min ischaemia (t=2-12 min post 
ischaemia for CFR), and n=4-5. Note: some error bars fall within the size of the symbol.
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F ig u re  4 .2 .2
The effect of increasing ischaemic insult on basal tension (A) and tissue bilirubin levels (B) in 
post-ischaemic control rat hearts perfused at a constant-pressure of 70mmHg.
Rats were treated with saline (24hour) prior to removal of heart. Values are expressed as mean ± 
SEM, * where p<0.05 compared with control hearts exposed to 20 min 1/R only or ** p<0.05 
compared to 20 and 30 min I/R (n=4-5).
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Figure 4.2.3.
The effect of increasing ischaemic insult on lactate washout in the post-ischaemic control rat 
heart perfused at a constant-pressure of 70mmHg.
Rats were pre-treated with saline (24hour). Values are expressed as mean ± SEM. * where 
p<0.05 30 min ischaemia compared with 20 min ischaemia and # p<0.05 40 min ischaemia 
compared with 20 min ischaemia, (n=5). Note: some error bars fall within the size of the symbol.
Increasing the duration of the ischaemic period seems to produce a more gradual 
lactate washout compared to the more rapid release seen after 20 min ischaemia 
(Figure 4.2.3), although total lactate release was not significantly affected by 
increasing the ischaemic insult. This response could be due to the reduction in 
reactive hyperaemia observed on CFR during the first 10 min + after reperfusion.
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4.2.2 The effect o f  haemin on the recovery o f  cardiac function follow ing 30min
o f  ischaemia at a constant pressure o f  70mmHg.
During reperfusion, CFR is significantly reduced in haemin-treated hearts 
subjected to 30 min I/R compared with control (p<0.05, t=2, 22-30) (Figure 
4.2.4A). This is in contrast to the data observed after 20 min ischaemia, where 
haemin and control hearts showed a similar pattern o f CFR after ischaemia. In 
addition, the reactive hyperaemia response to ischaemia is also abolished in both 
control and haemin-treated hearts as compared with CFRs recorded during 
reperfusion after a 20min ischaemic insult (see figure 4.1.4A).
The recovery o f cardiac function after I/R was significantly reduced as the 
ischaemic insult was intensified (Figure 4.2.4B). After 30min I/R, control hearts 
recovered to 3.4 ± 1% compared to 3.3 % after haemin pre-treatment. This data 
suggests that haemin pre-treatment does not increase recovery o f cardiac function 
after I/R compared with control. This is in agreement with the effect o f haemin 
treatment on recovery from I/R after 20 min ischaemia. After 20 and 30 min 
ischaemia, the hearts recovered to a similar extent in control and haemin-treated 
hearts. Supplementary to the effect on recovery o f cardiac function, 30 min I/R 
significantly increased basal tension in both haemin and control hearts compared 
with those subjected to 20 min ischaemia (Figure 4.2.5A). This is indicative of 
Ca overload, and may indicate a reason for the significant reduction in the 
restoration of contractility during reperfusion.
After 30 min I/R bilirubin levels are significantly increased in haemin-treated 
hearts compared with control (Figure 4.2.5B). Furthermore, the amount of 
bilirubin measured was significantly higher than that seen in hearts subjected to 
20 min I/R (p<0.05). This shows that as ischaemic injury increases, the levels of 
bilirubin increase in haemin-treated hearts.
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The effect of haemin on CFR (A) and recovery of LVDT (B) after 30min global ischaemia in the 
post-ischaemic haemin-treated rat heart perfused at a constant-pressure of 70mmHg.
Rats were treated with saline and 75 jumol/kg haemin (24hour) prior to heart removal. Values are 
expressed as mean ± SEM. * where p<0.05 compared with control after 30 min ischaemia (t=2, 
22-30 min post ischaemia for CFR) or # where p<0.05 compared with control and haemin after 
20 min ischaemia (n=5). Note: some error bars fall within the size of the symbol.
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(A) Basal tension during reperfusion
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Figure 4.2.5
The effect of haemin on basal tension (A) and tissue bilirubin levels (B) in the post-I/R in hearts 
perfused at a constant pressure of 70 mmHg following 20 and 30 min ischaemia.
Rats were pre-treated with i.p. injections of saline and 75 pmol/kg haemin (24hour). Values are 
expressed as mean ± SEM. * where p<0.05 compared with control and ** p<0.05 compared with 
control and haemin post 20 min I/R, (n=5).
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Figure 4.2.6
The effect of haemin on lactate washout in the first 5 min of reperfusion after 20 and 30min 
ischaemia in the rat heart perfused at a constant-pressure of 70mmHg.
Rats were pre-treated with saline or 75 fimol/kg (24hour). Values are expressed as mean ± SEM, 
* where p<0.05 compared with control (20 min Ischaemia) (n=5).
Increasing the duration o f the ischaemic period had very little effect on lactate 
washout or total lactate release during the first 5 min of reperfusion (Figure 
4.2.6). The only significant effect was demonstrated during the first 2 min of 
reperfusion, where lactate washout was decreased in control hearts after 30 min 
ischaemia compared with control hearts exposed to 20 min ischaemia (p<0.05).
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4.3 The effect of perfusion at a constant pressure of 130 mmHg on the action 
of haemin in the pre- and post- ischaemic rat heart.
The effect of haemin pre-treatment on the recovery o f cardiac function in hearts 
perfused at a constant pressure o f 130 mmHg was investigated to determine if  the 
pressure o f the perfusion system influenced the activity o f haemin treatment. In 
the constant flow perfused heart, during the initial perfusion period the CPP of 
control hearts reached around 130-140 mmHg and 70-90 mmHg in haemin- 
treated hearts. The following experiments determined if  a different initial 
pressure affected the recovery from I/R compared with a constant-pressure of 
70mmHg as used in the initial experiments.
4.3.1. The effect o f perfusion at a constant pressure o f 130 mmHg in the pre- 
ischaemic rat heart.
The CFR of haemin-treated hearts perfused at 130 mmHg (7.3 ±0 .1  ml/min) is 
significantly lower than that o f control hearts (12.8 ± 1.1 ml/min) (Figure
4.3.1 A). Therefore, the vasoconstrictor effect o f haemin is not dependent upon 
the pressure at which the tissue is perfused. The CFRs in hearts perfused at 130 
mmHg increase to almost double the CFRs measured at 70 mmHg in both 
control and haemin-treated hearts (Figure 4.1.1 A). Haemin treated hearts 
perfused at a constant pressure o f 130 mmHg did not display any significant 
difference in contractility compared with control (Figure 4.3.IB). This suggests 
that the influence o f HO-1 on the CFR does not affect the force of contraction, 
i.e. the vasoconstrictor effect of haemin does not induce a change in contractility. 
This may be due to the method of perfusion, as the constant-pressure perfusion 
system allows the flow rate to change and thus to accommodate any metabolic or 
vascular changes in the model. The LVDT o f hearts perfused at a constant- 
pressure o f 130 mmHg was markedly lower than those previously recorded at 70 
mmHg (Figure 4.1.IB). At a perfusion pressure o f 130 mmHg, haemin pre­
treatment had no significant effect on HR. Haemin pre-treatment increased heart 
rate after perfusion at 130 mmHg compared with haemin-treated hearts perfused 
at 70 mmHg (see Figure 4.1.2A). In the pre-ischaemic rat heart, there was no 
significant difference in basal tension in control and haemin-treated hearts 
perfused at 130 mmHg (Figure 4.3.2B).
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The effect of haemin pre-treatment on CFR (A) and LVDT (B) in the pre-ischaemic rat heart 
perfused at a constant pressure of 130 mmHg.
Rats were pre-treated with saline or 75 jimol/kg haemin (24hour). Values are expressed as mean 
± SEM, * where p<0.05 compared with control (n=5).
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The effect of haemin pre-treatment on heart rate (A) and basal tension (B) in the pre-ischaemic 
rat heart perfused at a constant pressure of 130 mmHg.
Rats were pre-treated with saline or 75 fimol/kg haemin (24hour). Values are expressed as mean 
± SEM (n=5).
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4.3.2 The effect o f  haemin pre-treatment on recovery from I/R in the rat heart
perfused at a constant pressure o f  130 mmHg.
During reperfusion, haemin pre-treatment reduced CFR after ischaemia 
compared to control (Figure 4.3.3A). The effect reached statistical significance 
when t=4-14 min. This indicates that the vasoconstrictor component of the 
response to haemin pre-treatment is not abolished by ischaemic insult in hearts 
perfused at 130 mmHg; this is in contrast to previous data recorded at 70 mmHg 
(Figure 4.1.3A), where the vasoconstrictor effect was not present during 
reperfusion. Therefore, the effect o f haemin pre-treatment is more evident at a 
higher perfusion pressure. This suggests that the basal tone o f the heart may 
affect the vascular effect o f haemin after I/R. In addition, the CFR is markedly 
increased in control and haemin-treated hearts perfused at 130 mmHg compared 
with hearts perfused at 70 mmHg (Figure 4.1.3 A). This is in agreement with the 
pre-ischaemic data where there is no evidence o f autoregulation.
Haemin pre-treatment significantly increased recovery o f contractility compared 
with control (Figure 4.3.3B) after I/R in hearts perfused at a constant pressure of 
130 mmHg. This is in contrast to previously recorded data at 70 mmHg, where 
haemin pre-treatment did not confer any protection from I/R compared to 
control. In addition, the overall recovery in both control and haemin-treated 
hearts perfused at 130 mmHg was markedly lower than both treatment groups 
perfused at 70 mmHg (Figure 4.3.3B). Therefore, these data demonstrate that 
haemin exerts a greater protective effect at a higher pressure, and is more evident 
when the recovery o f control hearts is reduced. In combination with figure 4.2.2, 
this indicates that in the constant-pressure-perfused rat heart, the level of 
protection conferred by HO-1 induction is dependent upon the basal pressure.
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Figure 4.3.3
The effect of haemin pre-treatment on CFR (A) and recovery of LVDT (B) in the post-ischaemic 
rat heart perfused at a constant pressure of 130 mmHg.
Rats were pre-treated with saline or 75 pmol/kg haemin (24hour). Values are expressed as mean 
± SEM. * where p<0.05 (t=4-14 min for CFR) compared with control (n=5).













The effect of haemin pre-treatment on basal tension (A) and tissue bilirubin levels (B) after I/R in 
the rat heart perfused at a constant-pressure of 130 mmHg.
Rats were pre-treated with i.p. injections of saline or 75 (imol/kg haemin (24 hour). Values are 
expressed as mean ± SEM. * where p<0.05 compared with control (n=5).
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The increased recovery o f contractile function in haemin-treated hearts is 
accompanied by a relatively low basal tension after I/R (Figure 4.3.4A). After 
I/R, tissue bilirubin levels are significantly increased in haemin-treated hearts 
perfused at 130 mmHg (10.2 jimol bilirubin/g wet weight tissue) compared with 
control (3.3 pmol bilirubin/g wet weight tissue, p<0.05)(Figure 4.3.4B). 
Therefore, the improved recovery in cardiac function after I/R induced by 
haemin pre-treatment may be due to a significant increase in bilirubin levels, 
whereby the antioxidant nature o f bilirubin aids the removal o f ROS produced 
upon reperfusion. Furthermore, the levels of bilirubin are similar to those 
measured in haemin-treated hearts perfused at constant flow (Chapter 3), where a 
significant increase in recovery was also observed. In addition, lactate washout 
during the first 5 min o f reperfusion was not significantly different in control and 
haemin-treated hearts perfused at 130 mmHg (Figure 4.3.5A). This suggests that 
the protective effect o f haemin pre-treatment at 130 mmHg is not produced by an 
increase in anaerobic glycolysis, and/or by increased ATP production. There is 
no significant effect on nitrite release in haemin-treated hearts prior to ischaemic 
insult compared to control (Figure 4.3.5B). Therefore, these data indicate that the 
vasoconstrictor effect o f haemin in the pre-ischaemic heart is unlikely to be 
produced by the inhibition of NO release. Haemin pre-treatment significantly 
reduces nitrite release in the post-ischaemic rat heart during the first 2 min of 
reperfusion (p<0.05). The previous data (Figure 4.3.3A) have indicated that 
haemin pre-treatment reduces the extent o f reactive hyperaemia, which may be 
produced due to the prevention o f NO synthesis or the removal o f available NO. 
Furthermore, it is also possible that nitrite may be released exclusively in the first 
5 min of reperfusion. Nitrite release is not increased in control hearts during 
reperfusion, suggesting that NO may not be responsible for the reactive 
hyperemia observed during reperfusion.
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Figure 4.3.5
The effect of haemin pre-treatment on lactate washout in the post-ischaemic rat heart (A) and 
nitrite release in the pre- and post-ischaemic rat heart perfused at a constant pressure of 130 
mmHg.
Rats were pre-treated with saline or 75 p.mol/kg haemin (24 hour). Values are expressed as mean 
± SEM. * where p<0.05 compared with control (n=5). Note: some error bars may fall within the 
size of the symbol.
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4.4 Investigation of the effect of the iron chelator desferrioxamine (DFO) on
the effect of haemin on the recovery from I/R in the rat heart perfused at a
constant-pressure of 70 mmHg
HO catalysis o f haem produces bilirubin, CO and iron. Free iron release may 
have both protective and detrimental effects within cells. Therefore, 
desferrioxamine (DFO), an iron chelator, was employed in this study to 
investigate the possibility that haemin-induced iron release was modulating 
cardiac function.
4.4.1 The effect o f desferrioxamine (DFO) perfusion in pre-ischaemic haemin- 
treated hearts.
DFO significantly increased CFR in both control and haemin-treated hearts 
(Figure 4.4.1 A). These data suggest that free iron is exerting a vasoconstrictor 
effect in control and haemin-treated hearts. Alternatively, as there is an increase 
in the CFR in both control and haemin-treated tissues, it is possible that DFO is 
having an effect independent o f haemin treatment.
In the presence o f DFO, LVDT is significantly reduced in haemin-treated hearts 
(3.9 g) as compared with hearts treated with haemin alone (6.6 ± 1 g, p<0.05) 
(Figure 4.4.IB). This suggests that the presence o f free iron significantly 
increased the force of contraction. This response is surprising as the converse 
might be expected as the presence o f ROS, as a result o f increased iron levels, 
has been shown to cause contractile dysfunction. The difference between DFO- 
treated and control samples was not statistically significant. This effect appears 
to be restricted to the force of contractility, as there is no significant difference 
on heart rate between treatment groups (Figure 4.4.2A). Therefore, the effect of 
DFO on contractility does not occur in response to a change in heart rate or vice 
versa. In addition, DFO did not significantly affect basal tension in control or 
haemin-treated hearts (Figure 4.4.2B).
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Figure 4.4.1.
The effect of DFO on CFR (A) and LVDT (B) in control and haemin-treated hearts prior to the 
onset of ischaemia.
Rats were pre-treated with saline or 75|nmol/kg (24hour). Values are expressed as mean ± SEM. * 
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Figure 4.4.2.
The effect of DFO on heart rate (A) and basal tension (B) in control and haemin-treated pre- 
ischaemic rat hearts perfused at a constant-pressure of 70mmHg.
Rats were pre-treated with saline or 75 pmol/kg (24hour). Values are expressed as mean ± SEM, 
(n=5).
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4.4.2 The effect o f  DFO on the recovery o f  cardiac function after 30 m in global
ischaemia and reperfusion in hearts perfused at a constant-pressure o f  70 mmHg.
DFO significantly increased CFR in control hearts during reperfusion (t=l 8-30 
min, p<0.05) (Figure 4.4.3B), suggesting that endogenous iron release has a 
vasoconstrictor effect under control conditions. In contrast, haemin-treated hearts 
exposed to DFO did not demonstrate any significant difference in CFR compared 
to haemin alone. These data indicate that free iron is not involved in the 
vasoconstrictor response o f haemin-treated hearts to I/R. The use of DFO 
significantly increased recovery o f cardiac function after 30 min I/R (Figure 
4.4.3B, p<0.05) in both control and haemin-treated hearts. After 30 min I/R, 
recovery was minimal in control and haemin-treated hearts (3.4 ± 1 %  and 3.3 % 
respectively), but on addition o f DFO, recovery increased in both treatment 
groups (18.3 ± 4 % for control and 22.7 ± 7 % for haemin treatment). Therefore, 
the increase in recovery is associated with DFO alone, and is not affected by 
haemin pre-treatment. This suggests that the removal o f free iron aids the 
recovery from I/R. Haemin in the presence o f DFO significantly reduced basal 
tension compared with haemin alone (Figure 4.4.4A). There was no statistically 
significant reduction in the basal tension o f control hearts perfused with DFO.
i
This suggests that haemin + DFO prevent the ischaemia-induced increase in Ca 
overload, as indicated by the basal tension.
Bilirubin production is significantly increased in haemin-treated hearts compared 
with control after 30 min I/R (Figure 4.4.4B, p<0.05). In contrast, haemin + DFO 
treatment significantly increased tissue bilirubin levels compared with haemin 
alone. Therefore, it is feasible that the increased bilirubin levels in haemin + 
DFO treated hearts could have contributed to the recovery o f cardiac function 
from I/R, due to its antioxidant nature, although this does not explain the 
increased recovery in control hearts, suggesting that different mechanisms could 
be responsible.
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The effect of DFO on post-ischaemic CFR (A) and recovery of LVDT (B) in control and haemin- 
treated hearts perfused at a constant-pressure of 70mmHg.
Rats were treated with saline or 75 pmol/kg haemin (24hour). Values are expressed as mean ± 
SEM. * where p<0.05 compared with control and # where p<0.05 compared with haemin (n=5).
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Figure 4.4.4
The effect of DFO on post-ischaemic basal tension (A) and tissue bilirubin levels (B) in control 
and haemin-treated hearts perfused at a constant-pressure of 70mmHg.
Rats were treated with saline or 75 pmol/kg haemin (24hour). Values are expressed as mean ± 
SEM. * where p<0.05 compared with control and # where p<0.05 compared with haemin (n=5).
126
-•-Control 
-© -  Control+DFO 
Haemin 
-B -  Haemin+DFO
30
25 -
_  20 -
o
E=t
^  15 -
Total Lactate Amounts
Control: 35±3fimol 
Control + DFO: 47±7fimol* 
Haemin: 36±8|iimol 




2 31 4 5
Time (Mins post ischaemia)
Figure 4.4.5
The effect of DFO on lactate washout after 30 min global ischaemia in control and haemin- 
treated hearts perfused at a constant-pressure of 70mmHg.
Rats were treated with saline or 75 fimol/kg haemin (24hour). Perfusate was collected for the 
initial 5 min and assayed for lactate content. Values are expressed as mean ± SEM and * p<0.05 
compared with control (n=5). Note: some error bars may fall within the size of the symbol.
DFO does not significantly affect the washout o f lactate during each minute post 
ischaemia in either control or haemin-treated hearts, but there is a significant 
increase in total lactate content o f control hearts treated with DFO (Figure 4.4.5). 
Therefore, in control hearts, the protection conferred from DFO may be produced 
by an increase in anaerobic glycolysis and the accompanying rise in ATP 
production.
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4.5. The effect of haemin on the autoregulation mechanisms of the constant-
pressure-perfused rat heart.
The following experiments concentrated on investigating the effect o f haemin 
pre-treatment on the autoregulation mechanisms involved in the control o f 
coronary flow. It was postulated that the significant vasoconstrictor effect 
induced in the pre- and post-ischaemic rat hearts reported in section 4.1 could 
have occurred as a result o f an inhibitory effect on the autoregulation 
mechanisms.
The data illustrated in figure 4.6.1 A are a representation of the absolute CFR at 
the end o f a 10 min period of perfusion at each pressure level. They indicate that 
there is no real evidence o f autoregulation mechanisms in control, haemin or 
SnPP -treated hearts. These data are in agreement with the CFR recorded in 
control and haemin-treated hearts perfused at 70 mmHg and 130 mmHg. For 
example, the CFR is doubled in both treatment groups at 130 mmHg compared 
with 70 mmHg, whereas the CFR would be expected to be the same at both 
pressures if  autoregulation mechanisms were active. Haemin and SnPP pre­
treatment alone significantly reduces CFR compared with control at the lower 
pressure values o f 100, 80 and 60 mmHg. The reduced coronary flow produced 
by haemin under these conditions may be dependent upon the basal pressure 
level. It is important to note that the large error bars on the group data for haemin 
+ SnPP are due to the small group size of 2. The small group size occurred due to 
an abnormal effect on the stability of the tissue during the first pressure change 
(data not shown). The hearts exhibited VF after the second pressure-change to 
120 mmHg in 3 o f the tissues investigated. Therefore, it is difficult to ascertain 
the degree of involvement of HO-1 in the results described above. It could be 
postulated that the induction o f VF occurred due to the combination of non­
specific effects from haemin and SnPP. In contrast, SnPP-treated hearts 
demonstrated CFRs similar to those recorded in haemin-treated hearts.
Over the initial change to 135 mmHg, there was an increase in CFR in all 
treatment groups except in hearts treated with haemin + SnPP (Figure 4.5.IB). 
The majority o f recordings from the groups o f hearts treated with haemin and
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SnPP were taken at the pressure o f 135 mmHg (n=5) prior to the VF response 
described earlier. From these measurements, haemin + SnPP appears to exert a 
combined effect by decreasing CFR compared with control. The lower CFR 
produced at the high pressure o f 135 mmHg may indicate a reason for the 
resultant VF upon lowering the pressure to 120 mmHg. The most likely cause for 
the low CFR is an additive effect from haemin and SnPP, as both appear to lower 
the CFR when administered on their own.
The pressure level was further reduced from 135 mmHg to 120 mmHg and 
measurements taken in control, haemin- and SnPP-treated hearts over the initial 2 
min period. The results illustrate that both haemin and SnPP treated hearts 
significantly decrease CFR compared with control over the first 20 min (p<0.05). 
This confirms the data recorded earlier, and suggests that haemin has a 
vasoconstrictor effect in the constant pressure rat heart. In addition, SnPP alone 
also produces a vasoconstrictor effect, resulting in a CFR similar to that seen in 
the haemin-treated heart. The inhibition and induction o f HO-1 activity appears 
to have the same effect. This may be due to the dual mechanism of action o f the 
metalloporphyrins, whereby HO-1 expression can be both inhibited and 
potentiated. Furthermore, the possibility that the VF experienced in hearts treated 
with haemin + SnPP is caused by an additive vasoconstrictor effect is 
strengthened by these data.
The further reduction in pressure from 120 mmHg to 100 mmHg (Figure 4.6.2B), 
100 mmHg to 80 mmHg (Figure 4.6.3A), and 80 mmHg to 60 mmHg (Figure 
4.6.3B) induced significant decreases in CFR in haemin- and SnPP-treated hearts 
compared with control (p<0.05). This result again confirms the vasoconstrictor 
effect of haemin and SnPP under these experimental conditions. The data 
indicate that the difference between haemin- and SnPP-treatment compared with 
control appears to increase as the pressure decreases. In addition, there do not 
appear to be any autoregulation mechanisms involved in the responses o f control 
and haemin-treated hearts, as there is a gradual decrease in response over the 
initial 2 min o f each pressure change.
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(A) Absolute CFRs upon constant pressure change
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The effect of haemin and SnPP pre-treatment alone and in combination on absolute CFRs at 
various pressures (A) and CFR during the initial change to 135 mmHg (B). Rats were pre-treated 
with saline, 75 jxmol/kg haemin (24hour) ± 40 |imol/kg SnPP (1 hour) and 40 (imol/kg SnPP 
alone. Values are expressed as mean ± SEM. * where p<0.05 compared with control, n=5 (apart 
from haemin + SnPP n=2). Note: some error bars may fall within the size of the symbol.
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The effect of haemin and SnPP pre-treatment on CFR in the first 2 min after the pressure 
conversion from 135 mmHg to 120 mmHg (A) and 120 mmHg to 100 mmHg (B).
Rats were pre-treated with saline, 75 |nmol/kg haemin (24hour) and 40 |imol/kg SnPP alone. 
Values are expressed as mean ± SEM. * where p<0.05 compared with control, (n=5).
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The effect of haemin and SnPP pre-treatment on CFR in the first 2 min after the pressure 
conversion from 100 mmHg to 80 mmHg (A) and 80 mmHg to 60 mmHg (B).
Rats were pre-treated with saline, 75 pmol/kg haemin (24hour) and 40 (imol/kg SnPP alone. 
Values are expressed as mean ± SEM. * p<0.05 in haemin-treated hearts compared with control, 
# p<0.05 SnPP alone compared with control (n=5).
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4.6 Chapter 4: Summary
•  At 70 mmHg, haemin pre-treatment produced a reduction in CFR, indicative 
o f a vasoconstrictor response. SnPP significantly reduced the force of 
contraction and haemin treatment produced a significant reduction in heart 
rate.
•  Haemin had no effect on CFR during reperfusion, although haemin + SnPP 
significantly reduced CFR. Recovery from I/R occurred in both control and 
haemin-treated hearts to a similar extent. SnPP abolished the recovery of 
contractility in control and haemin-treated hearts.
• Increasing ischaemic insult abolished reactive hyperaemia and recovery of 
contractility, although the vasoconstrictor effect was present during 
reperfusion of haemin-treated hearts. Tissue bilirubin levels increased in 
haemin-treated hearts compared with control after 30 min I/R.
• At 130 mmHg, haemin produced a vasoconstrictor effect and a reduction in 
contractility and heart rate compared with hearts perfused at 70 mmHg.
• During reperfusion, the CFR was markedly increased in control and haemin- 
treated hearts compared with those perfused at 70 mmHg, but the constrictor 
effect o f haemin was also present. The recovery o f cardiac contractility was 
significantly increased in haemin-treated hearts compared with control at 130 
mmHg.
• DFO significantly increased CFR and decreased the force of contraction in 
both control and haemin-treated hearts.
• During reperfusion DFO significantly increased the CFR in control hearts. 
Recovery of contractility was increased in both control and haemin-treated 
hearts perfused with DFO.
• The vasoconstrictor effect o f haemin did not appear to be produced by the 
modulation o f autoregulatory mechanisms.
133
CHAPTER 5:
THE EFFECT OF HAEMIN PRETREATMENT ON 
VASCULAR RESPONSIVENESS IN THE 
PERFUSED KIDNEY AND MESENTERY
134
Chapter 5: The effect of haemin pre-treatment on vascular
responsiveness in the perfused mesentery and kidney.
5,1 The effect of haemin pre-treatment on vascular responsiveness in the
perfused mesentery
Figure 5.1.1 shows a representative trace illustrating the effect o f bolus doses of 
histamine in the pre-contracted kidney (Trace A), the effect o f bolus doses of 
ACh in the pre-contracted mesenteric vascular bed (Trace B) and the effect of 
bolus doses o f ET-1 on the perfused mesenteric vascular bed (Trace C).
5.1.1. The effect o f haemin pre-treatment on the response to vasodilation in the 
perfused mesentery.
The mesentery preparation was cannulated as described in chapter 2, and 
perfused for 30 min prior to addition of 10 pM PE, to increase basal tone. The 
initial perfusion pressure was measured after 30 min perfusion in both control 
and haemin-treated mesentery preparations (Figure 5.1.2A).
Haemin pre-treatment did not significantly increase basal perfusion pressure 
(p>0.05, Figure 5.1.2A). Once tissue viability had been checked, the vascular 
tone of the tissue was increased using the al-agonist phenylephrine in order to 
investigate the effect o f haemin pre-treatment on vasodilation. Haemin pre­
treatment significantly reduced the vasoconstrictor effect o f PE compared with 
control (p<0.05, Figure 5.1.2B). If HO-1 expression were increased in haemin- 
treated tissues, it seems probable that this reduction would be due either to 
increased CO production after prolonged contraction, or to a non-specific side- 
effect of haemin treatment as yet unidentified.
Responses to bolus injections of 0.1-30 nmol ACh were abolished in haemin- 
treated but not control samples (p<0.05) (Figure 5.1.3A), while injections of 
histamine elicited dose-dependent vasodilatory responses in both control and 
haemin-treated tissues (Figure 5.1.3B). However, responses were smaller in 
absolute terms in the latter. Thus, the effect of haemin treatment on histamine- 
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Figure 5.1.IB
This is a representative trace o f the isolated 
perfused rat mesenteric vascular bed pre­
contracted with lOpM Phenylephrine (1), 




This is a representative trace of the isolated 
perfused rat kidney pre-contracted with 30mM 
K+ (1), followed by dose responses to 
histamine (0.1 to lOOnmol, 2-8).
5 m ins
Figure 5.1.1 C
This is a representative trace of the 
response to bolus doses o f ET-1 over a 
range of 1 to 300pmol (no. 1-6) in the 
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F ig u re  5 .1 .2
The effect o f  haemin pre-treatment on the basal perfusion pressure (A ) and the increased vascular 
tone induced by Phe infusion (B ) in the perfused mesenteric vascular bed.
Male wistar rats were pre-treated with saline or 75 |im ol/kg haemin. Values are expressed as 
mean ±  SEM and * p<0.05 compared with control (n=5-15).
It is important to note that it was very difficult to maintain the pre-contraction 
perfusion pressure in haemin-treated tissues, as there was a gradual reduction in 
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Figure 5.1.3
The effect of haemin pre-treatment on the vascular responsiveness to bolus injections of ACh (A) 
and histamine (B) in the pre-contracted mesentery.
Male wistar rats were pre-treated with saline or 75 pmol/kg haemin (24hour). Bolus injections of 
ACh, and histamine were investigated over a cycle period of 5 min. Values are expressed as 
mean ± SEM. * where p<0.05 compared with control (n=5). Note: some error bars may fall 
within the size of the symbol.
139
5.1.2. The effect o f  haemin pre-treatment on the response to vasoconstrictor
agents in the perfused mesentery.
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Figure 5.1.4
The effect of haemin pre-treatment on the vascular responsiveness to bolus injections of 
noradrenaline.
Male wistar rats were pre-treated with saline or 75 pmol/kg haemin (24hour). Bolus injections of 
NA were investigated over a cycle period of 5 min. Values are expressed as mean ± SEM (n=5). 
Note: some error bars may fall within the size of the symbol.
To investigate the reactivity o f the vessels cannulated, vascular responsiveness 
was monitored by measuring responses to NA (Figure 5.1.4). A dose-response 
curve can be drawn to illustrate how vascular responsiveness increased in 
response to bolus injections of 0.1-100 nmol NA in both control and haemin- 
treated tissues. Haemin pre-treatment did not significantly affect the response to 
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Figure 5.1.5
The effect of haemin and SnPP pre-treatment alone and in combination on the vascular 
responsiveness to bolus doses of phenylephrine in the perfused mesentery.
Male wistar rats were pre-treated with saline, 75 fimol/kg haemin (24hour) and 40 pmol/kg SnPP 
or haemin + SnPP. The peak height of the increase in perfusion pressure (A) and duration (B) 
were calculated, and values are expressed as mean ± SEM. * where p<0.05 compared with 
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Figure 5.1.6
The effect of haemin and SnPP pre-treatment alone and in combination on the vascular 
responsiveness to bolus doses of ET-1 in the perfused mesentery.
Male wistar rats were pre-treated with saline, 75 |imol/kg haemin (24hour) and 40 pmol/kg SnPP 
or haemin + SnPP. The peak height of the increase in PP (A) and duration (B) were calculated, 
and values are expressed as mean ± SEM. * where p<0.05 compared with control (n=5). Note: 
some error bars may fall within the size of the symbol.
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Haemin pre-treatment (± SnPP) did not significantly affect the vasoconstrictor 
response induced by PE, as compared with responsiveness in control tissue and 
tissue treated with SnPP alone (Figure 5.1.5A). Furthermore, neither haemin nor 
SnPP affected the duration of the PE-induced vasoconstrictor response (Figure 
5.1.5B).
The effect o f haemin pre-treatment on ET-1-induced vasoconstriction was also 
investigated. Results from these investigations indicated that neither haemin nor 
SnPP exerted a significant effect on the peak response to any o f the doses o f ET- 
1 used (Figure 5.1.6A). However, the duration o f action o f ET-1 (lnm ol) was 
significantly reduced in tissues treated with haemin alone, SnPP alone and 
haemin + SnPP (Figure 5.1.6B). This could be another demonstration o f the non­
specific effects o f haemin and SnPP. Angiotensin II was found to have no effect 
on perfusion pressure in either control or haemin-treated hearts (data not shown).
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5.2 The effect of haemin pre-treatment on vascular responsiveness in the
perfused kidney
5.2.1. The effect o f haemin pre-treatment on the vasodilator activity of the 
perfused kidney.
The effects o f vasodilators were also determined in the isolated perfused rat 
kidney. Kidneys were removed from rats treated with saline, 75 |imol/kg haemin 
(24hours) ± 40 pmol/kg SnPP (lhour) or SnPP alone. The tissue was perfused 
for 30 min before vascular tone was increased so that the effects o f vasodilator 
substances could be investigated. The vascular tone was increased by perfusing 
with Krebs solution containing 30 mM K+.
Haemin treatment did not significantly affect the basal perfusion pressure o f the 
perfused kidney (p>0.05, Figure 5.2.1A). After 30 min perfusion with normal 
Krebs, the perfusate was changed to Krebs containing 30 mM K+ in order to 
induce an increase in perfusion pressure. This solution was used in the case o f 
the kidney because it was very difficult to maintain a stable perfusion pressure 
with PE in the kidney. After pre-contracting the tissue with 30 mM K+, there was 
no significant difference in the perfusion pressure o f either control or haemin- 
treated hearts after 30 min (Figure 5.2.IB).
The first agent tested was histamine, which was used because it produced the 
best dose-response curve from all the vasodilators investigated (Figure 5.2.2A). 
In kidneys pre-treated with haemin, the dose-dependent response to histamine 
was not significantly different from that seen in controls (p>0.05).
In contrast, it was very difficult to achieve a gradual dose response curve to ACh 
in either control or haemin-treated kidneys (Figure 5.2.2B). Thus, we can 
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Figure 5.2.1
The effect on haemin pre-treatment on the basal perfusion pressure (A) and perfusion pressure of 
perfused kidney preparations pre-contracted with Krebs containing 30 mM K+(B). Values are 
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The effect of haemin pre-treatment on the vascular responsiveness to bolus injections of 
histamine (A) and ACh (B) in the K+ pre-contracted kidney.
Bolus injections of ACh and histamine were investigated over a cycle period of 5 min. Values are 
expressed as mean ± SEM (n=10). Note: some error bars may fall within the size of the symbol.
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5.2.2. The effect o f  haemin pre-treatment on the response to vasoconstrictor
agents in the perfused kidney.
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Figure 5.2.4
The effect of haemin and SnPP pre-treatment on the vascular responsiveness to phenylephrine in 
the perfused kidney.
Rat kidneys were pre-treated with saline, 75fimol/kg haemin ± 40|nmol/kg SnPP or 40fimol/kg 
SnPP alone.
Bolus injections of PE were investigated over a cycle period of 5 min. The peak height (A) and 
duration (B) were calculated, and values are expressed as mean ± SEM. * where p<0.05 
compared with control and # compared with haemin (n=5). Note: some errors may fall with the 
symbol size.
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Figure 5.2.4 shows the effect o f haemin ± SnPP on renal vasoconstrictor 
responses to bolus doses o f PE. Haemin pre-treatment significantly reduced 
responses to PE at higher doses such as 1, 3 and 10 nmol. In contrast, SnPP 
treatment significantly reduced the duration o f response to PE compared with 
control (Figure 5.2.4B). Therefore, these data suggest that inhibition of HO 
decreased the length o f response to PE.
The effect of haemin pre-treatment on the dose response to ET-1 was also 
investigated. Haemin pre-treatment significantly reduced the response to ET-1 at 
the highest dose tested, whereas SnPP significantly increased the response to 100 
pmol ET-1 (Figure 5.2.5A). Haemin pre-treatment significantly reduced the 
duration o f response at the top end of the dose response curve, while SnPP 
significantly reduced duration o f response at the lower end o f the dose-response 
curve (Figure 5.2.5B).
Finally, the effect o f haemin pre-treatment was examined on the response to 
sarafotoxin-6 c (SX6 C), an ETb agonist (Figure 5.2.6A and B). The only 
significant effect on vascular responsiveness induced by haemin on SX6 C, was 
observed at the lowest dose of lpmol and there was no significant difference in 
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The effect of haemin and SnPP pre-treatment on the vascular responsiveness to endothelin-1 (ET- 
1) in the perfused kidney.
Rat kidneys w ere pre-treated w ith saline, 75|Limol/kg haem in ±  40p m ol/k g  SnPP or 40(im ol/kg  
SnPP alone.
Bolus injections of ET-1 were investigated over a cycle period of 5 min. The peak height (A) and 
duration (B) were calculated, and values are expressed as mean ± SEM. * where p<0.05 haemin 
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The effect of haemin and SnPP pre-treatment on the vascular responsiveness to sarafotoxin-6c 
(SX6C) in the perfused kidney.
Rat kidneys were pre-treated with saline or 75pmol/kg haemin (24 hour).
Bolus injections of SX6C were investigated over a cycle period of 5 min. The peak height (A) 
and duration (B) were calculated, and values are expressed as mean ± SEM (n=5). Note: some 






6.1. Determination o f methods to evaluate HO-1 expression and release o f HQ 
products
The investigation of the effect o f increased HO-1 expression in the constant flow 
rat heart was carried out by pre-treating rats with haemin. Haemin has been 
demonstrated to increase expression o f HO-1, as it is the substrate for HO, and 
the resulting increase in availability o f haem results in induction o f HO-1 
expression (Maines 1997, Clark et al., 2000). It was established that treatment 
with 75 pmol/kg haemin (24 hour) sufficiently increased HO-1 protein 
expression in the rat heart. SnPP did not inhibit the induction o f HO-1 expression 
by haemin, but may act to inhibit HO activity.
The measurement o f a product from haem catalysis was important for the 
identification o f possible mediators involved in the haemin-induced responses 
and as an estimation o f HO activity. Therefore, the method by Van Roy et al., 
(1971) was employed and modified for the measurement of tissue bilirubin 
content. As the tissue was freeze-clamped at the end o f each experiment, tissue 
bilirubin levels can only be commented upon with regards to I/R injury.
6.2 The effect o f haemin-induced HO-1 expression on the pre-ischaemic rat 
heart.
6.2.1 The effect o f  haem in pre-trea tm ent on the constant flow -perfu sed  ra t heart.
In the pre-ischaemic heart, haemin pre-treatment produced a vasodilator effect in 
a dose dependent manner compared with control. The most likely cause for this 
reduction in CPP is the release o f CO via the HO-mediated catalysis o f haemin; it 
should be noted that CO is a known vasodilator (Durante & Schafer, 1998, 
Kozma et al., 1999). Thus, increased availability of the substrate haem leads to 
increased breakdown and the release o f CO, biliverdin and iron. In the presence
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of SnPP, these data implicate that the vasodilator response induced by HO is only 
partially inhibited by SnPP, but it is also possible that other vasodilator mediators 
such as NO or PGI2 are involved in the response. Leffler et al., (2001) have 
suggested that an interaction between these modulators is plausible due to the 
close juxtaposition o f NOS, COX and HO in the vasculature. Furthermore, the 
dilator effect may be produced as a result o f the inhibition o f a vasoconstrictor 
mediator, such as ET-1. For example, Coceani et al., (1997) reported that CO- 
induced dilation in the lamb ductus arteriosus was induced by the inhibition o f 
ET-1 production.
Haemin pre-treatment did not affect the contractility or heart rate o f the tissue 
suggesting that HO-1 up-regulation may not have any impact on the control o f 
contractility in the rat heart perfused under constant flow conditions. However, 
HO-2 and lower, basal levels o f HO-1 do appear to be involved in the regulation 
o f contractility and heart rate, as indicated in rat hearts treated with SnPP alone. 
The non-specific inhibition of guanyl cyclase by SnPP (Grundemar & Ny, 1997) 
may result in a decrease in cardiac cGMP levels. This could also be explained as 
a result o f the direct inhibition o f HO-2, which is the constitutive form of the 
HO. This might also be expected to decrease cardiac cGMP levels, as CO 
released via the HO-2-mediated catalysis o f haem produces its effect by 
activating guanyl cyclase and increasing cGMP levels, and could therefore 
account for the increased force of contraction. However, in Kelly’s experiments 
the rat heart, gave a very different result: an increase in the force of contraction 
produces a reduction in heart rate, a phenomenon known as the negative staircase 
effect (Kelly & Hoffmann, 1960).
6.2.2 The effect o f  haem in-induced HO -1 expression in the constant-pressure- 
p erfu sed  ra t heart.
At a constant pressure of 70 mmHg, haemin pre-treatment significantly reduced 
CFR indicating a vasoconstrictor response. These data are in opposition to data 
recorded at constant-flow. Furthermore, the vasoconstrictor effect of haemin pre­
treatment conflicts with the results o f other studies where HO-1 induction has 
been reported to induce a vasodilator response due to the release of CO
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(Furchgott & Jothianandan, 1991, McFaul & McGrath, 1987). However, a report 
by Imai et al., (2001), has shown that the selective overexpression o f HO-1 in 
mouse transgenic VSMCs significantly increased blood pressure, due to an 
inhibitory effect on NO-induced vasodilatation. It is possible that the induction of 
HO-1 expression by haemin may have an inhibitory effect on the natural 
vasodilator control mechanisms in the constant-pressure-perfused rat heart.
SnPP did not inhibit the effect of haemin pre-treatment on the CFR. This may be 
for a number o f reasons. Firstly, HO-1 may not be completely inhibited by the 
dose o f SnPP selected. Secondly, the effect could be produced as a result o f some 
non-specific action o f haemin; thus, as the response was not completely inhibited 
by SnPP, this could suggest the involvement o f other vasoactive mediators. (For 
example, haemin treatment has been shown to increase iNOS expression and NO 
release (Suzuki et al., 1995). Thirdly, the involvement o f further vasoactive 
mediators may prevent complete inhibition. For example, in the gracillis muscle 
arteriole, the constrictor effect of SnPP was increased after NOS inhibition 
(Johnson et al., 2002). Furthermore, HO-2 is unlikely to be involved in the 
endogenous control o f CFR in control hearts perfused at a constant pressure of 
70 mmHg (as was indicated by the results o f experiments using SnPP alone).
HO-1 induction does not appear to affect the force o f contraction in the pre- 
ischaemic rat heart perfused at constant pressure. This result is surprising as the 
dilator response might be expected to induce a reduction in the force of 
contraction, according to the Gregg phenomenon (Gregg, 1963). Furthermore, 
SnPP significantly reduced the force of contraction in both control and haemin- 
treated hearts, and this was not related to an effect on heart rate. Therefore, the 
lack of selectivity o f SnPP in the presence and absence o f haemin suggests that 
this effect may be due to a non-specific effect from SnPP treatment. 
Metalloporphyrins have been shown to induce cell death as a result o f ROS 
generation (Ohse et al., 2001), a phenomenon that would affect the force of 
contraction in the pre-ischaemic rat heart regardless of haemin pretreatment. 
However, this effect would be expected to become potentiated in the presence of 
haemin, which is another agent o f ROS generation (Schmitt et al., 1993).
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6.2.3 The effect o f  N O  and  C O X  products  in the pre-ischaem ic  constant-flow  
p erfu se d  ra t heart.
L-NO-Arg significantly increased CPP in haemin pre-treated hearts, suggesting 
that NO release is important in the vasodilator response to haemin pre-treatment. 
The dual involvement o f NO and CO have been previously demonstrated in the 
ischaemic heart, where the release o f CO and NO together serves to potentiate 
their effects on cGMP generation (Maulik et al., 1996). For example, an 
induction o f HO-1 expression and an increase in CO release may combine to 
increase the formation of NO, thus potentiating the response to haemin alone. 
However, L-NO-Arg did not affect CPP in control hearts. This is an unexpected 
result as previous studies have demonstrated a reduced coronary flow and an 
increased CPP in the constant-pressure and constant-flow-perfused heart systems 
respectively after NOS inhibition (Kodja et al., 1997). Moreover, NOS inhibition 
has been shown to reduce the hyperaemic response, and to enhance the auto­
regulation of blood flow (Pohl & de Wit., 1999).
L-NO-Arg had little effect on LVDT in haemin-treated hearts, indicating that NO 
release does not appear to be important in the control of contractility in this 
system. This is in agreement with a study by Nawrath et al., (1995) where NO 
donors were shown to have little effect on myocardial contractility in heart 
muscle preparations from guinea pig, rat, rabbit and man. In the normal rat heart, 
it has been postulated that endogenous NO has a positive inotropic effect (Kodja 
et al., 1997). In order to account for the fact that NOS inhibition had little effect 
on contractility, the following possible explanations: 1) the concentration o f L- 
NO-Arg is insufficient to completely inhibit NOS, and 2) in this particular 
system, NO is not a major factor in the control of contractility. Therefore, the 
difference in force o f contraction in control and haemin-treated hearts may be too 
small to demonstrate that L-NO-Arg exerts any significant effect. However, it is 
important to note that NO may play a role in the control of cardiac rhythm as 3 o f 
the total of 8  hearts pre-treated with haemin and perfused with L-NO-Arg 
exhibited complete VF within 5-10 min o f exposure to L-NO-Arg (Data not 
shown). However, NO release does not appear to affect the heart rate in the pre- 
ischaemic rat heart in either treatment group. This is in contrast to the results o f a 
study by Kojda et al., (1997) where both endogenous and exogenous NO were
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shown to alter heart rate; thus, for example, the use o f L-NO-Arg decreased heart 
rate in their experiments.
Inhibition o f COX with indomethacin did not significantly inhibit the vasodilator 
effect induced by haemin pre-treatment or alter the CPP in control hearts. This is 
in agreement with a number o f studies, where there was little evidence for the 
role o f prostaglandins in the regulation o f coronary blood flow in the normal 
myocardium under physiological conditions (Harlan et al., 1978, Altman et al., 
1992). Consequently, these data suggest that COX products, primarily the 
vasodilator PGI2, are not involved in the CPP response induced by haemin pre­
treatment. This is in opposition to a study by Leffler et al., (2001) where 
prostanoids and NO have been shown to contribute to CO-induced 
cerebrovascular dilation in pig pial arteries, although in this system, the 
interaction o f COX products was determined after direct exposure to CO. In 
addition, as COX activity is dependent upon the binding of haem for regulation 
o f its catalytic activity (Smith & Mamett, 1991), it could be envisaged that the 
increased expression o f HO-1 may reduce cellular haem concentrations and 
influence the activity of COX (Maines, 1997), a response that could occur during 
the 24 hour exposure time to haemin prior to death. Furthermore, the anticipated 
increase in free iron release may affect COX activity. For example, 
cardiomyocytes exposed to iron loading demonstrate an increase in COX activity 
and COX-2 expression, which is accompanied by arachidonic acid release and by 
increased eicosanoid production (Qui & Quilley, 1999). Haider et al., (2002) 
confirm this in a study where COX expression and the release o f prostaglandins 
are inhibited in cells transfected with the human HO-1 gene. Thus, the reduction 
in CPP appears to involve the coordinated actions o f NO and CO, but not PGI2. 
COX inhibition significantly increased developed tension in haemin pre-treated 
hearts, although the inhibition o f COX in control hearts did not affect 
contractility. Heart rate was significantly reduced in haemin-treated hearts after 
COX inhibition. The combination of an increase in contractility and a decrease in 
heart rate in haemin- and indomethacin-treated hearts suggests that a similar 
mechanism is involved in both responses. This can be explained by the negative 
staircase effect, where an increase in heart rate induces a decrease in the force of 
contraction in the rat heart (Kelly & Hoffmann, 1960). Therefore, as a number of
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COX products have been implicated in the control o f heart rate, it is possible that 
COX inhibition may primarily affect heart rate. For example, PGI2 has been 
shown either to increase or to decrease heart rate, as both tachycardia and 
bradycardia can be produced after i.v. injections o f PGI2 depending upon the 
basal heart rate (i.e. when the heart rate was high PGI2 produced a bradycardia 
(Chiavarelli et al., 1982)). COX products have been demonstrated to produce 
various effects on cardiac tissue. For example, i.v. administration o f PGI2 can 
produce bradycardia (Chappie et al., 1980), or else it can activate ‘C’-fibres to 
induce a reflex bradycardia (Baker et al., 1979). Furthermore, PGE2 can induce 
tachycardia (Chappie et al., 1980).
6.3 The effect of haemin pre-treatment on the recovery o f cardiac function after 
I/R.
6.3.1 The recovery o f  cardiac fu n c tio n  in the c o n s ta n tflo w  p erfu sed  ra t heart. 
Haemin pre-treatment induced a dose-related increase in recovery of contractility 
after 20 min I/R, with 75 pmol/kg haemin significantly increasing recovery. This 
finding is in agreement with the original study by Clark et al., (2000), the source 
of the dose of haemin used throughout the project. It is important to note that the 
conditions of perfusion were slightly different, as there was a longer ischaemic 
period o f 30 min, higher constant flow rate o f 15 ml/min and a higher K+ 
concentration of the Krebs solution (5.9 mM K+). Therefore, the common factors 
in the recovery o f the heart tissue from I/R are the pre-treatment with 75 pmol/kg 
haemin for 24 hours, and the use of constant-flow perfusion. In addition, a recent 
paper has shown that the cardiac-specific expression o f HO-1 has been shown to 
reduce cardiac dysfunction and cardiomyocyte apoptosis after ischaemia 
(Vulapulli et al., 2002). These data provide evidence that the protective effect o f 
haemin during reperfusion is due to a directly beneficial action on the cardiac 
myocytes; this was independent of any changes in coronary flow because it was 
achieved using a constant flow perfusion system, and therefore there could be no 
changes in the supply o f substrates, or in the washout o f damaging substances.
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Furthermore, haemin pre-treatment with 75 jimol/kg haemin significantly 
increased tissue bilirubin levels. The direct correlation between the level of 
bilirubin and the associated recovery o f cardiac function makes it a prime 
candidate for involvement in this protective effect, as bilirubin is an anti-oxidant 
(Maines, 1997), and has previously been shown to be protective in the treatment 
o f I/R when given exogenously (Clark et al., 2000). The protective role of 
bilirubin may include the removal of ROS that can be responsible for the tissue 
damage associated with I/R (Granger & Forthuis, 1995).
The protective effect o f haemin pre-treatment does not appear to be related to a 
reduction in Ca2+-overload as there is no significant effect on basal tension, 
although the combination o f haemin and SnPP significantly reduced basal 
tension compared with haemin alone. This latter effect may have occurred as a 
result o f increased oxidative stress due to the ROS-generating capacities of 
haemin and SnPP, in combination with the already increased stress levels 
induced by I/R (Schmitt et al., 1993, Ohse et al., 2001). Furthermore, haemin has 
been shown to inhibit the activity o f the Na+/K+ pump (Yasuhara et al., 1991), an 
important mechanism involved in the eventual induction o f Ca2+ overload (Allen 
& Xiao, 2000).
SnPP did not significantly reduce the recovery o f cardiac function in the presence 
o f haemin pre-treatment, suggesting either that FIO inhibition is not complete, or 
that other factors may be involved. The former suggestion implies that the dose 
o f SnPP administered may not be high enough to sufficiently inhibit HO-1, but 
the dose selected was taken from Clark et al., (2000), where treatment with 40 
pmol/kg SnPP for one hour abolished the protective effect o f haemin so this 
seems unlikely. Alternatively, SnPP could be responsible for further effects 
contributing to I/R recovery; for example, metalloporpyrins have been described 
as peroxynitrite scavengers (Crow, 2000). It is important to note that the direct 
effect of SnPP on these parameters during reperfusion is dependent upon either 
the amount of circulating SnPP (which may be too low to produce such an 
effect), or the inhibition/stimulation of enzymes during the exposure to SnPP 
prior to the animals death. Incomplete inhibition o f the improved recovery of
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contractility induced by haemin pre-treatment may occur as a result o f 
insufficient inhibition o f bilirubin production. These data are also an indication 
o f HO activity and suggest that HO activity is not completely inhibited.
The improved recovery o f contractility is accompanied by a significant reduction 
in CPP during reperfusion, which is in agreement with the pre-ischaemic data, 
where a vasodilator response to haemin was also observed. This confirms the 
involvement of a vasodilatory mediator or the decreased release of a 
vasoconstrictor agent that is not dependent on ischaemic insult, in the response to 
haemin pre-treatment. As suggested in the pre-ischaemic heart, the most likely 
mediator is the vasodilator CO. The increase in HO activity (as measured by 
bilirubin production) suggests that CO production would be expected to be 
upregulated. However, in view of the fact that coronary flow was constant at 10 
ml/min during the course o f the experiment, this vasodilatation would not 
improve substrate supply to, or the washout o f waste products, from the heart. 
Therefore, it is unlikely that change in vascular tone contributed to the beneficial 
effect on LVDT, although in an in vivo situation, where flow could change, this 
vasodilatation would be expected to have additional beneficial effects. The 
vasodilation produced by CO could be involved in an increase in tissue 
reperfusion; although the flow rate remains constant, the reduction in CPP may 
aid the prevention o f tissue damage produced by the “garden-hose” hypothesis 
(Arnold et al., 1968, Poche et al., 1971). This phenomenon is described as the 
distention o f coronary vessels that results in an increase in cardiac sarcomere 
length. Hence, in a system where CPP is increased, the force o f contraction might 
be expected to increase. Therefore, vasodilation leads to not only a decrease in 
the “garden-hose effect” but also a decrease in energy consumption. 
Furthermore, peripheral vasodilation would also lead to a decreased load on the 
heart, and may increase flow to the deeper subendocardium. Thus, these data 
suggest that a reduction in CPP induced by haemin-pre-treatment could further 
increase recovery o f cardiac function after I/R in our experiments. However, 
these data are not in agreement with Clark et al., (2000), as 75 |nmol/kg haemin 
pre-treatment did not induce any significant change in CPP after I/R. In fact, part 
o f the protective response to haemin was postulated to involve the maintenance
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o f CPP at pre-ischaemic levels. In an earlier study in our lab, hearts perfused at 
the higher K+ concentration o f 5.9 mM, demonstrated no significant reduction in 
CPP in the pre-ischaemic rat heart perfused at 10 ml/min (Data not shown). This 
may suggest that, under the conditions described by Clark et al., (2000), the 
maintenance o f CPP may be due to the use o f a Krebs solution containing 5.9 
mM K+.
SnPP did not significantly abolish the dilator response to haemin during 
reperfusion. It is possible that this occurred because HO inhibition is not 
complete, and that the response to haemin could still be mediated by HO 
expression. SnPP may also inhibit the response to HO-1 expression and CO 
release by the inhibition o f guanyl cyclase (Grundemar & Ny, 1997). This could 
prevent CO from initiating both the activation of GC, and also the accompanying 
vasodilation. Furthermore, as discussed in the case o f the pre-ischaemic heart, 
haemin pre-treatment has been shown to increase NOS activity (Suzuki et al., 
1995), thus suggesting that other vasoactive mediators may be released.
6.3.2 The effect o f  haem in pre-trea tm en t on recovery o f  cardiac fu n c tio n  in ra t 
hearts p erfu sed  a t a constant-pressure o f  70 mmHg.
After ischaemia the vasoconstrictor effect observed in the haemin-treated pre- 
ischaemic heart was abolished. It is possible that vasodilator mediators released 
during the reactive hyperemia response to I/R may serve to counteract the 
vasoconstrictor effect of haemin. However, haemin and SnPP produced a 
significant vasoconstrictor effect compared with control and SnPP. This suggests 
that haemin and SnPP are having a non-specific effect on the CFR during 
reperfusion as neither haemin or SnPP had any effect when acting alone. An 
example o f a non-specific effect o f SnPP is the inhibition of NO-mediated 
responses in the rat aorta, and this could affect the vascular responsiveness to NO 
(Vreman et al., 2000). Therefore, as haemin pre-treatment may reduce the 
responsiveness o f guanyl cyclase to NO (Imai et al., 2001), this effect could be 
potentiated in combination with SnPP.
Recovery of contractility was marked (-80 %) in both haemin-treated and control 
hearts, suggesting that the method of perfusion used may increase recovery (in
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comparison, the recovery observed in control hearts perfused at constant-flow 
was -15  %). In the constant-flow model, we postulated that the reduction in CPP 
could aid recovery from I/R due to inhibition o f the “garden-hose” effect. A 
study by Takeo et al., (1995) has demonstrated that reperfusion at reduced flow 
rates (over a range o f 0.9-8 ml/min) can enhance the recovery o f cardiac 
contractility post-ischaemia in comparison to a normal flow rate o f 9 ml/min. 
Protection at low CFR was suggested to be due to a reduction in ischaemia- 
induced Ca2+ and Na+ overload, and was not induced by changes in either ROS 
generation or rate o f Ca2+ delivery. This is compatible with our suggested 
reduction in the garden hose effect, which could cause cardiac myocytes to 
stretch, and thereby cause them to contract more forcefully (via the Starling 
effect), resulting in an increase in energy use. However, as there is no significant 
difference in CFR post-ischaemia, it is unlikely that a reduced flow rate pre- 
ischaemia is responsible for the high levels of recovery.
The reduction in recovery from I/R in SnPP-treated hearts may be related to an 
effect observed in the pre-ischaemic heart, where increased ROS generation 
potentiated the cellular damage associated with I/R. This could also be linked to 
an increase in Ca2+ overload, as the destructive effect o f Ca2+ overload is 
produced by regulation of a number o f Ca2+-regulated enzymes such as 
phospholipases and degradative enzymes.
In the constant-pressure model, haemin pre-treatment did not significantly 
increase tissue bilirubin levels, which suggests that haemin pre-treatment did not 
confer any protection from I/R, due to the absence o f an accompanying increase 
in bilirubin levels. This is in opposition with the data recorded in the constant- 
flow model, and also that observed by Clark et al., (2000), where the protection 
from I/R by haemin pre-treatment is reported to be due to bilirubin release. 
Furthermore, the amount o f bilirubin measured in constant-pressure perfused 
hearts was found to be similar to that detected in control hearts perfused at 
constant flow, which were associated with a lower level o f recovery. Under 
conditions of constant flow, bilirubin levels were increased 2 -fold in haemin- 
treated hearts. SnPP reduced the recovery from I/R but increased bilirubin levels, 
in the presence o f haemin. The increase in bilirubin production may be due to an
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increase in the availability o f the substrate haem. Hence, it appears that levels of 
bilirubin do not correlate with increased recovery from I/R in this model o f 
perfusion. The increased level o f bilirubin may actually be detrimental to the 
cells, as reported by Suttner and Dennery (1999), where high levels o f HO-1 
expression actually increased cell death.
6.3.3 The contribution o f  N O  and C O X  products on the recovery fro m  I/R  o f  
haem in treated hearts.
The release o f NO as a result o f haemin pre-treatment does not appear to be 
involved in the recovery o f cardiac function after I/R. There has been some 
controversy about the positive or negative role o f NO in I/R, although of the 
studies involved around 73 % conclude that NO has a protective role in both 
partial and global ischaemia models (Bolli, 2001). O f these studies, Wesselcouch 
et al., (1995) and Ferdinandy et al., (1997) have reported that endogenous NO 
has little effect on the recovery from ischaemic insult. This is in agreement with 
the data presented here, as control hearts exposed to NOS inhibition did not 
demonstrate a significant reduction on recovery o f cardiac function. A reduction 
in Ca2+ overload was observed in the presence o f L-NO-Arg, but this had little 
influence on contractility under these conditions. Furthermore, this was 
accompanied by a lack o f influence on tissue bilirubin levels, suggesting that the 
degree o f protection that remains after NOS inhibition may be solely due to the 
maintenance of bilirubin levels. NO release is involved in the vasodilator 
response to haemin treatment post-ischaemia, which is in agreement with the 
effect observed in the pre-ischaemic heart, and also a study by Wesselcouch et 
al., (1995), where the inhibition o f NO synthesis produced coronary 
vasoconstriction, although this was accompanied by cardiac depression. 
However, as there was little change in control hearts, it seems that this effect was 
initiated by pre-treatment with haemin.
After I/R, COX inhibition significantly reduced the recovery o f cardiac function 
induced by haemin pre-treatment. These data implicate the involvement o f COX 
products in the recovery of cardiac function induced by haemin pre-treatment
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and are in agreement with our data from the pre-ischaemic heart, where COX 
products appear to increase the force o f contraction. A study by Morbert & 
Becker, (1998) demonstrated that COX inhibition exacerbated the recovery of 
cardiac function after ischaemia. This is also shown in the guinea pig heart, 
where aspirin-induced inhibition of COX aggravated post-ischaemic cardiac 
dysfunction (Heindl & Becker, 2001). The exogenous administration o f a PGI2 
analogue has been shown to increase recovery o f cardiac function after I/R 
(Maulik et al., 1997). Hence, COX inhibition may significantly reduce recovery 
o f cardiac function due to inhibition o f PGI2 production. In addition, the 
reduction in the improved recovery o f contractility induced by haemin pre- 
treatment was not related to an effect on Ca overload, as indicated by the lack 
o f effect on basal tension.
Indomethacin reduced the CPP response to haemin pre-treatment. This is in 
opposition to data observed in the pre-ischaemic heart, where there was no 
significant effect on haemin-induced vasodilation. This may be related to the fact 
that previous studies have demonstrated that reperfusion is a potent stimulus for 
PG synthesis (Karmazyn, 1986). COX products have also been implicated in the 
induction of cardiac reactive hyperaemia after ischaemia (Gryglewski et al., 
1996). Moreover, in a rat model of low-flow ischaemia, COX inhibition using 
indomethacin prevented the preservation of vasodilation after ischaemia, which 
is associated with the protection of endothelial function (Bouchard & 
Lamontagne, 1999). Furthermore, COX inhibition can lead to substrate diversion 
to the lipoxygenase pathway, resulting in the production o f leukotrienes (LT), 
which are potent vasoconstrictors (Maulik et al., 1997).
The inhibition o f COX in haemin-treated hearts significantly increased tissue 
bilirubin production. Therefore, COX inhibition appears to influence the activity 
of HO-mediated haem breakdown. As COX activity is dependent upon the 
binding o f haem for the regulation o f its catalytic activity (Smith & Mamett, 
1991), it is possible that inhibition of COX results in the increase in free haem 
and bilirubin production.
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6.4 The effect o f  increasing the duration o f  the ischaem ic period on the recovery
o f  cardiac function.
6.4.1 The effect o f  30 m in ischaem ic insult on recovery o f  cardiac fu n c tio n  in the  
constant - flow -perfu sed  ra t heart.
The recovery o f cardiac function post 30 min I/R was significantly reduced in 
both control and haemin-treated hearts. This data is not in agreement with the 
study by Clark et al., (2000), where rats hearts pre-treated with 75 pmol/kg 
haemin (24hours) were exposed to a 30 min ischaemic period; this may be 
because o f slight experimental differences between the 2 studies. Interestingly 
the lack o f protection was not accompanied by a reduction in tissue bilirubin 
levels. The increase in ischaemic period has probably produced an irreversible 
damage compared to a 20 min ischaemic period (Taegtmayer et al., 1997). 
Furthermore, as bilirubin levels are not significantly affected, we postulate that 
the level o f tissue bilirubin is insufficient to prevent the increased tissue damage 
caused by an additional 1 0  min of ischaemia, and therefore we conclude that the 
cells may already be damaged by ischaemia in this case. Thus, the limiting factor 
in determining the degree of recovery of cardiac function from I/R in this system 
is the length o f ischaemic insult.
The eradication o f the protective response from haemin pre-treatment is also 
accompanied by an absence o f vasodilation during reperfusion. These data are in 
agreement with Clark et al., (2000), where little change in CPP above baseline 
was recorded in hearts treated with haemin. This response is likely to occur as a 
result o f either increased vasoconstrictor release, decreased vasodilator release or 
diminished vascular responsiveness as a result o f endothelial cell injury post 
ischaemia, or a combination o f all. Therefore, the recovery o f cardiac function 
after I/R under our experimental conditions appears to require a vasodilatory 
mediator, rather than an increase in tissue bilirubin production, after an 
ischaemic insult o f 30 min.
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6.4.2 The effect o f  increasing the duration o f  the ischaem ic p e r io d  on recovery o f  
cardiac fu n c tio n  in the constant-pressure per fu sed  ra t heart.
In control hearts subjected to 30 and 40 min ischaemia, there was a significant 
reduction in the reactive hyperemia response. Reactive hyperemia is a 
vasodilator response that occurs in response to I/R, and its removal may be 
caused be either a decrease in vascular responsiveness, a decrease in release of 
vasodilators, or an increase in release o f a vasoconstrictor. For example, 
adenosine, NO, and K a t p  channels have all been implicated in reactive 
hyperemia o f the guinea-pig heart (Kingsbury et al., 2001). A study by 
Kirkeboen et al., (1994), has indicated that endothelium-derived NO may be 
involved in reactive hyperemia after a short duration o f coronary no-flow 
ischaemia but that it is absent or reduced in reactive hyperemia after a prolonged 
ischaemia. This is also true o f K At p  channel activity in the rat heart (Shinoda et 
al., 1997). This evidence suggests that reactive hyperemia is abolished due to 
increases in ischaemic insult. An alternative suggestion for the reduction in CFR 
may be due to oedema formation, which can cause cell swelling to occlude 
vessels, another mechanism of the “no-reflow” phenomenon (Korthuis et al, 
1994). Our data suggest that there is a greater vasoconstrictor effect in haemin -  
treated hearts after increased ischaemic insult. It is possible that the balance of 
vasoactive mediators may become disrupted after extended ischaemia, so that the 
removal of vasodilator mediators such as NO and adenosine (Kingsbury et al., 
2001, Kirkeboen et al., 1994) enhances the effect o f HO-1 induction.
The increased ischaemic insult significantly reduced recovery o f contractility 
after I/R to a similar extent indicating that there is only a very small therapeutic 
window in which the hearts will demonstrate almost complete recovery from I/R 
in this model. This is in agreement with the current understanding that as the 
ischaemic insult increases, recovery from I/R becomes impaired due to the 
change from reversible damage after 2 0  min ischaemia to irreversible damage 
after 30 min+ (Taegtmayer et al., 1997). Haemin pre-treatment did not confer 
any added protection from prolonged I/R injury. This result was observed in both 
the constant-flow and the constant-pressure-perfused rat heart. This is in 
opposition with previously recorded data, where haemin pre-treatment or HO-1 
overexpression significantly increased recovery after a 30 min ischaemic insult in
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the constant-pressure-perfused heart (Yet et al., 2001), but it should be noted that 
there were slight experimental differences between the 2  studies, such as higher 
flow rates and different methods of HO-1 induction and perfusion. It is difficult 
to comprehensively determine the true effect o f HO-1 expression in the in vitro 
perfused heart due to the diverse methods used to investigate such effects.
The reduced recovery o f contractility is accompanied by a significant increase in 
Ca" overload. As it can be postulated that acidosis may be potentiated during the 
prolonged ischaemic insult as a result o f increased ATP depletion (Bolli et al.,
^ I
1990), it is likely that increases in intracellular Ca upon reperfusion may be 
enhanced.
Tissue bilirubin levels were increased in a time-dependent manner in control and 
haemin-treated hearts. The increased bilirubin levels do not confer protection 
from I/R, but it is conceivable that this result occurs in response to the increasing 
oxidative stress seen after increased ischaemic insult, as HO-1 activity can be 
increased in the presence o f ROS generation (Vile et al., 1994, Panchenko et al., 
2000). It is also possible that increased tissue damage and cellular apoptosis may 
increase free haem levels (Maines, 1997) and thus increase substrate levels for 
the production o f bilirubin. The increased tissue bilirubin levels may be present 
as a result o f a decreased washout due to the vasoconstrictor effects observed 
during reperfusion. Furthermore, in cardiomyocytes exposed to hypoxia and 
reoxygenation, haem availability is the rate-limiting factor involved in the 
protection conferred by HO-1 induction (Foresti et al., 2001).
6.5. Does perfusing the rat heart at 130mmHg affect the recovery o f cardiac 
function after I/R?
In control hearts perfused at a constant flow o f 10 ml/min the initial CPP 
averaged 130 mmHg compared with 70-90 mmHg in haemin-treated hearts. 
Therefore, the effect of perfusion at a constant pressure of 130 mmHg was 
investigated to determine the influence of the pressure level on recovery from I/R 
and vascular responsiveness. Haemin pre-treatment produced a vasoconstrictor 
response, indicating that this effect is not dependent on the pressure o f system. 
Furthermore, the CFRs o f control and haemin-treated hearts were approximately
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double those recorded previously in hearts perfused at 70 mmHg, indicating that 
autoregulatory mechanisms are not present in this system. At 130 mmHg, 
contractility is decreased and heart rate is increased. The increase in heart rate 
may induce a reduction in contractility in the phenomenon known as the 
“negative staircase” (Kelly & Hoffmann, 1960), where an increase in heart rate 
produces a decrease in contractility or vice versa.
Upon reperfusion, haemin pre-treatment produced a vasoconstrictor response 
compared with control; this is in agreement with pre-ischaemic data. There 
appears to be an inhibitory effect (which is not present at 70 mmHg) on reactive 
hyperemia in haemin-treated hearts. This suggests that the vasoconstrictor effect 
post-ischaemia is dependent upon the basal pressure. In a study by Wagner et al., 
(1997), the expression o f HO-1 has been shown to be regulated by 
haemodynamic forces in vascular smooth muscles. For example, the passage of 
blood through the cardiovascular system induces endothelial cell elongation in 
response to shear stress via cytoskeletal rearrangement and the secretion of 
various bioactive molecules. However, the time course of this experiment is not 
long enough to demonstrate an increase in HO-1 expression, although an increase 
in HO activity could occur. For example, a study by Carraway et al., (2000) has 
indicated that the pattern o f HO-1 expression does not correspond with the 
pattern of HO activity in the chronic hypoxic lung. Therefore, this may suggest 
that there may be a post-translational mechanism involved in increasing HO 
activity after expression.
Haemin conferred significant protection on the recovery o f contractility at 130 
mmHg compared with control. However, the degree o f recovery o f contractility 
was significantly reduced at 130 mmHg compared with that previously recorded 
at 70 mmHg. This suggests that the conservation of cardiac function by haemin- 
induced HO-1 may be pressure-sensitive under constant-pressure perfusion 
conditions. Furthermore, the reduction in recovery of contractility is not 
connected to an increase in intracellular Ca2+ overload.
Haemin pre-treatment increased bilirubin levels compared with control. The 
recovery o f contractility in haemin-treated hearts appears to involve an increase
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in bilirubin production. It is possible that this effect may be produced by a direct 
effect on muscle contraction. For instance, Samb et al., (2001) reported that HO 
and bilirubin control smooth muscle reactivity to ROS-induced phosphorylation 
of the myosin light chain in the guinea pig trachea.
6 .6  The effect of haemin-induced HO-1 expression on anaerobic glvcolvsis in the 
post-ischaemic rat heart
The main aim for the investigation o f the effect o f haemin pre-treatment on 
anaerobic glycolysis was to determine whether the protective effect o f haemin on 
I/R was related to an increase in ATP production during ischaemia, or a 
reduction in the build-up of detrimental metabolites such as lactate and H+. For 
example, in the preconditioned dog heart, it is postulated that preconditioning 
protects the heart by reducing the metabolic requirements o f the ischaemic 
myocardium, and therefore preserving ATP or limiting the production of 
catabolite accumulation (such as lactate) (Murry et al., 1990).
Treatment with haemin did not significantly affect lactate release compared with 
control at constant-flow and constant-pressure, indicating that the protective 
effect o f haemin post I/R is not due to an increase in anaerobic ATP production 
via glycolysis. The involvement o f the activation o f cGMP in the regulation of 
glucose metabolism has been previously demonstrated by the use o f cGMP 
analogues to decrease glucose uptake and glycolytic flux (Depre et al., 1999). 
Therefore, we questioned whether CO release in haemin-treated hearts may 
influence glucose metabolism due to its action on cGMP. Our results suggest that 
this is not the case. Furthermore, a recent study by Chang et al., (2003), has 
suggested that HO-1 gene activation can occur as a result o f glucose deprivation, 
via a mechanism which involves the generation o f free radicals. However, the 
reduction in recovery o f hearts treated with a combination of haemin + SnPP 
may be related to an accumulation of glycolytic metabolites such as lactate and 
H+ (Murry et al., 1990). Alternatively, any increase in lactate would be expected 
to be accompanied by an increase in ATP production, a protective response to 
I/R. Inhibition of NO release may significantly reduce ATP production during 
ischaemia and promote the accumulation o f toxic metabolites such as lactate.
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Furthermore, this effect appears to occur regardless o f haemin pre-treatment and 
is exclusively related to the release o f NO. This is in agreement with a study by 
Depre et al., (1995), where NO donors were found to increase glucose 
metabolism in the ischaemic heart. The negative value recorded during the fifth 
minute of reperfusion in the presence o f L-NO-Arg suggests that some lactate 
may have been pumped back into the cardiac tissue. COX products do not appear 
to influence the production of ATP from anaerobic glycolysis in the ischaemic 
rat heart. This suggests that the reduction in recovery o f cardiac function in the 
presence o f indomethacin is not produced as a result o f decreased ATP 
production from anaerobic glycolysis or increased metabolite accumulation. 
Finally, after increasing the duration of the ischaemic period to 30 min at 
constant-flow, total lactate release is increased in control hearts, compared with a 
decrease in control hearts perfused at constant-pressure. These contradicting data 
suggest that by increasing the ischaemic period in control hearts perfused at 
constant-flow, a prolonged period o f anaerobic glycolysis is brought about as 
indicated by the increase in lactate. However, as there is no significant difference 
in the total lactate release at constant-pressure, it is possible that the reduction 
observed during the first 2  min may occur as a result o f the significant 
vasoconstrictor effect observed. In contrast, as there is no difference in haemin- 
treated hearts, this suggests that, as the ischaemic period increases, anaerobic 
glycolysis or the increase of glucose uptake for glycogen formation may be 
inhibited. In theory, there should be the same amount of substrate available in 
both control and haemin-treated hearts.
Thus, at a constant pressure o f 130 mmHg, the improved recovery o f contractility 
after I/R is not related to an effect on anaerobic glycolysis or ATP production. 
However, according to Taegtmayer et al., (1997) tissue ATP content does not 
correlate with contractile function. This seems also to be true for haemin pre­
treatment, as it induces increased recovery but no difference in lactate release. 
The improvement o f recovery in the presence of DFO is not assisted by a 
reduction in lactate production or washout.
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6.7 What effect does haemin pre-treatment have on the release o f  nitrite ?
Nitrite release is decreased in haemin -treated hearts and increased in SnPP- 
treated hearts. Haemin pre-treatment may decrease NO production in the pre- 
ischaemic rat heart, thereby bringing about a vasoconstrictor effect. This 
corroborates with the data published by Imai et al., (2 0 0 1 ) where vascular- 
specific expression o f HO-1 produced an increase in blood pressure by 
suppressing the vasodilatory response to NO. Moreover, a study by Kostic et al., 
(1996), suggests that NO is involved in the control o f basal coronary flow as 
indicated by a reduction in CFR after NOS inhibition. Therefore, the important 
role o f NO under basal conditions indicates that increases in HO-1 expression 
can reduce NO release (Maines, 1997) and produce an overall constrictor effect. 
These data may suggest a role for HO-2 in the control o f NO release, although 
this does not affect the overall CFR compared with control. At a constant 
pressure o f 130 mmHg, haemin does not significantly affect the release o f NO in 
the pre-ischaemic rat heart compared with control, implying that the 
vasoconstrictor effect does not involve an action on NO release. Rubanyi & 
Vanhoutte, (1986), have reported that the action o f NO is potentiated as a result 
o f an increased flow-induced mechanism. Thus, the constrictor effects o f haemin 
pre-treatment are produced via different mechanisms at 70 and 130 mmHg.
Upon reperfusion at 70 mmHg or 130 mmHg, the release o f nitrite is 
significantly reduced in haemin-treated hearts compared with control during the 
first 2 min of reperfusion. Inhibition of NOS has been shown to decrease the 
duration o f the hyperemic response, but it is important to note that a reactive 
hyperemia is still present, thus excluding NO as the main mediator o f reactive 
hyperemia (Pohl & Cor de Wit, 1999). SnPP increased nitrite release over the 
initial 5 min of reperfusion. This indicates that a non-specific effect o f SnPP is 
taking place, as there is no significant difference between treatment with SnPP 
alone or in the presence o f haemin. This data is in opposition with a previous 
observation that metalloporphyrins reduce NO-mediated responses in the rat 
aorta (Vreman et al., 2000). However, a report by Chakder et al., (1996), 
suggests that the metalloporphyrin ZnPP can stimulate NOS activity in the rabbit 
internal anal sphincter, albeit at very high non-specific doses.
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6.8 D oes the removal o f  free iron using the iron chelator desferrioxamine affect
the pre-ischaemic heart or increase the recovery from I/R?
DFO reversed the vasoconstrictor effect o f haemin pre-treatment, suggesting that 
there is an element o f iron involvement in the control o f CFR perfused at 
constant pressure. However, this may occur due to a non-specific effect o f DFO. 
Studies have reported that DFO can act as a direct scavenger o f hydroxyl radicals 
(Hoe et al., 1982). DFO may also influence the recovery o f coronary flow after 
ischaemic insult (Ambrosio et al., 1987); this effect does not appear to be directly 
related to DFO itself as other iron chelators such as desferriexochelin have been 
proven to increase the recovery o f portal venous blood flow, decreased 
hepatocyte injury and reduced oxidative stress levels in the I/R liver model 
(Amersi et al., 2001).
Furthermore, iron released during haem degradation could further inhibit NOS 
mRNA synthesis by inhibiting nuclear transcription (Weiss et al., 1994). 
However, ROS have been implicated in the production of a vasodilatory effect 
(Shattock et al., 1982). DFO reduced the force o f contractility in haemin-treated 
hearts, implying that free iron may have a significant influence in the regulation 
o f the force o f contraction in haemin-treated hearts. This is surprising as the 
converse might be expected, as the presence o f ROS produced by increased iron 
levels have been shown to cause contractile dysfunction (Farber et al., 1988). It is 
possible that this effect may be caused by continued perfusion with DFO 
throughout the duration o f the experiment. Other non-specific actions of DFO 
such as the removal o f hydroxyl ions could also affect contractility (Hoe et al., 
1982). However, the addition o f DFO did not affect heart rate.
A 30 min ischaemic insult provided a large enough therapeutic window to 
demonstrate the potential impact of DFO treatment on the recovery from I/R. 
DFO treatment significantly increased recovery from I/R in both control and 
haemin-treated hearts to a similar extent. The involvement o f free iron has been 
demonstrated in the pathogenesis o f I/R (Berenshtein et al., 1997), and may 
occur as a result o f the rapid release o f iron from ferritin under anaerobic 
conditions (Bolli et al., 1990), or after attack by superoxide radicals (Antonius et
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al., 1988). Ambrosio et al., (1987) have demonstrated a significant increase in 
recovery o f myocardial function and energy metabolism after global ischaemia 
when DFO is added upon reperfusion. DFO has been proven to reduce the 
occurrence of reperfusion-induced VF in rat hearts (Bernier et al., 1986). 
Myocardial “stunning”, described as the prolonged reduction in contractility in 
the reperfused myocardium after reversible ischaemic insult, has also been 
inhibited by the presence o f DFO, and this has been suggested to be due to the 
reduction o f iron-catalyzed ROS production (Bolli et al., 1990). Furthermore, the 
improved recovery from I/R in haemin-treated hearts in the presence o f DFO 
may be related to a reduction in intracellular Ca2+ overload.
An increase in CFR was associated with the DFO-induced improvement in 
recovery of contractile function in control hearts. This is in agreement with a 
study by Badylak et al., (1987), which indicated that DFO reduced the increased 
vascular resistance associated with reperfusion. Furthermore, DFO has been 
shown to influence the recovery of coronary flow after ischaemic insult 
(Ambrosio et al., 1987). Further studies have demonstrated an improved recovery 
o f coronary flow from DFO treatment after hypothermic ischaemia, but this was 
not accompanied by a beneficial effect on recovery o f contractility (Myers et al., 
1986). The removal o f the free iron generated by ischaemia may aid a protective 
response by increasing CFR and thereby preventing the onset o f the events 
described in the garden “hose” hypothesis (Arnold et al., 1968, Poche et al., 
1971). The beneficial effects o f DFO are not restricted to CFR, as there is no 
significant increase in the CFR of haemin-treated hearts. However, the anti- 
apoptotic effect of HO-1 appears to be related to an ability to increase cellular 
iron efflux via the upregulation of an uncharacterized iron pump (Brouard et al., 
2000). Alternatively, the upregulation of HO-1 activity and associated increase in 
free iron release also increases the expression o f ferritin (Vile et al., 1994). These 
factors could explain why ischaemic insult exerts little effect on the CFR of 
haemin-treated hearts exposed to DFO. However, it is possible that the iron-DFO 
complex that is produced can still facilitate an increase in HO-1 expression, and 
thereby bring about an increase in bilirubin production.
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6.9 Is the vasoconstrictor effect o f  haemin-induced HO-1 expression caused by
an effect on the autoregulation mechanisms of the rat heart?
Coronary autoregulation is described as the capacity to maintain a stable blood 
flow supply within the coronary circulation in the face o f wide-ranging change in 
perfusion pressure. The heart achieves this by initiating vascular myogenic 
changes in response to alterations in pressure, and by a number o f metabolic 
changes. For example, increased pressure results in an initial increase in flow, 
which enables the washout of metabolites leading to vasoconstriction and 
eventually normalized flow (Pohl & Cor de Wit, 1999). It is possible that 
increased expression o f HO-1 and CO production may interact with these 
vasoactive mediators and autoregulation mechanisms.
Haemin pre-treatment produced a vasoconstrictor effect at 100, 80 and 60 
mmHg, providing further evidence that haemin has a vasoconstrictor effect at 
various pressure levels. However, haemin does not significantly reduce CFR at 
135 and 120 mmHg in this system. Interestingly, the combination o f haemin and 
SnPP produced VF after the initial pressure change in 3 of the 5 tissues 
examined. It is difficult to explain the mechanism behind such responses, 
although it is possible that there was an interaction between haemin + SnPP that 
proved detrimental at a higher pressure level. This could not be confirmed by 
referral to previous experiments at 130 mmHg, as the effect of SnPP had not 
been investigated in these cases. SnPP treatment produced a CFR similar to 
haemin-treated hearts. This effect could be another demonstration o f the dual 
mechanism of action thought to be produced by various metalloporphyrins, in 
particular SnPP (Maines, 1997). Alternatively, the increased ROS generation 
produced by SnPP (Ohse et al., 2001) may act to reduce the half-life o f NO, and 
thereby bring about an overall constrictor reponse.
The CFR was measured over an initial period o f 2 min after the pressure change 
in each treatment group. After the initial pressure change to 135 mmHg, there 
was a significant reduction in the CFR of tissues treated with haemin and SnPP 
compared with control. This low flow rate at a relatively high pressure may 
suggest a reason for the production o f VF relatively soon after the pressure
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change. The overall conclusion of this experiment is that there is no clear 
evidence o f any autoregulation mechanisms in both control and haemin-treated 
hearts as demonstrated by the gradual reduction in CFR as the pressure level is 
reduced. This is in agreement with the data measured at 130 mmHg, where the 
CFR doubled compared with hearts perfused at 70 mmHg. If autoregulation 
mechanisms were active, the CFR would remain the same regardless o f the 
perfusion pressure.
In the presence o f NO, there is a prominent autoregulation effect in the heart, 
although Pohl & Cor de Wit, (1999) have suggested that NO can actually 
attenuate autoregulation during myogenic autoregulation. NO has been shown to 
be one of the primary mediators involved in metabolic control o f coronary 
autoregulation, although the actual mechanisms involved in autoregulation are 
likely to be more complex. Furthermore, Jakovljevic et al., (1999) have reported 
an interaction between the L-arginine-NO system and COX products in the 
regulation of coronary autoregulation. Thus, it is possible that as there has been 
previous evidence that HO-1-derived CO can also interact with NO and COX 
products, there may some sort o f interaction under these conditions. It has been 
established that in a situation where there is a permanent effect on either tissue 
activity or metabolic changes, autoregulation mechanisms can be reset to new 
levels. As the use o f SnPP continually reduced CFR throughout the experiment, 
it can be postulated that endogenous CO production may be important in 
autoregulation mechanisms. However, the data observed in haemin-treated hearts 
also produced a conflicting effect where a negative role was implicated for 
increased HO-1 expression in the autoregulation response. Alternatively, this 
may be a first example of a possible opposing effect from HO-1 and HO-2 in the 
control of vasoreactivity.
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6.10 The effect o f  haemin pre-treatment on vascular tone in other vascular beds.
Investigation o f haemin pre-treatment in the perfused mesentery and kidney 
provided an opportunity to study the effect o f HO-1 in other vascular beds. 
(However, immunoblot analysis was not carried out in these tissues to determine 
whether HO-1 expression was significantly increased. Therefore, any effect of 
HO-1 on vascular responsiveness in haemin-treated preparations must be 
considered to be purely speculative.)
6.10.1 H ow  does haem in-induced HO -1 expression influence vascular  
responsiveness in the per fu sed  m esentery ?
In the perfused mesentery, haemin pre-treatment produced a small increase in the 
initial perfusion pressure although this was not statistically significant. In 
contrast, haemin did attenuate the vasoconstrictor effect o f PE (10 pM), but did 
not affect the response to bolus doses o f NA. In addition, in haemin pre-treated 
mesenteric vascular beds, it was very difficult to maintain a high enough 
perfusion pressure to investigate the activity of vasoconstrictor agents. Therefore, 
it is possible that if  haemin pre-treatment induces HO-1 expression, the 
prolonged increase in basal tone induced by PE may be influenced by CO 
release, resulting in attenuation of the PE-induced perfusion pressure. For 
example, in a model o f hypertension involving the chronic perfusion of 
angiotensin II, HO-1 expression has been reported to increase in the rat aorta and 
heart as a result o f haemodynamic / mechanical stress and pressure overload 
(Ishizaka et al., 1997, Ishizaka et al., 2000).
The responses to ACh were very small in haemin-treated tissues compared with 
control, which may be due to the influence of HO-1-induced CO release. HO-1 
has been shown to protect against vascular constriction (Duckers, 2001). Hence, 
it is possible that haemin reduces the response to ACh through a direct effect on 
M 3 receptors. The most likely effect is the potentiation o f relaxation by NO, the 
effector molecule responsible for vasodilation via the M3 receptor. The role of
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NO in response to haemin-induced HO-1 expression has been an important 
theme throughout this study.
In contrast, haemin does not affect the response to histamine apart from at the 
highest dose. Therefore, it is possible that this is in response to the force of 
vasoconstriction induced by a high dose o f histamine, and may not be 
specifically linked to a histamine receptor-mediated event. The second 
messenger system involved in generating the response to histamine HI receptor
I
activation produces an overall increase in intracellular Ca levels. Therefore, an 
increase in HO-1 expression may not influence intracellular Ca2+ levels at lower 
doses. Alternatively, as CO has been shown to inhibit the activity o f the Kca
I
channel (Wang & Wu, 1997), it is likely that the levels o f intracellular Ca may 
not be increased at levels where CO can exert an effect (apart from at the highest 
dose o f 30 nmol histamine).
The effect of haemin-induced HO-1 expression on vasoconstriction in response 
to PE, ET-1, NA and Ang II was investigated. At the highest dose of PE, haemin 
treatment significantly reduced the vasoconstriction. This suggests that HO 
activity may be increased in response to an increase in the degree and duration of 
response to PE as haemodynamic stress is an inducer o f HO activity (Wagner et 
al., 1997). However, there was no effect on the dose-response curves of 
vasoconstriction versus NA or Angiotensin II. Both haemin and SnPP (alone and 
in combination) reduced the duration o f response to ET-1 (highest dose only). 
Therefore, haemin pre-treatment does not affect the mesenteric response to 
vasoconstrictors except after a prolonged exposure time. CO has recently been 
attributed as an endogenous endothelial-derived vasodilator in the mesenteric 
circulation (Naik et al., 2003), but its role in the response to vasoconstrictors is as 
yet undetermined.
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6.10.2 How does haemin-induced HO-1 expression regulate vascular
responsiveness in the perfused kidney ?
Many studies have recorded a HO-1-induced protective effect in the rat kidney. 
Haemin pre-treatment did not significantly affect basal perfusion pressure. This 
suggests either that upregulation of HO-1 expression does not influence basal 
pressure in the rat kidney perfused at constant-flow, or that the selected dose o f 
haemin did not elevate HO-1 expression. However, a study by Wiesel et al., 
2001, demonstrated that HO-1 gene removal did not significantly affect basal 
perfusion pressure in the mouse kidney. To investigate the effect o f HO-1 
expression on vasodilators, the basal tone was increased using 30 mM K+; this 
K+ -induced increase in perfusion pressure was not affected by haemin. 
Therefore, HO-1 induction did not affect vasoconstriction induced by K+. Kaide 
et al., (2001), also reported that the induction o f HO-1 and CO release did not 
significantly affect the vasoconstrictor response to KC1 in the kidney. This 
indicates that HO-1 does not minimize the KCl-induced increase in cytosolic 
Ca2+ in smooth muscle cells (Wang et al., 1998), and could indicate that even if 
HO-1 expression is increased, it is not active under these conditions.
The vasodilator dose-response curve obtained in response to histamine in the 
control and haemin-treated kidneys were almost exactly the same. Thus, the 
presumed induction o f HO-1 does not modulate the vasodilator response to 
histamine. As histamine produces a vasodilation via activation o f Hi receptors
94-and an increase in intracellular Ca , this indicates that CO does not influence
9-1-histamine-induced Ca mobilization. In accordance with a study previously 
carried out in our lab (Laight, 1994), it was very difficult to achieve a vasodilator 
dose-response curve to ACh. The effect o f haemin pre-treatment in response to 
vasoconstrictors was also determined in the perfused kidney. Dose-response 
curves o f PE, ET-1 and SX6 C were obtained in both control and haemin-treated 
kidneys. Haemin pre-treatment significantly reduced the peak height response to 
PE compared with control (p<0.05). A similar effect has previously been 
illustrated in the rat kidney, where HO-1 induction was found to reduce the 
sensitivity to PE; this was shown to be due to CO release acting on Kca channels 
(Kaide et al., 2001). In contrast, SnPP, which inhibited HO, produced a
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significant decrease in duration o f response to PE (0.3 to 10 nmol) in haemin- 
treated kidneys. In the study by Kaide et al., (2001), the inhibition o f HO resulted 
in an increase in sensitivity to PE. This was not manifested as a change in the 
size o f the response, but suggests that a HO-2 product may be important in the 
duration o f response. For example, under normal conditions it is possible that 
HO-2 mediated CO release may be responsible for a slower return to baseline 
than as exhibited in the SnPP-treated tissues. These responses may be important 
in pathological situations, such as the chronic hypoxic rat kidney, where chronic 
hypoxia has been shown to increase HO-1 activity, and the resultant CO release 
is important in the production o f a vasodilatory influence in the kidney 
(O’Donaughy & Walker, 2000).
Haemin pre-treatment attenuated the constriction effect o f the highest dose of 
ET-1, and also reduced the duration o f response at 30 and 100 pmol ET-1. The 
reduction of the peak height response to the highest doses o f ET-1 may occur as 
a non-specific response to the highest dose. To further investigate this response, 
the effect o f haemin treatment on the constrictor nature of the ETb agonist SX6 C 
was examined. The extent and duration o f the response to SX6 C was similar in 
both control and haemin-treated tissues. Therefore, the effect of haemin 






7.1 The opposing vascular effects o f haemin pre-treatment in the constant-flow
and constant-pressure-perfused rat hearts.
Throughout the course o f the study, haemin has been used as an inducer o f HO-1 
expression. One o f the most interesting observations to be made from the rat 
heart experiments has been the opposite vascular responses in the pre- and post- 
ischaemic rat hearts. In the constant-flow heart model, haemin-induced HO-1 
expression was associated with a vasodilator effect, as indicated by a reduction in 
CPP, in the pre- and post-ischaemic rat heart. We postulate that this may be due 
to HO-1-mediated CO release. In contrast, in the constant-pressure-perfused rat 
heart, the same dose o f haemin produced a reduction in CFR (which is indicative 
o f a vasoconstrictor response) in the pre-ischaemic heart, but this was not so 
pronounced in the post-ischaemic heart. The causes o f this vasoconstrictor effect 
are not clear, but they may involve an effect on NO generation/release. The two- 
perfusion systems used give an opportunity to study different parameters, and to 
investigate the control systems involved in the regulation o f coronary flow or 
pressure. For example, the constant-flow perfusion system allows changes in 
contractility to occur which are independent o f substrate delivery, as flow is 
maintained when heart rate is changed or regional ischaemia occurs (Sutherland 
& Hearse, 2000). We believe that due to the different perfusion techniques used, 
this is the first study indicating such a complex effect after HO-1 induction. The 
constant-pressure perfusion system is the more physiological of the two systems 
examined, as it represents the nearest approximation to the regulation o f pressure 
in the human body.
Therefore, do these data indicate that HO-1 expression could produce a 
constrictor effect in vivo? The majority o f the data previously obtained from in 
vivo situations suggests that induction of HO-1 causes a reduction in blood 
pressure, whereas there is only one report o f increased blood pressure after 
cardiac-specific induction of HO-1 expression (Imai et al., 2001). Therefore, it 
would be premature to suggest that our data imply that HO-1 induction 
constitutes a detrimental effect in the whole body. For example, the experimental
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systems from which both sets of data were recorded are cardiac-specific and do 
not take into consideration any the other systems involved in the regulation of 
vascular tone and blood pressure. Nevertheless, it is important to note that the 
coronary vasoconstrictor effect was also observed at the higher perfusion 
pressure o f 130 mmHg, throughout the autoregulation experiments, and after an 
ischaemic insult o f 30 min. The measurement o f nitrite enabled the examination 
o f the effect o f HO-1 expression on NO release and suggested that an element of 
the constrictor response may involve a reduction o f NO release. This is in 
contrast with the data observed in the constant-flow-perfused rat heart, where 
NOS inhibition indicated that NO release worked alongside HO-1 induction to 
bring about a dilator response to haemin pre-treatment. The interactions between 
NOS/NO and HO-1/CO have been well documented. Therefore, it is possible 
that, while NO may be involved in both responses, the method o f perfusion and 
the regulatory mechanisms incorporated in the control o f pressure/flow affect the 
nature o f the involvement.
To further investigate this, the following experiments would be useful:
1. The investigation o f the effects o f the constant-flow and constant-pressure 
perfusion systems on specific HO-1 inhibition using oligodeoxynucleotides, or in 
a cardio-selective knockout system.
2. The use o f cardiac-specific HO-1 up-regulation techniques to eliminate any 
non-specific actions o f haemin treatment.
3. The investigation of the effects of HO-1 induction on the expression of NOS 
under each individual perfusion condition, and its relationship to the vascular 
responses observed.
4. The examination of the effects of various constant-pressure perfusion levels on 
HO activity, in relation to the data recorded at 130 mmHg.
5. The analysis of further doses o f SnPP to determine whether complete 
inhibition o f haemin-induced responses could be achieved.
6 . The further exploration of the possible non-specific side effects o f both 
haemin and SnPP in these systems.
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7.2. The role o f  HO-1 induction in recovery from I/R in both the constantflow-
and constant-pressure-perfused rat heart.
The control o f vascular dynamics may be important in regulating the degree of 
recovery from I/R; does the method o f perfusion used in our experiments affect 
haemin-induced recovery after I/R? In the constant-flow-perfused heart, haemin 
pre-treatment increased contractile recovery following 20 min ischaemia. This 
was postulated to be due to the antioxidant properties o f bilirubin, levels of 
which were significantly increased after haemin pre-treatment. In contrast, when 
hearts were perfused at constant-pressure following 2 0  min ischaemia, recovery 
was improved to about 80 % in the controls and haemin-treated hearts. 
Therefore, in this system, haemin-induced HO-1 expression did not increase 
protection compared with control, and similar levels o f bilirubin were seen in 
both treatment groups, and as no changes were seen it did not seem relevant to 
investigate the influence o f any further drugs. Further studies were performed 
using a longer ischaemic period o f 30 min to establish if haemin could improve 
recovery from a more severe ischaemic insult. However, in the constant-flow and 
constant-pressure perfusion systems, there was a complete elimination of 
recovery from 30 min I/R in both control and haemin-treated hearts. This is not 
in agreement with the study by Clark et al., (2000), that also used a constant-flow 
system, and was used as reference point for the present study. Clark et al., (2000) 
reported a significant increase in recovery in haemin-treated hearts compared to 
control after 30 min ischaemia under constant-flow conditions o f 15 ml/min, 
experimental conditions which are slightly different from ours. This discrepancy 
may have influenced the degree of recovery induced by haemin pre-treatment. In 
addition, other studies have indicated that HO-1 induction is protective after 30 
min ischaemia (Yet et al., 2001). Although in this study, bilirubin levels in hearts 
perfused in constant-flow and constant-pressure systems were increased in 
response to increased HO-1 activity, these increases did not always confer 
protection o f cardiac function. Thus, the mechanisms involved in the protective 
effect o f HO-1 induction are more complex than a simple increase in bilirubin 
activity.
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In the constant-pressure system, haemin-induced protection from I/R was 
observed at a constant pressure o f 130 mmHg, suggesting that the protection 
produced by haemin-induced HO-1 expression in the constant-pressure-perfused 
rat heart is pressure-sensitive or flow-dependent. In conclusion, the induced 
recovery from I/R in the constant-pressure-perfused rat heart appears to be more 
complex than in the constant-flow-perfused rat heart. This is could be due to the 
over-ride o f autoregulatory mechanisms involved in the control o f coronary flow 
during reperfusion.
7.3 The effect o f  H O -m edia ted  products  in the constant-flow  and  constant- 
pressure-perfused  ra t heart.
HO-1-mediated breakdown o f haem produces equimolar concentrations o f CO, 
iron and bilirubin. Therefore, as HO-1 induction has been indicated as a 
protective factor in response to I/R under constant-flow conditions and at high 
constant-pressure levels, what role do the breakdown products o f haem play in 
this response? In addition, does the absence o f any o f these factors explain the 
lack o f protection observed in the constant-pressure system at 70 mmHg? In the 
constant-flow-perfused rat heart, the haemin-induced dilator response is likely to 
be produced as a result o f CO release. In addition, the release o f CO may act to 
potentiate the release of NO, as demonstrated by the increase in CPP seen upon 
treatment with L-NO-Arg. There is no direct evidence for the involvement o f CO 
in the constant-pressure-perfused rat heart, as the techniques used to measure CO 
would be difficult to employ in conjunction with a perfused heart setup. 
Furthermore, as the half-life o f CO is very short, this means that it is difficult to 
measure CO directly from tissue at the end of an experiment. However, as HO-1 
expression and CO release have been shown to inhibit NOS and NO release, it is 
possible that the release of CO may have an inhibitory effect on NO release, 
thereby producing the constrictor action.
We hypothesize that HO-1 induction’s protective response to I/R maybe due 
mainly to the activity of bilirubin, as ROS generation has been shown to be 
important in the development of ischaemia-induced tissue injury and contractile 
dysfunction. In the constant-flow rat heart, bilirubin production is increased,
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which suggests a mechanism for the significantly improved recovery from I/R. 
This may be an important finding, as a number o f previous studies have 
suggested that the protective effect of HO-1 induction is due to bilirubin release. 
However, bilirubin levels are not increased in the constant-pressure rat heart, 
where the degree o f recovery from I/R is very high in both control and haemin- 
treated hearts, which may indicate that bilirubin is not important under these 
conditions. This is further demonstrated in the constant pressure system after an 
increased ischaemic insult o f 30 min, where the recovery from I/R is completely 
abolished in both treatment groups, even though bilirubin levels are significantly 
increased in haemin-treated hearts. Therefore, it seems that the method o f 
perfusion and pressure used in the experimental system is important in regulating 
the degree o f protection conferred by bilirubin. To further investigate this effect, 
I would like to continue the study by perfusing both control and haemin pre­
treated hearts with bilirubin, whilst exposing the tissue to 30 min I/R, and 
investigating whether recovery is improved under these circumstances.
The possible effect o f iron in the response to haemin pre-treatment in the 
constant-pressure rat heart was also examined by using the iron chelator DFO. 
However, DFO had effects on both control and haemin-treated hearts. 
Interestingly, DFO increased CFR in both control and haemin-treated pre- 
ischaemic hearts in the constant-pressure experimental system. After I/R, iron 
removal improved recovery of cardiac function in control and haemin-treated 
hearts to a similar extent, suggesting that iron can be detrimental to the course o f 
I/R injury. Therefore, the results of these experiments implicate CO, bilirubin 
and iron in the regulation o f vascular tone, and in the prevention of I/R injury in 
the constant-flow- and constant-pressure-perfused rat heart. Further 
investigations to clarify these effects could involve the investigation of the 
vascular and post-ischaemic responses to exogenous treatment with CO and iron.
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7.4. The effect o f haemin pre-treatment in the control o f vascular responsiveness
in the perfused mesenteric vascular bed and kidney.
The effect o f haemin-induced HO-1 expression on vascular tone was also 
determined in the perfused mesentery and kidney. What effect does haemin 
treatment have on the response to changes in vascular tone in these tissues? As it 
was difficult to determine haemin-induced HO-1 expression, the direct role o f 
HO-1 in haemin-induced tissues was unclear. The main effect o f haemin pre­
treatment in the mesenteric bed was that it rendered prolonged vasoconstriction 
with PE more difficult to maintain. As there is no direct evidence for the 
involvement o f HO-1 it can only be postulated that this effect may occur in 
response to increased release o f CO if  haemin increases HO-1 expression in this 
tissue. In addition, the vasodilator response to ACh in the presence o f PE was 
also significantly reduced in the presence o f haemin. Therefore, haemin pre­
treatment (either through HO-1 induction or via a non-specific effect) appears to 
counteract the response to some of the vasoconstrictors investigated.
In the kidney, haemin pre-treatment did not affect the responses to vasodilators 
or to prolonged exposure to vasoconstriction after pre-contraction with 30 mM 
K+. This was possibly due to the different mechanism of action utilised to induce 
an increase in basal tone. Nevertheless, in response to the vasoconstrictors ET-1 
and PE, haemin pre-treatment produced a reduction in the peak height response 
compared with control. Therefore, haemin pre-treatment was found to aid the 
response to vasoconstrictors; this may be due to HO-1 induction and the possible 
release o f CO, or to a further non-specific effect. Thus, to further investigate this 
effect in the kidney, I would like to investigate two other doses o f haemin (lower 
and higher than 75 jimol/kg haemin), and also the effect o f SnPP on vasodilator 
responses. In addition, it would be interesting to consider the effect o f haemin 
pre-treatment in the constant-pressure-perfused rat kidney. Finally, I would also 
like to investigate the effect o f the by-products o f HO-1-induced haem catalysis: 
CO iron and bilirubin, on the vascular responsiveness o f the rat kidney.
185
7.5. Final conclusion
In conclusion, the protective nature o f HO-1 expression is as yet unclear. This 
study indicates that the protective nature o f HO-1 is dependent both on the 
method o f perfusion, and on the perfusion pressure used. These factors affect 
vascular responses to HO-1 expression, making it difficult to speculate on the 
effect o f HO-1 in the intact human body. Such difficulties are also illustrated by 
the varying effects o f haemin pre-treatment on vascular responsiveness in the 
perfused mesentery and kidney. Thus, the results o f this study (and other 
published results) suggest that HO-1 has a very important yet complex role in the 
body. Finally, the further investigation o f HO-1 in various pathological 
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